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ABSTRACT 
Coronary artery disease (CAD) is a disease of inflammatory aetiology, and remains the 
commonest cause of death globally despite therapeutic advances.  Monocytes are implicated 
in the pathogenesis of CAD, but also in reparative mechanisms after myocardial infarction 
(MI) due to subset heterogeneity.  The aim of this thesis was to provide a detailed phenotypic 
comparison of differences between the three human monocyte subsets in CAD and after MI, 
with particular emphasis on CD16+ monocytes which have previously been analysed as a 
single population rather than two distinct subsets.  Longitudinal changes were analysed 
following MI and relationships explored with plasma cytokines. Multiple significant novel 
changes in monocyte phenotype attributable to specific subsets were identified, particularly 
related to the CD14++CD16+CCR2+ ‘Mon2’/‘Intermediate’ subset which increased in 
number on day 1 after MI and appeared highly functionally active.  There were significant 
changes in expression of a range of receptors associated with inflammation, migration and 
reparative processes.  Significant relations to plasma cytokines and the degree of myocardial 
damage were observed.  Most monocyte parameters predictive of left ventricular ejection 
fraction six weeks after MI were related to the Mon2 subset.  This suggests an important role 
for this subset in the acute phase of MI. 
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CHAPTER 1 
 
MONOCYTE SUBSETS AND THEIR ROLE IN PLAQUE 
DESTABILISATION AND MYOCARDIAL INFARCTION  
  
2 
 
1.1 ATHEROSCLEROSIS, CORONARY ARTERY DISEASE AND MYOCARDIAL 
INFARCTION 
 
1.1.1 Epidemiology of coronary artery disease and myocardial infarction 
Cardiovascular disease is already the commonest cause of death in industrialised countries, 
but it is also projected to become so in developing countries by 2020 (Murray & Lopez, 
1997).  More specifically, coronary artery disease (CAD) is the most common cause of death 
globally with over 7 million deaths annually, accounting for 12.8% of all mortality (WHO, 
2011).  The prevalence of angina increases with age and is estimated to be 2-4000/100,000, 
with an annual mortality rate of up to 1.4% (Fox et al, 2006).  The annual incidence of ST-
elevation myocardial infarction (STEMI) is approximately 66/100,000 (Widimsky et al, 
2010).  The average incidence of non ST-elevation myocardial infarction (NSTEMI) is 
approximately 300/100,000 (Fox et al, 2010).  The incidence of STEMI appears to be 
declining, in contrast to the incidence of NSTEMI which is rising (Yeh et al, 2010; Roger et 
al, 2012).  Within Europe, in-hospital mortality following STEMI varies between countries, 
ranging from 6% to 14%, with an average of approximately 12% within 6 months 
(Mandelzweig et al, 2006).  Survivors of myocardial infarction (MI) have a high risk of 
recurrent re-infarction, measured at 17.4% at 1 year in a population study (Milonas et al, 
2010).  These secondary events may occur because MI itself accelerates underlying 
atherosclerosis, rather than occurring as a simple manifestation of pre-existing advanced 
disease (Dutta et al, 2012).  Although there have been major advances in the management of 
MI over the last 60 years, there clearly remains a significant morbidity and mortality 
associated with this condition.  The figures speak for themselves; atherosclerosis remains a 
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major healthcare problem and even optimally treated patients may experience recurrent 
ischaemic and thrombotic events.  This drives the need for ongoing research into the 
pathophysiological determinants of plaque development, progression, instability, rupture and 
MI. 
 
1.1.2 Coronary artery disease and angina 
The term angina pectoris was coined by William Heberden in 1772 (Heberden, 1772), and the 
underlying mechanism proposed by Parry in 1799 (Parry, 1799).  This refers to the typical 
symptoms of chest discomfort, precipitated by exercise and relieved by rest, caused by 
atheromatous plaques in coronary arteries of sufficient proportion (typically >50% luminal 
diameter reduction) to reduce coronary blood flow beyond that which can be maintained by 
reduction of coronary vascular bed resistance.  This results in an imbalance between myocyte 
oxygen supply and demand which causes myocardial ischaemia and pain.  Angina is 
diagnosed clinically on the basis of typical symptoms, complemented by invasive or non-
invasive tests of coronary ischaemia (Fox et al, 2006).  Of note, all subjects recruited for the 
stable CAD control group in my study (see 3.1.2.1) had symptoms typical of angina and 
angiographic evidence of obstructive coronary artery narrowings, and received standard 
treatment according to contemporary guidelines (Fox et al, 2006).  This maximised 
homogeneity amongst this cohort.  
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1.1.3 Definition of myocardial infarction 
Due to variation in the definition of MI, a joint consensus statement from the European 
Society of Cardiology (ESC) and American College of Cardiology (ACC) ‘First Global MI 
Task Force’ was published in 2000 (ESC/ACC, 2000).  Subsequently, there have been major 
changes in the availability and sensitivity of biomarkers used for the diagnosis of MI, 
meaning that hitherto undetectable small amounts of myocardial damage can now be 
identified.  However, the fundamental principle remains that the diagnosis of MI can be made 
when there is evidence of myocardial necrosis in a clinical context consistent with myocardial 
ischaemia.  The criteria to make the diagnosis of MI were summarised in the 2007 ‘Universal 
Definition of MI’ consensus document, summarised in table 1.1 (Thygesen et al, 2007).  This 
was the contemporary guidance during the conception and conduct of my study. 
 
Table 1.1  Universal definition of myocardial infarction 
UNIVERSAL DEFINITION OF MYOCARDIAL INFARCTION 
 
Detection of rise and/or fall of cardiac biomarker values (preferably troponin) with at least 
one value above the 99th percentile of the upper reference limit and with at least one of the 
following: 
 
 Symptoms of ischaemia 
 New or presumably new significant ST-T changes or new left bundle branch block 
 Development of pathological Q waves on the electrocardiogram 
 Imaging evidence of new loss of viable myocardium, or new regional wall motion 
abnormality 
 Identification of an intracoronary thrombus by angiography or autopsy. 
 
 
The universal definition of MI was updated in 2012 to include the diagnosis of MI under 
special circumstances (related to angioplasty, cardiac surgery or coronary stent thrombosis), 
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and a classification of subtypes of MI based on the underlying pathology (Thygesen et al, 
2012).  This update does not affect the inclusion criteria for my study (see 3.1.1.1).    
 
In my study, the diagnosis of STEMI was made acutely at the time of hospital admission on 
the basis of symptoms and electrocardiogram (ECG) changes of ST elevation (see 3.1.1), 
rather than the development of Q waves, regional wall motion abnormalities or identification 
of intracoronary thrombus which are retrospective diagnostic criteria.  When the diagnosis of 
STEMI was made, all patients proceeded immediately to primary percutaneous coronary 
intervention (PPCI).  The detection of a longitudinal rise and fall of biomarkers (troponin) is 
confirmatory and is made in the days after STEMI.  Similarly, NSTEMI in my study was 
diagnosed on the basis of characteristic symptoms of myocardial infarction and compatible 
ECG changes (ST segment depression and/or T wave changes, but no ST elevation).  All 
NSTEMI patients had a rise in biomarkers indicative of myocardial damage (see 3.1.1).  This 
distinguishes this cohort as a group with definite myocardial infarction, compared to groups 
with ‘troponin-negative acute coronary syndromes’ or ‘unstable angina’ where symptoms 
may be due to ischaemia alone rather than additional infarction per se.  This ensured that the 
NSTEMI cohort was as homogeneous as possible. 
 
It should be noted that the ESC guidelines for diagnosis and management of both STEMI and 
NSTEMI were updated after the conception and initiation of this study.  The contemporary 
STEMI guidelines during the conduct of this study were those published in 2008 (Van de 
Werf et al, 2008), subsequently updated in 2012 (Steg et al, 2012).  The contemporary 
NSTEMI guidelines during the conduct of this study were those published in 2007 (Bassand 
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et al, 2007), subsequently updated in 2011 (Hamm et al, 2011).  There are no major changes 
in these updates relevant to the management of patients in my study.  There is a subtle change 
in terminology in the new guidelines, whereby the umbrella term of ‘acute coronary 
syndromes’ (ACS) is now used to encompass patients with a range of clinical phenotypes 
related to similar underlying pathophysiological substrate (see 1.1.4).  The terms ‘ST-
elevation acute coronary syndrome’ (STE-ACS) and ‘non ST-elevation acute coronary 
syndrome’ (NSTE-ACS) have been introduced to define the acute presentation with ischaemic 
chest pain and ECG changes before the cardiac biomarkers (usually troponin) are measured.  
Most STE-ACS will progress to STEMI.  Patients with NSTE-ACS are subsequently 
discriminated based on the presence (NSTEMI) or absence (‘unstable angina’) of biomarker 
elevation.  
 
1.1.4 Underlying pathology 
Atherosclerosis is a complex disease of inflammatory aetiology, characterised by the 
formation of atherosclerotic plaques in the wall of medium and large diameter arteries. These 
plaques are composed of lipids, lipid-laden monocyte-derived macrophages (foam cells), 
inflamed smooth muscle cells, endothelial cells and immune cells (Gerrity, 1981).    
Inflammation as identified by elevated levels of high-sensitivity C-reactive protein (hsCRP) 
in the blood was found to be a strong predictor of future major adverse cardiovascular events 
in the prospective JUPITER clinical trial (Ridker et al, 2008). 
 
The initial events of plaque development include impairment of endothelial function 
promoting vasoconstriction, enhanced coagulation and leucocyte adhesion.  This endothelial 
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activation may result from numerous triggers including disturbed arterial flow, modified low-
density lipoprotein (LDL), bacterial antigens and endogenous inflammatory mediators. 
Endothelial activation promotes leucocyte invasion into the intima and proliferation of 
smooth muscle cells, leading to the formation of a potentially reversible ‘fatty streak’, which 
may be present even during intrauterine life in humans (Napoli et al, 1997).  Fatty streaks are 
the precursors of mature atherosclerotic plaques and are characterised by accumulation of 
foam cells in the vascular intima (Jonasson et al, 1986).  These atherogenic macrophages are 
predominantly derived from the proinflammatory Ly6C
hi
 subset of monocytes in mice 
(discussed in section 1.2) (Swirski et al, 2007).  Over time, the plaque core becomes 
surrounded by a fibrous cap composed of smooth muscle cells and collagen-rich matrix which 
confers biomechanical strength.  The biological role of this process is thought to be 
elimination of excessive amounts of toxic oxidised LDL from the vascular wall via a number 
of monocyte scavenger receptors (Teupser et al, 1999; Febbraio et al, 2000; Silverstein & 
Febbraio, 2000).  Although this may initially be a physiologically beneficial process, 
excessive lipid accumulation by foam cells leads to their death and the resultant self-
perpetuating process of plaque progression. This constitutes progressive core enlargement, 
deposition of collagen, fibrosis, calcification, extracellular matrix formation and migration of 
smooth muscle cells into the intima, ultimately resulting in plaque expansion into the arterial 
lumen and obstruction of coronary blood flow (Gerrity, 1981).  
 
STEMI and NSTEMI represent an acute and potentially life-threatening manifestation of 
atherosclerosis.  The underlying CAD is often previously clinically quiescent, as the 
responsible plaque alone is often not sufficiently large to cause a significant reduction in 
luminal cross-sectional area to obstruct coronary flow during rest or exercise and may not 
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therefore cause stable exertional angina (Stone et al, 2011).  The hitherto stable CAD is 
complicated by atherosclerotic plaque erosion and rupture.  Activation of inflammatory cells 
within the atherosclerotic plaque is a key feature of this destabilisation process (Libby, 1995).  
The presence of a single ‘inflamed’ plaque as the substrate for MI has more recently been 
extended to the concept of a more generalised inflammatory process with multiple vulnerable 
plaques (Buffon et al, 2002).  Plaque rupture is associated with varying degrees of platelet 
aggregation, thrombosis and vasoconstriction, causing acute obstruction and reduction in 
coronary artery blood flow.  Myocardial infarction due to ischaemia-induced death of 
myocardial cells in the territory of the heart supplied by the culprit coronary artery is the end 
result of this process (Stone et al, 2011).  Although this may lead to sudden death, the most 
frequent presentation is with characteristic chest pain associated with a number of 
accompanying features including dyspnoea, nausea and diaphoresis.  Rarely, the cause of 
STEMI or NSTEMI is not due to atherosclerotic plaque rupture.  Alternative causes include 
an imbalance between myocardial oxygen supply and demand (e.g. profound sustained 
hypotension), spontaneous coronary artery dissection, trauma, intense vasospasm 
(spontaneous ‘Prinzmetal’s angina’, or related to cocaine use) and coronary arteritis.  It should 
be noted that the underlying pathological mechanism in all STEMI and NSTEMI patients in 
my study was coronary atherosclerosis (3.1.1).  This ensured pathophysiological uniformity 
amongst these cohorts.   
 
1.1.5 Contemporary management of ST-elevation myocardial infarction 
Since the 1960s there has been an exponential rise in research into MI.  The precise 
management of MI inevitably varies, within countries, regions, hospitals and between doctors.  
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Efforts have been made to collate available evidence into consensus guidelines to aid 
physicians in delivering optimal care at institutional level and to individual patients. 
The aims of treating MI in the acute phase are to relieve the symptoms associated with 
coronary ischaemia and to promptly restore coronary artery blood flow to improve both the 
short and long-term prognosis.  The management of MI has undergone major changes over 
the last few decades which have been paralleled by an impressive reduction in morbidity and 
mortality.  Initially, the treatment for MI was based on managing the symptoms, primarily 
relief of pain, and the complications rather than treating the underlying condition.  In 1961, 
Desmond Julian described the treatment of cardiac arrest as a complication of MI in 5 patients 
with cardiac massage and electrical cardioversion (3 by direct cardiac massage via 
thoracotomy and 2 by external chest compressions) (Julian, 1961).  Although only 1 of the 5 
patients ultimately survived, the experiences gained highlighted the need for rapid, co-
ordinated treatment of patients with MI by experienced staff and lead to the establishment of 
coronary care units (CCU) and resuscitation protocols for cardiac arrest.  Management of 
STEMI patients on CCU alone lead to a reduction in the rate of death for MI patients by 
approximately one-third (Julian, 1968). 
 
1.1.5.1 Reperfusion strategies 
The central management strategy in treating STEMI is prompt and successful restoration of 
flow within the ‘culprit’ coronary artery, so called ‘reperfusion’ therapy.  This reperfusion 
may occur spontaneously, but the 2 mainstays of active therapy are (i) pharmacological with 
drugs to break down the thrombus with ‘clot-busting drugs’, known as ‘thrombolysis’ or (ii) 
mechanical by PPCI.   
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1.1.5.1.1 Thrombolysis 
The landmark UK co-ordinated ISIS-2 study (International study of infarct survival) 
published in 1988 was a randomised trial comparing intravenous streptokinase, aspirin, 
neither or both in 17, 187 patients with acute STEMI.  The combination of aspirin with 
streptokinase was significantly better than either agent alone, with a marked improvement in 
vascular deaths and all cause mortality.  The vascular mortality rate in the placebo arm was 
13.2% at 35 days, compared to 8.0% in the aspirin + streptokinase arm (p<0.00001), a 42% 
reduction by the combination (ISIS-2 collaborative group, 1988).  The striking reduction in 
mortality associated with early thrombolysis highlighted the crucial requirement to deliver 
proven treatments as soon as possible after the onset of MI.  Although the attendant risks 
associated with both aspirin and especially streptokinase (principally haemorrhage) were 
noted, the overwhelming balance was clearly in favour of these drugs, and they subsequently 
became a routine treatment for STEMI.  Subsequently, the tissue plasminogen activator (tPA) 
drugs (alteplase, retaplase and tenectaplase) were shown to be more potent thrombolytic 
agents compared with streptokinase, at the cost of an increased risk of haemorrhagic 
complications (GUSTO investigators, 1993).  Emphasis was placed on giving thrombolytic 
drugs expeditiously, thus minimising the ‘door to needle time’, by re-organisation and 
streamlining of care for patients with STEMI, for example by direct admission to CCU. 
 
1.1.5.1.2 Primary percutaneous coronary intervention 
PPCI is defined as ‘emergent percutaneous catheter intervention in the setting of STEMI, 
without previous fibrinolytic treatment’ (Steg et al, 2012).  This involves a percutaneous ‘key 
hole’ approach, where the culprit coronary artery occlusion is visualised by angiography and 
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treated mechanically to restore flow.  This may involve removal of thrombus, dilating the 
occluded area with a balloon catheter and deployment of a metal stent to maintain patency.  A 
landmark meta-analysis by Keeley et al in 2003 assessed 23 randomised trials comparing 
thrombolysis versus PPCI for STEMI.  The results showed a significant benefit in reduction 
in major adverse cardiac events (MACE) including death in both the short and long term 
(Keeley et al, 2003).  The net benefit appeared to be due to a combination of improved 
restoration of coronary blood flow with a concomitant avoidance of the complications of 
thrombolysis, principally haemorrhage.  This data prompted a sea-change in the way STEMI 
care has been delivered.  PPCI has emerged as the reperfusion modality of choice, as long as 
this can be delivered without unacceptable delays in transfer to PPCI-capable centres.  Major 
organisational and logistical changes were required to deliver the 24 hours a day, 7 days a 
week (24/7) primary PCI service that exists for the majority of the UK population.  Recent 
data from the Freeman Hospital in Newcastle-upon-Tyne showed that this is achievable with 
no differences seen in short or long-term mortality between STEMI patients presenting to the 
PPCI service during working-hours compared to outside working-hours (Noman et al, 2012).  
Peri-procedural adjuncts during PPCI recommended to further increase the net benefit of 
PPCI include radial rather than femoral arterial access (Jolly et al, 2011), thrombus aspiration 
(Svilaas et al, 2008) and the use of drug-eluting stents (Kastrati et al, 2007). 
 
1.1.5.2 Pharmacological therapy 
All patients undergoing PPCI are recommended to receive two oral anti-platelet drugs, so 
called ‘dual antiplatelet therapy’ (DAPT), with aspirin and an adenosine diphosphate (ADP) 
receptor antagonist (Steg et al, 2012).  Aspirin is prescribed for life (ISIS-2 collaborative 
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group, 1988).  The second drug is prescribed for 12 months, until the coronary stent has re-
endothelialised.  The aim of antiplatelet drugs is to maintain patency of the culprit coronary 
artery occlusion by prevention of recurrent thrombosis.  Until recently, clopidogrel (Chen et 
al, 2005) was the most widely used ADP antagonist, but this has been superceded by 
prasugrel (Wiviott et al, 2007); the third recommended agent is ticagrelor (Wallentin et al, 
2009; Steg et al, 2012) but use of this drug is not yet widespread in the UK, and no patients in 
my study received it. 
 
An intravenous anticoagulant is recommended in all patients undergoing PPCI (Steg et al, 
2012), which may be unfractionated heparin (UFH), low-molecular weight heparin (LMWH) 
(Montalescot et al, 2011) or bivalirudin (a direct thrombin inhibitor) (Stone et al, 2008).  The 
use of platelet glycoprotein IIbIIIa receptor inhibitors may also be considered in selected 
cases at the operator’s discretion, usually where the thrombus burden is judged to be high.  
Options include abciximab (De Luca et al, 2005), tirofiban (Valgimigli et al, 2010) and 
eptifibatide (Zeymer et al, 2010).  
 
1.1.5.3 Long-term management 
There are several evidence-based drugs which are routinely recommended for long-term 
therapy post-MI to improve prognosis.  These included HMG co-enzyme A reductase 
inhibitors (‘statins’) (Cannon et al, 2004; Ray et al, 2005) and angiotensin converting enzyme 
(ACE) inhibitors (Fox, 2003).   The aldosterone antagonist eplerenone may be used in patients 
with evidence of a left ventricular ejection fraction ≤ 40% or symptoms of heart failure (Pitt et 
al, 2003).   
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Emphasis is placed on optimal control of recognised modifiable CAD risk factors including 
dyslipidaemia, hypertension and diabetes, which may involve lifestyle and pharmacological 
treatment.  Lifestyle advice includes smoking cessation, regular exercise, healthy diet and 
maintaining normal BMI.  Other therapies with proven mortality benefit after MI include 
cardiac rehabilitation (Lawler et al, 2010) and induced hypothermia after cardiac arrest 
acutely after STEMI (Bernard et al, 2002; Holzer et al, 2002). 
 
1.1.6 Contemporary management of non ST elevation myocardial infarction 
Many of the broad management principles described above for STEMI patients in terms of 
long-term secondary prevention strategies with pharmacological agents (DAPT, ACE 
inhibitors and statins) and lifestyle measures to improve prognosis also apply to NSTEMI 
patients (Hamm et al, 2011).  Additionally, beta-blocker drugs are routinely used to reduce 
symptoms of ischaemia but there is no evidence that they alter prognosis.  The main 
difference between STEMI and NSTEMI is that the underlying pathology in NSTEMI is 
usually not complete occlusion of the coronary artery.  Although both conditions are 
associated with significant acute complications, NSTEMI does not require an urgent 
interventional procedure in the form of PPCI.  A range of ‘risk-stratification’ tools can be 
employed to help identify those NSTEMI patients who are likely to benefit from an ‘invasive’ 
management strategy to reduce the risk of recurrent ischaemia and resultant complications 
(Fox et al, 2010).  This invasive approach involves timely assessment of the coronary arteries 
by angiography with a view to ‘revascularisation' by either PCI or coronary artery bypass 
grafting (CABG), or continuation of drug-treatment alone – ‘optimised medical therapy’ 
(OMT).  The most commonly used risk stratification systems for NSTEMI are the TIMI 
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(Antman et al, 2000) and GRACE (Fox et al, 2006) scores.  The decision between 
revascularisation by PCI or CABG depends upon factors including co-morbidities and the 
angiographic pattern of coronary artery narrowing(s) (Hamm et al, 2011).  
 
As for STEMI patients, all NSTEMI patients receive initial DAPT with aspirin and 
clopidogrel.  This DAPT is continued for 12 months after PCI, followed by lifelong aspirin.  
Additionally, anticoagulation with either fondaparinux (factor Xa inhibitor) or LMWH is 
recommended for the first few days (Hamm et al, 2011).  Fondaparinux is not in widespread 
use in the UK currently; all NSTEMI patients in my study received LMWH (see 3.1.4).  
Additional anticoagulant therapy with platelet glycoprotein receptor IIbIIIa inhibitors or 
bivalirudin may be used ‘upstream’ before PCI, or as a peri-procedural adjunct during PCI.  
Use of these drugs is at the discretion of the individual physician and consequently varies 
widely. 
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1.2  MONOCYTES AND MONOCYTE SUBSETS 
 
1.2.1 Monocytes 
Monocytes were first recognised to be derived from haematopoietic precursor cells in the 
bone marrow. They develop from a common myeloid progenitor cell shared with neutrophils. 
Entry into the blood is regulated by CCR2.  They circulate for three to five days, then reside 
in reservoirs including the spleen or migrate into tissues and develop into macrophages and 
dendritic cells (Ebert & Florey, 1939; Volkman & Gowans, 1965; van Furth & Cohn, 1968; 
Swirski et al, 2009; van der Laan et al, 2013).  More recently, the development of precursors 
which give rise to monocytes outside the bone marrow (‘extra medullary monocytopoiesis’) 
has been described (Robbins et al, 2012; Leuschner et al, 2012).  Monocytes in circulation 
exist in a constant but reversible interaction with platelets (‘monocyte platelet aggregates’, 
MPAs) which is calcium dependent (Shantsila et al, 2014).  Monocytes exhibit high 
developmental plasticity and intrinsic heterogeneity (van de Veerdonk & Netea, 2010). 
Moreover, the monocyte pool may include a population of cells with pluripotent progenitor 
potential (Zhao et al, 2003). 
 
The primary function of circulating monocytes is in host defence against foreign pathogens as 
part of the innate immune system, primarily by phagocytosis.  However, accumulating 
evidence indicates that monocytes and macrophages also play key roles at all stages of 
atherosclerotic cardiovascular disease (reviewed by Pamukcu et al, 2010).  These roles 
include processes taking place within the plaque itself but also whilst the monocyte is in the 
circulation.  This indicates that monocyte-associated plaque generation, progression and 
destabilisation is both a local and systemic process.   
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A role for monocytes and macrophages in atherogenesis was first hypothesised when they 
were detected in atherosclerotic plaques of animals (Watanabe et al, 1985) and humans 
(Gown et al, 1986).  Monocyte depletion from circulation was found to significantly reduce 
plaque formation in rabbits (Ylitalo et al, 1994), although this depended upon the stage of 
atherosclerosis.  Indeed, depletion of monocytes at the early stages of atherosclerosis 
decreases the number and activity of macrophages within plaques, inhibits lesion 
development, and alters plaque composition by reducing collagen content and necrotic core 
formation.  However, monocyte depletion at more advanced stages of atherosclerosis does not 
yield such effects (Stoneman et al, 2007).  This highlights the principle that monocytes play 
fundamental roles from the very earliest stages of lesion formation, at least in experimental 
studies. 
 
In addition to these pathological processes, monocytes may also exert beneficial effects such 
as a contribution to angiogenesis and tissue repair. Indeed, monocytes express a wide range of 
angiogenic factors and appear to be critical for orchestrating arrangement of different cell 
types in neovessels (Shantsila et al, 2008). 
 
1.2.2 Monocyte subsets and heterogeneity 
The numerous and very distinct roles attributed to monocytes in homeostasis, inflammation 
and repair lead to the concept of monocyte heterogeneity and the hypothesis that monocytes 
may commit to specific functions whilst in circulation (reviewed by Woollard & Geissmann, 
2010). This prompted the identification of phenotypic subsets in humans and mice (Ziegler-
Heitbrock et al, 1988; Passlick et al, 1989).  However, the majority of research into monocyte 
subsets in atherogenesis has been performed in mice, and as humans and animals do not 
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express directly comparable monocyte surface markers, comparisons between species and 
therefore extrapolation of data are difficult and require caution. 
 
1.2.2.1 Mouse monocytes 
Mouse monocyte subsets were first identified according to their expression of CCR2, CD62L 
(L-selectin) and fractalkine chemokine receptor 1 (CX3CR1).  Subsequently Ly6C (part of the 
epitope of GR1) was identified as an additional marker of CCR2
+
 monocytes, and two mouse 
monocyte subsets were described; CCR2
+
CD62L
+
CX3CR1
lo
Ly-6C
hi
 and CCR2
-
CD62L
-
CX3CR1
hi
 Ly-6C
lo 
(or more simply Ly-6C
high 
and Ly-6C
low
, respectively) (Gordon & Taylor, 
2005).  Mouse monocyte subsets do not arise from distinct progenitors but convert from the 
Ly-6C
high
 to the Ly-6C
low
 subset (Yona et al, 2013).  Subsequently, evidence emerged 
identifying subset-specific involvement in the pathophysiology of atherosclerosis (Swirski et 
al, 2007; Tacke et al, 2007). 
 
Ly-6C
high
 monocytes (see 1.2.2.1) produced by extramedullary haematopoiesis infiltrate 
atherosclerotic plaques (Robbins et al, 2012).  They are derived from splenic stores where 
release is mediated by angiotensin II and bone marrow pools where release is mediated by 
CCR2 (Swirski et al, 2009).  Release from bone marrow is triggered by the sympathetic 
nervous system and may be inhibited with β3 adrenoceptor blockers (Dutta et al, 2012).  Ly-
6C
high
 monocytes actively migrate into the myocardium during the early phase of MI 
(Nahrendorf et al, 2007).  This has recently been imaged in real time, in-vivo, using intravital 
microscopy (Lee et al, 2012; Jung et al, 2013).  In mice, monocytes within infarcted 
myocardium turnover very quickly; after an average of 20 hours they become apoptotic and 
are replaced by newly recruited cells (Leuschner et al, 2012). 
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Ly-6C
high
 monocytes have prominent proinflammatory, proteolytic and phagocytic properties 
within plaques.  Through protease activity they digest dead cells and extra cellular matrix and 
clear the debris by phagocytosis to allow for the subsequent healing processes of elaboration 
of granulation tissue and scar formation.  They are implicated in plaque destabilisation via 
production of cytokines, myeloperoxidase and matrix metalloproteinases (MMPs) (Swirski et 
al, 2007; Libby et al, 2008).  Prolongation of Ly-6C
high
 monocytosis seen in atherosclerotic 
mice disturbs resolution of inflammation, impairs infarct healing and is associated with 
adverse left ventricular (LV) remodelling following experimental MI (Panizzi et al, 2010).  
Blockade of their recruitment improves LV healing after MI (Majmudar et al, 2013). 
 
In contrast, Ly-6C
low
 monocytes play a role in the immune response, including replenishing 
the population of tissue-macrophages and dendritic cells (Auffray et al, 2009).  They 
differentiate from the Ly-6C
high
 subset and have a lower content of inflammatory molecules 
and proteases. They feature more in the recovery phase following MI, where they promote 
healing and repair of the myocardium via myofibroblast accumulation, deposition of collagen 
and stimulation of angiogenesis via expression of vascular endothelial growth factor (VEGF) 
and transforming growth factor-β (Nahrendorf et al, 2007).  Recent data suggests that Ly-
6C
low
 monocytes are enriched within capillaries and function as intravascular scavenging 
‘housekeepers’ that recruit neutrophils to mediate focal necrosis of endothelial cells and 
phagocytosis of cellular debris (Carlin et al, 2013).  These two phases of monocyte 
recruitment after MI should not be viewed in isolation, as there is a close relationship between 
the acute inflammation during the early days after MI and the ensuing chronic inflammation 
that promotes remote recruitment of inflammatory cells which fuels progression of plaque 
growth and destabilisation (Dutta et al, 2012; Swirski et al, 2013).  
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1.2.2.2 Human monocytes  
Human monocytes were first identified by their abundant expression of CD14 (part of the 
lipopolysaccharide (LPS) receptor) (Passlick et al, 1989).  Differential expression of CD16 
(the low affinity receptor for IgG) allowed the discrimination of two subsets; CD14
++
CD16
-
 
(~85% total monocytes) and CD14
+
CD16
+ 
(~15% total monocytes) by two-colour flow 
cytometry (Ziegler-Heitbrock et al, 1988; Passlick et al, 1989). 
 
CD14
+
CD16
-
 monocytes are large cells with inflammatory roles, high phagocytic and 
proteolytic activity.  They respond to LPS stimulation in vitro by releasing interleukin (IL)-10 
(Skrzeczyńska-Moncznik et al, 2008).  The remaining monocytes in humans have usually 
been considered as one subset, CD14
+
CD16
+
.  In contrast with the CD14
+
CD16
-
 subset, 
CD14
+
CD16
+ 
monocytes are small and possess low phagocytic activity.  They ‘patrol’ the 
endothelium and rapidly extravasate in response to inflammatory stimuli (Auffray et al, 2007) 
in a similar manner to the mouse Ly-6C
low
 subset (Cros et al, 2010). 
 
CD16+ monocyte numbers are significantly increased in subjects with CAD (Schlitt et al, 
2004; Hristov et al 2010).  High CD16+ monocyte count was associated with subclinical 
atherosclerosis assessed by an association with increased carotid artery intima medial 
thickness (Rogacev et al, 2010).  In one study of patients with acute MI treated by PPCI, 
CD14
+
CD16
-
 and CD14
+
CD16
+
 monocytes were sequentially mobilised with peaks in venous 
blood on day 3 and day 5 respectively. The CD14
+
CD16
-
 monocyte count was inversely 
correlated with LV recovery after MI (Tsujioka et al, 2009).  Subsequently, the peak 
CD14
+
CD16
-
 monocyte count following MI was significantly higher in-patients with 
evidence of ongoing microvascular obstruction detected by gadolinium enhanced 
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cardiovascular magnetic resonance imaging (MRI), which is associated with LV impairment 
and a poor prognosis (Tsujioka et al, 2010).  CD16+ monocytes were positively associated 
with the presence of vulnerable coronary plaques (Kashiwagi et al, 2010) and with fibrous cap 
thickness (Imanishi et al, 2010).  Recent data from post-mortem tissue from humans describes 
the spatio-temporal distribution of monocytes in the myocardium following MI.  In the ‘early’ 
stage after MI (3 - 12 hours), there were no differences in myocardial monocyte number or 
distribution compared to controls.  In the acute ‘inflammatory’ phase after MI (12 hours - 5 
days), monocytes accumulated in the infarct border zone surrounding the necrotic core, 
adjacent and adherent to viable cardiomyocytes, of which approximately 85% were 
CD14+CD16- monocytes versus 15% CD14+CD16+ monocytes.  In the ‘proliferative’ phase 
after MI (5 - 14 days), there was a massive accumulation of monocytes in the infarct core 
consisting of granulation tissue, with very few in the border zone.  At this stage 60% were 
CD14+CD16-, and 40% CD14+CD16+.  After acute MI, the number of monocytes (CD14+ 
cells) in the bone marrow was 39% lower than controls, and in the spleen was 58% lower than 
controls (van der Laan et al, 2013), suggesting that the spleen may be an important reservoir 
for monocytes in humans.  This temporal pattern described mirrors the previous observations 
in peripheral blood by Tsujioka and colleagues where CD14+CD16+ monocyte number 
peaked on day 5 after MI.  Unfortunately there was no discrimination between the CD16+ 
monocytes in these studies (Tsujioka et al, 2009; van der Laan et al, 2013), so it is unclear 
which of the CD16+ subsets is implicated in these observations.     
 
The majority of studies, including even the most recently published (Arslan et al, 2013; van 
der Laan et al, 2013), consider CD16+
 
monocytes as a single population, whereas it is 
increasingly apparent there are two distinct subsets within this group (Zawada et al, 2011; 
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Wong et al, 2011, Ziegler-Heitbrock & Hofer, 2013).  This is a major limitation of many 
studies.  Initial attempts at categorisation divided CD16+ monocytes into CD14
low
CD16
+ 
and 
CD14
+
CD16
+ 
subsets (Table 1.2).  However, this is not an ideal nomenclature as expression 
of CD14 represents a continuum, and division into CD14
low
 and CD14
+ 
is inherently artificial 
and therefore inexact.  More recently efforts have been made to definitively discriminate 
CD16+
 
cells phenotypically as two distinct subpopulations (Kim et al, 2010; Tallone et al, 
2011; Shantsila et al, 2011; Hristov et al, 2012; Ziegler-Heitbrock & Hofer, 2013).  Our 
research group described that the three human monocyte subsets can be unequivocally defined 
by addition of CCR2 to the panel of the markers which allows accurate discrimination 
between CD16+ cells.  We define the three subsets as: ‘Mon1’ (CD14++CD16-CCR2+), 
‘Mon2’ (CD14++CD16+CCR2+), and ‘Mon3’ (CD14+CD16++CCR2-) (Shantsila et al, 
2011) (Table 1.3).  These definitions of monocyte subsets are used in my study.  Our findings 
are in keeping with the work of Zawada and colleagues who demonstrated a 2-fold higher 
expression of TIE2 protein by the ‘intermediate’ subset (Zawada et al, 2011). 
 
The definition of human monocytes as three subsets is a recent change, and there have 
consequently been few studies specifically investigating their individual functions. However, 
emerging data has been very interesting, with the potential to focus in and refine our 
understanding of their individual roles in cardiovascular disease.  Of particular interest, 
amongst CD16+ monocytes the CD14++CD16+ subset appears to be especially pro-
atherogenic.  CD14++CD16+ monocytes selectively express the chemokine receptor CCR5 
(Ancuta et al, 2003; Zawada et al, 2011; Rogacev et al, 2011) which has been associated with 
atherosclerosis in experimental and epidemiological studies (Gonzalez et al, 2001; Pai et al, 
2006; Muntinghe et al, 2009).  They are also major producers of reactive oxygen species 
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which propagate atherosclerosis (Zawada et al, 2011).  Furthermore, the pro-angiogenic 
features of CD14++CD16+ monocytes (Venneri et al, 2007; Zawada et al, 2011) may link 
them to the process of plaque neovascularization seen in advanced stages of atherosclerosis 
which is associated with instability and the potential for rupture (Michel et al, 2011).  In a 
recent observational cohort study, CD14++CD16+ monocytes were the only independent 
predictor of adverse cardiovascular outcomes after adjustment for cardiovascular risk factors 
(Rogacev et al, 2012).  This association with atherosclerosis is in keeping with evidence of the 
proinflammatory capacity of CD16+ monocytes (Zawada et al, 2011; Belge et al, 2002) along 
with their preferential affinity and adherence to activated endothelial cells (Steppich et al, 
2000; Ancuta et al, 2003).  Additionally, CD16+ monocytes secrete IL-6, matrix 
metalloproteinases (MMPs), and chemokines which attract further monocytes and 
lymphocytes (Ancuta et al, 2006) propagating atherosclerosis.  These findings raise the 
possibility that CD14++CD16+ monocytes may represent a future therapeutic target in the 
treatment of cardiovascular disease, and highlight the requirement for more research in this 
area.  
 
The association of CD14++CD16+ monocytes with cardiovascular risk is in keeping with 
mouse data suggesting they are the human counterparts of pro-atherogenic Ly-6C
high
 
monocytes (Cros et al, 2010).  However, drawing parallels between mouse and human 
monocyte subset data has been difficult, as most mouse studies of monocyte heterogeneity 
considered only two subsets, Ly6C
high
 and Ly6C
low
.  Moreover, many mouse studies have 
been performed in apolipoprotein knockout mice fed an atherogenic diet.  This induces 
marked elevations in lipid levels which may cause massive rises in Ly6C
high
 monocyte 
numbers but no effect on Ly6C
low
 numbers.  Such changes were not seen in wild-type mice 
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fed this diet (Swirski et al, 2007).  Cros and colleagues recently showed that both human 
CD14++CD16- and CD14++CD16+ monocytes cluster together with mouse Ly6C
high
 
monocytes, whereas CD14+CD16++ monocytes cluster together with Ly6C
low
 monocytes 
(Cros et al, 2010) which has helped reconcile the differences (see table 1.3).   
 
Differences in terminology and definitions of monocyte subsets between studies have been 
confusing and have lead to difficulties in comparing data.  To address this issue, the 
International Union of Immunological Sciences and the World Health Organisation issued a 
statement in 2010, proposing a consensus on monocyte subset nomenclature.  This document 
recommends describing human monocytes as three subsets, namely ‘Classical’ (CD14+CD16-
), ‘Intermediate’ (CD14++CD16+) and ‘Nonclassical’ (CD14+CD16++) (Ziegler-Heitbrock 
et al, 2010), where ‘+’ denotes an expression level 10-fold above the isotype control and ‘++’ 
denotes expression level 100-fold above the isotype control.  The consensus statement 
suggests that they correspond to three equivalent populations in mice, as summarised in table 
1.2.   
    
Table 1.2  Definition of monocyte subsets (adapted from Ziegler-Heitbrock et al, 2010) 
INTERNATIONAL UNION OF IMMUNOLOGICAL SCIENCES & 
WORLD HEALTH ORGANISATION 
DEFINITION OF MONOCYTE SUBSETS 
 
 Human Mouse 
Classical CD14++CD16- Ly6C++CD43+ 
Intermediate CD14++CD16+ Ly6C++CD43++ 
Nonclassical CD14+CD16++ Ly6C+CD43++ 
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This consensus nomenclature proposal is a welcome attempt to introduce consistency in 
describing subsets.  The majority of current data published was conceived and executed 
before this nomenclature was proposed, including that in this thesis.  The definitions of 
monocyte subsets in this thesis are those our group first described in healthy subjects in 2011 
(Shantsila et al, 2011).  Characteristics of these subsets and their correspondence to the 2010 
nomenclature are described in table 1.3.  
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Table 1.3  Characteristics of human monocyte subsets  
Human monocyte 
subsets 
‘Classical’ 
CD14
+
CD16
-
CCR2
+ 
‘Mon1’ 
‘Intermediate’ 
CD14
+
CD16
+
CCR2
+ 
‘Mon2’ 
‘Non-classical’ 
CD14
low
CD16
+
 CCR2
- 
‘Mon3’ 
Ziegler-Heitbrock et al, 2010 
Shantsila et al, 2011 
Corresponding 
mouse subset 
Ly-6C
high
 Not clear Ly-6C
low
 Grage-Griebenow et al, 2001 
Geissmann et al, 2003 
Ly6C++ CD43+ Ly6C++ CD43++ Ly6C+ CD43++ Ziegler-Heitbrock et al, 2010 
 
Approximate 
proportion of 
overall monocytes 
85% 5% 10% Ziegler-Heitbrock et al, 1988 
Passlick et al, 1989 
Shantsila et al, 2011 
Size ++ +++ + Shantsila et al, 2011 
Granularity ++ ++ + Shantsila et al, 2011 
Number in plaques Frequent, associated 
with plaque 
destabilisation 
 Infrequent Swirski et al, 2007 
Primary roles 
 
Rapid recruitment to 
sites of inflammation 
Phagocytosis 
Scavenging necrotic 
debris 
Release of MMPs 
Cytokine production 
Give rise to 
macrophages in 
atheromata 
Angiogenesis 
Anti-inflammatory 
cytokine production 
(IL-10)  
Anti-inflammatory 
Collagen deposition 
Healing 
‘Patrol’ endothelium  
 
Sunderkötter et al, 2004 
Swirski et al, 2007 
Libby et al, 2008 
Skrzeczyńska-Moncznik et al, 2008 
Auffray et al, 2007 
Cros et al, 2010 
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Phagocytic activity High High Low Cros et al, 2010 
Shantsila et al, 2011 
NFĸB activity High Moderate Moderate Shantsila et al, 2011 
Chemokine 
receptors 
 
Mobilisation via 
CCR2 receptor in 
response to MCP-1 
Mobilisation via 
CX3CR1 in response 
to fractalkine 
Data not available Weber et al, 2000 
Aukrust et al, 1998 
Ancuta et al, 2004 
LPS stimulated 
cytokine 
production 
Potent producers of  
IL6, IL-1β, MCP-1 
Maximal production 
of IL10 
 
Unresponsive to LPS Shantsila et al, 2011 
Frankenberger et al, 1996 
Mizuno et al, 2005 
Surface expression 
of angiogenic 
receptors 
(VEGFR1, 
VEGFR2, CXCR4, 
Tie 2)  
Low High Low Shantsila et al, 2011 
Zawada et al, 2011 
Surface expression 
of adhesion 
molecules (ICAM, 
VCAM)  
Moderate expression 
of ICAM-1 and 
VCAM-1 
High expression of 
ICAM-1 receptor.  
 
High expression of 
adhesion molecules 
and increased 
monocyte endothelial 
adherence  
High expression of 
VCAM-1 receptor 
Shantsila et al, 2011 
 
 
Ancuta et al, 2004 
Surface expression 
of scavenger 
receptors 
CD163 
CD204 
 
 
 
Medium 
Low 
 
 
 
High   
Medium 
 
 
 
Low 
High 
 
 
 
Shantsila et al, 2011 
Buechler et al, 2000 
 
27 
 
Change in stroke No effect Increased, and 
predictive of 
subsequent infections.  
High level associated 
with better survival. 
Decreased Urra et al, 2009 
Change in severe 
asthma  
Not studied Increased 
Decrease on allergen 
challenge 
No effect Moniuszko et al, 2009 
Kowal et al, 2012 
Change in 
rheumatoid arthritis 
Decreased Increased 
High level predicts 
reduced response to 
therapy 
 Cooper et al, 2012 
Changes in 
colorectal cancer 
 Increased, especially 
in localised rather than 
metastatic cancer 
 Schauer et al, 2012 
Changes in 
survivors of ALL 
 Increased  Sulicka et al, 2013 
Association with 
adverse CV events 
in CKD dialysis 
patients 
 Positive association 
with adverse 
outcomes 
 Heine et al, 2008 
Rogacev et al, 2011 
Association with 
adverse CV events 
in patients 
undergoing elective 
coronary 
angiogram 
 
 
 
 Positive association 
with adverse 
outcomes 
 Rogacev et al, 2012 
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Changes in heart 
failure 
Increased in acute 
heart failure 
Increased in acute and 
chronic heart failure. 
Increased expression 
of markers of 
activation (CD14) and 
chemotaxis (CCR2). 
Associated with 
adverse prognosis 
No difference Wrigley et al, 2013 
 
ALL, Acute Lymphoblastic Leukaemia; MMP, Matrix Metalloproteinase; ECM, Extra-Cellular Matrix; ROS, Reactive Oxygen Species; 
IL-10, Interleukin 10; NFĸB, Nuclear Factor Kappa B; LPS, Lipopolysaccharide; IL-6, Interleukin 6; IL-1β, Interleukin 1β; MCP-1, 
Monocyte Chemoattractant Protein-1; VEGFR1, Vascular Endothelial Growth Factor Receptor 1; VEGFR2, Vascular Endothelial 
Growth Factor Receptor 2, CXCR4, C-X-C chemokine receptor type 4; ICAM-1, Intercellular Adhesion Molecule-1; VCAM-1, Vascular 
Cell Adhesion Molecule-1; CCR2, Chemokine (C-C motif) Receptor 2; CX3CR1, Chemokine (C-X3-C motif) receptor; CV, 
cardiovascular; CKD, chronic kidney disease; CAD, coronary artery disease  
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1.3 THE ROLE OF MONOCYTES IN ATHEROSCLEROTIC PLAQUE 
DESTABILISATION 
 
1.3.1 Plaque development 
Although the primary function of circulating monocytes is in host defence against foreign 
pathogens as a part of the innate immune system, there is a growing body of data which has 
linked specific monocytes subsets to plaque formation and destabilisation in animals and 
human studies.  Plaque development as the first step in the development of atherosclerosis 
was discussed in section 1.1.4.   
 
1.3.2 Plaque destabilisation 
Plaque destabilisation is an extremely complex multifaceted process, triggered by 
inflammatory environment within the plaque (van der Wal et al, 1994).  Mechanisms 
implicated include an unbalanced generation of inflammatory cytokines and angiogenic 
growth factors which promote pathological plaque neovascularisation (Maseri & Fuster, 
2003).  However, not all atherosclerotic plaques become unstable and rupture.  The risk of 
plaque rupture depends on plaque composition rather than size per se, of which monocyte and 
macrophages are key determinants.  Macrophages (Moreno et al, 1994) and T-lymphocytes 
(Neri Serneri et al, 1997) are the principal inflammatory cells in human coronary unstable 
plaques where they are present in increased density compared to stable plaques (Richardson et 
al, 1989; Lendon et al, 1991; Davies et al, 1993).  Characteristic histological features of 
vulnerable plaques include a thin fibrous cap, high ratio of macrophages to vascular smooth-
muscle cells (Moreno et al, 1994), reduced collagen content and high lipid content. 
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Beside the cellular interactions taking place inside the plaque, plaque destabilisation is also 
facilitated by circulating monocytes which are able to generate and secrete mediators of all 
the major factors involved in plaque destabilisation, including inflammation, matrix 
degradation, and thrombogenesis (Shantsila & Lip, 2009).  This indicates that plaque 
destabilisation is both a local and systemic process.  Intriguingly, recent data suggests that 
after MI in experimental mice, pre-existing plaques become larger with a more advanced 
‘vulnerable’ morphology.  This acceleration of disease progression was maintained over time 
and was associated with a significant and persistent increased recruitment of monocytes.  
These monocytes are liberated from the bone marrow and spleen via sympathetic nervous 
system signalling after MI (Dutta et al, 2012).   
 
Hitherto stable atherosclerotic plaques may progress to become acutely unstable which is the 
substrate for MI.  The fibrous cap which separates the plaque’s content from contact with 
blood becomes thinned and may rupture. This exposes the plaque’s procoagulant contents to 
circulating clotting factors and discharges plaque debris and tissue factor. Activation of the 
coagulation cascade results in thrombus formation, coronary occlusion, tissue ischaemia and 
necrosis. Early identification of coronary plaques prone to rupture is challenging as they are 
often clinically silent, are non-obstructive and appear similar to stable plaques on a coronary 
angiogram. 
 
However, there is emerging evidence linking plaque vulnerability with changes in circulating 
levels of specific monocyte subsets.  For example, an increased count of CX3CR1-expressing 
monocytes was associated with coronary plaque rupture in patients with unstable angina 
(Ikejima et al, 2010).  Imanishi and colleagues examined fibrous cap thickness of non-culprit 
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lipid-rich plaques by optical coherence tomography (OCT) in patients with unstable angina 
who underwent PCI.  Monocytes were measured and OCT performed at baseline (day of PCI) 
and 9 months post PCI.  Monocyte populations were defined as CD14
+
CD16
+
CX3CR1
+
 and 
CD14
+
CD16
-
CCR2
+
.  At 9 months, fibrous cap thickness increased by 100% in subjects 
taking statins and 73% in those not on statins.  The percentage change in fibrous cap thickness 
was significantly correlated with the percentage change in CD14
+
CD16
+
CX3CR1
+
 
monocytes, but not CD14
+
CD16
-
CCR2
+
 monocytes.  The percentage change in 
CD14
+
CD16
+
CX3CR1
+
 monocytes was significantly decreased in the statin group compared 
to the non-statin group (Imanishi et al, 2010).  This study therefore demonstrates a negative 
correlation between CD14
+
CD16
+
CX3CR1
+
 monocytes and fibrous cap thickness, suggesting 
a relationship between this monocyte subset and coronary plaque vulnerability, which statins 
may be able to modulate.  As statins have the ability to increase fibrous cap thickness 
(Takarada et al, 2009), the finding of a correlation between statin use and a decreased 
percentage in CD14
+
CD16
+
CX3CR1
+
 monocytes suggests that statins may have the potential 
to increase integrity and thickness of the fibrous cap by reducing number of 
CD14
+
CD16
+
CX3CR1
+
 monocytes.  A limitation of this study is the consideration of 
CD14
low
CD16
+
 and CD14
+
CD16
+
 monocytes as a single population (defined as 
CD14
+
CD16
+
CX3CR1
+
), so it is not possible to ascertain which of the CD16
+ 
monocytes may 
be implicated in this regard. 
 
An elevated CD14
+
CD16
+
 monocyte count has also been associated with characteristics of 
plaque vulnerability assessed by multidetector computed tomography (CT) in patients with 
stable CAD without raised hs-CRP (Kashiwagi et al, 2010).  Whether this monocyte subset 
has a causal role in plaque vulnerability or is a marker of an inflammatory process in the 
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coronary artery is unclear.  Again, this study did not discriminate subsets of CD16
+
 
monocytes which should be considered a potential study limitation. 
 
 
1.3.3 The monocyte journey towards plaque destabilisation 
The pathogenesis of atherosclerosis and plaque destabilisation begins with the activation of 
monocytes and mobilisation from the bone marrow into the circulation, and thence 
recruitment to the vascular wall.  This process occurs in response to the inflammatory milieu 
of chemokines produced locally by damaged tissues or released in the context of systemic 
inflammation. This is reflected by high circulating levels of pro-inflammatory cytokines and 
adhesion molecules in atherosclerotic disease (Ross, 1986). 
 
 
1.3.3.1 Monocyte activation 
Plaque destabilisation is closely associated with monocyte activation and change in 
phenotype.  Activated T cells within vulnerable plaques produce interferon (IFN)  which 
subsequently activates plaque monocytes and macrophages (Serneri et al, 1992).  Monocytes 
are activated via a number of pattern-recognition receptors, such as the endotoxin receptor 
CD14 and toll-like receptors (TLRs) (Medzhitov, 2007).  Bone marrow-derived monocytes 
expressing TLR2 and TLR4 are pivotal in arteriogenesis and collateral artery growth in mice 
(de Groot et al, 2011).  TLR1, TLR2, and TLR4 are upregulated in the endothelium and 
expressed by monocytes within atherosclerotic plaques (Vink et al, 2002).  TLRs may be 
stimulated by a variety of molecules expressed during cardiovascular injury (Ohashi et al, 
2000; Okamura et al, 2001; Smiley et al, 2001; Johnson et al, 2002; Termeer et al, 2002; 
Scheibner et al, 2006) with the net result of activation of monocytes via the nuclear factor  B 
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(NF B pathway).  TLR4, functionally linked to its co-receptor CD14 is overexpressed on the 
surface of monocytes at sites of atherosclerotic plaques (Ishikawa et al, 2008).  The number of 
circulating TLR4
+
CD14
+
 monocytes is twice as high in ACS patients compared to subjects 
with stable CAD (Ishikawa et al, 2008).  The density of CD14 on the monocyte surface is 
much higher in patients with MI (Methe et al, 2005).   
 
Overexpression of TLR4 by monocytes in circulation and on ruptured plaques following acute 
MI has been associated with high levels of inflammatory cytokines, IL-6 and tumour necrosis 
factor (TNF)  (Ishikawa et al, 2008).  Prolonged expression of these markers which amplify 
the inflammatory response after MI has been associated with the development of heart failure 
(Satoh et al, 2006).  The intracellular NF B signalling pathway is the principal mechanism for 
the monocyte inflammatory response at every stage of atherosclerosis, including plaque 
destabilisation (Ghosh & Karin, 2002).  The NF B pathway regulates expression of 
lipoxygenase (Zhao & Funk, 2004) and cyclo-oxygenase (Burleigh et al, 2002) involved in 
the atherogenic modification of LDL.  The NF B pathway also regulates the expression of 
adhesion molecules, including P-selectin, E-selectin, intracellular adhesion molecule (ICAM)-
1 and vascular cell adhesion molecule (VCAM)-1 (Collins et al, 2000; Cybulsky et al, 2001).  
Furthermore the NF B pathway regulates transcription of the extracellular matrix-degrading 
enzymes, MMP-9 and myeloperoxidase (Sugiyama et al, 2001; Tavora et al, 2009) in 
monocytes found in fibrous caps.  Indeed, overexpression of these cytokines is closely linked 
to plaque destabilisation and atherothrombosis. 
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1.3.3.2 Monocyte mobilisation 
Monocyte chemoattractant protein (MCP-1) is the most important chemokine implicated in 
the regulation of mobilisation, migration and infiltration of monocytes and macrophages. 
There is much evidence highlighting its contributions to vascular inflammation, thrombosis, 
plaque formation, progression and destabilisation.  MCP-1 accelerates atherosclerosis in 
apolipoprotein E (ApoE)-deficient mice (Aiello et al, 1999).  Production in vitro is 
upregulated by inflammatory cytokines (Morimoto et al, 2006) and by the interaction between 
monocytes and endothelium (Lukacs et al, 1995) where it is tethered to proteoglycans on the 
luminal surface of endothelial cells.  MCP-1 levels were found to be significantly elevated in 
samples taken distal to the culprit coronary artery lesion immediately after PPCI in STEMI 
patients compared to samples taken in patients with stable angina (Benson et al, 2013).  
Localised overexpression of MCP-1 by the vascular wall promotes macrophage infiltration 
and development of atherosclerosis (Namiki et al, 2002), neovascularization (Salcedo et al, 
2000) and expression of cytokines and chemokines (Morimoto et al, 2006; Park et al, 2005). 
Additionally, MCP-1 promotes smooth muscle proliferation and plaque neovascularisation, 
leading to rapid lesion progression and instability (Doyle & Caplice, 2007).  Also, MCP-1 
may enhance MMP expression and release by plaque monocytes leading to the plaque rupture 
(Robinson et al, 2002).   
 
Although the underlying mechanism is unknown, an elevated level of MCP-1 and associated 
monocytosis are linked with an adverse prognosis following MI (de Lemos et al, 2003; de 
Lemos et al, 2007).  This may reflect a greater extent of atherosclerotic disease, a 
prothrombotic state related to monocytosis which facilitates recurrent occlusive coronary 
events, or a more intense and persistent proinflammatory state with ongoing ‘vulnerable 
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plaques’. Indeed, MCP-1 gene polymorphisms were associated with up to 2-fold increased 
prevalence of MI in-patients in the Framingham Heart Study (McDermott et al, 2005).  
Excess MCP-1 may cause abnormal accelerated monocyte recruitment into the arterial wall 
and myocardium, and an imbalance in the pathological and reparative roles of monocytes. 
Importantly, MCP-1 level varies with sampling time after MI (Korybalska et al, 2010), which 
may be related to the sequential recruitment of different monocyte subsets following MI 
(Nahrendorf et al, 2007; Tsujioka et al, 2009) as described in section 1.2. 
 
Interestingly, in contrast to the post-MI setting, plasma MCP-1 levels appear to have little 
prognostic importance in patients with stable CAD (Haim et al, 2005).  This may be due to a 
disparity between local and systemic MCP-1 levels.  High local expression of MCP-1 on the 
luminal surface of endothelial cells in the vascular wall at the site of a plaque, which promotes 
localised monocyte migration, may not be associated with elevated MCP-1 level in 
circulation.  
 
Genetic deletion of MCP-1 (Gu et al, 1998) or its receptor (CCR2) (Boring et al, 1998) 
reduces development of atherosclerotic lesions in mice.  The technique of Ribonucleic acid 
interference (RNAi) directed towards silencing monocyte CCR2 improves healing and 
attenuates LV remodelling after MI in apoE-/- mice with a 41% reduction in LyC6
high
 
monocyte recruitment to infarcted myocardium (Majmudar et al, 2013).  Blockade of the 
MCP-1 pathway using gene therapy (Ni et al, 2001) or an inhibitory antibody (Lutgens et al, 
2005) attenuates initiation and progression of the atheroma (Inoue et al, 2002) in ApoE 
knockout hypercholesterolaemic mice.  Moreover, plaques develop a more stable phenotype, 
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with reduced macrophage content and more smooth muscle cells and collagen. These 
beneficial effects are likely due to a reduction in recruitment and activation of monocytes. 
 
HMG Co-enzyme A reductase inhibitor (‘Statin’) drugs decrease MCP-1 expression and 
neointimal inflammation in a rabbit model of atherosclerosis (Bustos et al, 1998) and reduce 
MCP-1 levels in circulating monocytes from hypercholesterolaemic humans (Rezaie-Majd et 
al, 2002; Lewandowski et al, 2008).  Via suppression of NFκB activity, the lipid-modifying 
drug ezetimibe reduces plaque MCP-1 expression, monocyte migration and hence plaque 
macrophage and lipid content in a rabbit model of atherosclerosis (Gómez-Garre et al, 2009). 
These mechanisms may promote plaque stabilisation, which could contribute to the beneficial 
effects of these drugs in human atherosclerotic disease. 
 
1.3.3.3 Monocyte adhesion and migration 
In addition to their systemic actions in the circulation, monocytes migrate into the vascular 
wall where they exert local effects contributing to plaque destabilisation.  The migration of 
different monocyte subsets to the endothelium depends on specific chemokines (Huo et al, 
2001; von Hundelshausen et al 2005) causing differential receptor upregulation and 
interaction with specific ligands.  In mice, Ly6C
high
 monocytes are dependent upon CCR2, 
CX3CR1 and CCR5 for effective recruitment, whereas recruitment of Ly6C
low
 monocytes is 
CCR5-dependent and not CCR2-dependent (Tacke et al 2007; Combadière et al, 2008).  The 
hypothesis that CCR2 specifically mediates the recruitment of ‘harmful’ monocytes but not 
‘reparative’ monocytes suggests that this may be a potential therapeutic target.  In humans, 
the CD14
+
CD16
-
 subset expresses CCR2 and migrates in response to MCP-1, whereas 
CD14
+
CD16
+ 
monocytes express CX3CR1 and respond to the chemokine CX3CL1 
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(fractalkine) (Weber et al, 2000; Ancuta et al, 2003; Nahrendorf et al, 2007).  This illustrates 
the ability of the endothelium to selectively recruit monocyte subsets dependent upon specific 
local chemokines expression.  Of note, polymorphisms of the CX3CR1 gene in humans are 
reported to be associated with a genetic predisposition to CAD.  Heterozygosity for CX3CR1-
V2491/T280M is associated with a marked reduction in risk of thrombotic coronary events 
(Moatti et al, 2001), possibly due to impaired ability of CX3CR1-expressing monocytes to 
invade the vascular wall and contribute to plaque development and destabilisation.   
 
Healthy arterial endothelium resists adhesion and recruitment of monocytes.  However, under 
the proinflammatory shift driven by cardiovascular risk factors including hypertension, 
dyslipidaemia, hyperglycaemia and cigarette smoking, the endothelium becomes activated 
(Falk, 2006) and upregulates expression of a variety of adhesion and chemoattractant 
molecules (Nelken et al, 1991; Couffinhal et al, 1993; Hansson et al, 2002).  The key 
molecules involved in monocyte adhesion include P-selectin, E-selectin, VCAM-1 and 
ICAM-1.  P-selectin and E-selectin mediate the tethering and rolling of circulating monocytes 
upon the endothelium (van der Wal et al, 1992; Weyrich et al, 1995).  The selectins stimulate 
monocyte expression of integrins including ICAM-1 and VCAM-1 (Weyrich et al, 1995) 
which are over-expressed locally at sites of atherosclerosis (Gerszten et al, 1998) and can be 
seen in high concentration in the circulation from the early stages of an ACS (Meisel et al, 
1998).  Aggregation with platelets and formation of MPAs leads to upregulation of monocyte 
receptors to adhesion molecules (Simon et al, 1993) which may facilitate monocyte migration 
to sites of inflammation and atherogenesis. The interaction between monocytes and the 
endothelium activates monocytes, which results in an inflammatory cytokine cascade.  This is 
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enhanced by high levels of CRP or heat shock proteins (HSP) seen in ACS (Satoh et al, 
2006). 
 
1.3.3.4 Monocyte proliferation 
The ongoing survival, proliferation and differentiation of monocytes in atherosclerotic 
plaques is dependent upon macrophage colony-stimulating factor (M-CSF), granulocyte-
macrophage colony-stimulating factor (GM-CSF) and MCP-1 (Irvine et al, 2009).  
Stimulation of macrophages by M-CSF increases expression of scavenger receptors 
(including scavenger receptors A and B, CD36, CD68 and CXCL16) which promote 
phagocytosis of modified lipoproteins and apoptotic cells.  The reduction in atherosclerosis in 
M-CSF deficient mice results from markedly decreased macrophage accumulation within 
plaques (Smith et al, 1995). 
 
1.3.4 Proteolytic enzyme pathways  
Systemic and local inflammation adversely influences collagen metabolism, the major 
component of the extracellular matrix that determines strength and stability within the fibrous 
cap.  Inflammation results in degradation and proteolytic destruction of the extracellular 
connective tissue matrix and inhibition of production of new collagen by smooth muscle cells.  
This degradation of collagen leads to reduced tensile strength, thinning and weakening of the 
fibrous cap, especially in the ‘shoulder’ regions which are subject to intense shear stress.  This 
ultimately leads to plaque destabilisation and rupture (Galis et al, 1994; Schwartz et al, 2007). 
 
Monocyte-derived macrophages were first implicated in plaque destabilisation by 
demonstration that their incubation with human aortic plaques was associated with an increase 
39 
 
in collagen breakdown (Shah et al, 1995).  Macrophages were subsequently acknowledged as 
the predominant source of a variety of synergistically-acting extracellular proteases 
responsible for plaque rupture.  One of the additional beneficial mechanisms of statin drugs 
may be the inhibition of macrophage activation and subsequent protease production (Bocan, 
2002). 
 
1.3.4.1 Matrix metalloproteinases 
The major enzymes responsible for active breakdown of the collagen-rich connective tissue 
matrix are the MMPs (Newby, 2008).  In humans they comprise a family of 23 genetically-
related proteins classified according to their structure and substrate.  MMPs are produced as 
pro-enzymes requiring activation.  Monocytes within atherosclerotic plaques and in the 
circulation are a major source of MMPs as well as molecules regulating their activation and 
inhibition, emphasising the key role of monocytes as mediators of plaque integrity (Table 
1.4).  Tissue homeostasis is maintained via a precarious balance between beneficial and 
deleterious effects of MMPs.  Abnormal activity of MMPs in inflammation overwhelms the 
inhibitory effects of tissue inhibitors of metalloproteinases (TIMPs), which tips the balance 
towards plaque instability.  Hence, TIMP gene transfer or TIMP knock-out may alternately 
promote plaque stability or instability (Johnson et al, 2006).  Importantly, both the absolute 
level of MMP content within a plaque and its activation status are crucial in determining 
whether the net outcome is beneficial or destructive.  For example, physiological levels of 
MMP-9 may promote plaque stability by promoting smooth muscle migration and fibrous cap 
formation (Johnson et al, 2005).  Conversely, higher levels of activated MMP-9 may promote 
plaque inflammation, matrix destruction and hence instability and rupture (Luttun et al, 2004).  
Of note, circulating monocytes in humans with MI significantly overexpress MMP-2 and 
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MMP-9 genes even prior to their migration to the tissues.  MMP-9 overexpression by 
macrophages induces plaque instability and rupture in Apo-E deficient mice (Gough et al, 
2006).  Conversely, MMP-9 knockout mice are less likely to suffer myocardial rupture 
following induced MI (Heymans et al, 1999), suggesting the presence of attenuated 
myocardial damage. 
 
MMP synthesis by monocytes occurs in response to a complex interwoven network of stimuli.  
Catecholamines were shown to potentiate LPS-induced synthesis of MMP-1 and MMP-9 in 
circulating monocytes and macrophages (Speidl et al, 2004).  Oxidised LDL also stimulates 
monocyte expression of the urokinase receptor and consequent urokinase-mediated MMP-9 
generation (Ganné et al, 2000).  Increased monocyte expression of extracellular MMP inducer 
(EMMPI) and cyclooxygenase-2 which enhances the production of MMP-1 and MMP-9 has 
also been demonstrated in acute MI (Schmidt et al, 2006).  High expression of TNF  and 
reactive oxygen species (ROS) by monocytes further promotes MMP production by other cell 
lines within the vascular wall (Poitevin et al, 2008).  Moreover, human monocytes stimulated 
with TNF-  release angiotensin II, which additionally mediates an increase in MMP-1 
synthesis (Kim et al, 2005). 
 
As MMPs produced by monocytes appear to be central to plaque destabilisation, this pathway 
has been investigated as a therapeutic target to reduce the risk of plaque rupture.  For 
example, reduced plaque expression of MMP-9 and MMP-13 by a gene transfer technique 
preserves interstitial collagen (Herman et al, 2001) which is considered to be a critical 
determinant of plaque stability.  Inhibition of MMP-2 with drugs or gene deletion protects 
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against cardiac rupture in mice by reducing matrix degradation and impairing the removal of 
necrotic myocardium by macrophages (Matsumura et al, 2005). 
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Table 1.4  Effects of manipulation of Tissue Inhibitors of Metalloproteinases or Matrix Metalloproteinases in atherosclerosis 
 
TIMP or MMP Setting Mechanism Observation Reference 
TIMP-1 ApoE null 
mice 
overexpression by 
gene therapy 
Reduces atherosclerotic 
lesions 
Rouis et al, 1999 
TIMP-2 ApoE knock-
out mouse  
Inhibition by gene 
therapy 
Reduces plaque 
progression 
Reduces plaque instability 
Johnson et al, 2006 
Humans with 
ACS 
Gene expression 
evaluation 
Monocytes in ACS 
overexpress TIMP-2 
Kułach et al, 2010 
MMP-2 Humans with 
ACS 
Gene expression 
evaluation 
Monocytes in ACS 
overexpress MMP-2 
Standard ACS treatment 
down-regulates MMP-2 
gene 
Kułach et al, 2010 
MMP-3 ApoE/MMP 
knock-out 
mouse 
Reduced 
expression 
Limits plaque growth 
Promotes stable plaque 
phenotype 
Johnson et al, 2005 
MMP-7 ApoE/MMP 
knock-out 
mouse 
Reduced 
expression 
No effect on plaque 
growth or stability 
Johnson et al, 2005 
MMP-9 ApoE null 
mice
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Overexpression 
by gene therapy 
Promotes plaque 
instability 
Gough et al, 2006 
Humans with 
ACS 
Gene expression 
evaluation 
Monocytes in ACS 
overexpress MMP-9 
Kułach et al, 2010 
ApoE/MMP 
knock-out 
mouse 
Reduced 
expression 
Limits plaque growth 
Promotes stable plaque 
phenotype 
Johnson et al, 2005 
ApoE/MMP 
knock-out 
MMP-9 
deficiency 
Reduced atherosclerotic 
burden 
Luttun et al, 2004 
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mouse Reduced macrophage 
infiltration 
Reduced collagen 
deposition 
MMP-12 ApoE/MMP 
knock-out 
mouse 
Reduced 
expression 
Promotes lesion expansion 
Promotes plaque 
destabilisation 
Johnson et al, 2005 
ApoE/MMP 
knock-out 
mouse 
MMP-12 
deficiency 
No effect on lesion growth Luttun et al, 2004 
 
TIMP: Tissue Inhibitor of Metalloproteinase; MMP: Matrix Metalloproteinase; ApoE: Apolipoprotein E; ACS: Acute Coronary Syndrome 
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1.3.4.2 Cathepsins 
The cathepsin enzymes of the cysteine protease family have emerged as another key 
component involved in the activation of the innate and adaptive immune systems. 
Additionally, through their involvement in breakdown of the extracellular matrix and 
overexpression in unstable plaques, they have been shown to contribute to atherogenesis and 
its complications.  Macrophages in human plaques produce cathepsins F, K, L, S and V, 
which have proteolytic activity, degrade collagen and elastin (Sukhova et al, 1998; Yasuda et 
al, 2004; Li et al, 2009; Barascuket al, 2010) and modify LDL (Oörni et al, 2004).  These 
processes are linked with macrophage apoptosis, necrosis of the plaque core and cap rupture 
supporting their role in plaque destabilisation. 
 
Under normal physiological conditions, human arteries express cystatin C, an endogenous 
inhibitor of cathepsins, whereas atherosclerotic plaques express reduced levels of the enzyme 
(Liu et al, 2004).  Interestingly, the genes encoding several of the cathepsins are expressed in 
adipose tissue and their deregulation is increased with elevated body mass index (Lafarge et 
al, 2010).  This may represent one of the mechanisms linking obesity with cardiovascular risk. 
 
The effects of reduced levels of cathepsins, either through deficiency or blockade further 
demonstrate their importance in atherosclerotic plaque progression and stability.  Cathepsin 
deficiency in a mouse model of atherosclerosis reduces collagen and elastin degradation, 
macrophage accumulation and overall plaque burden (Sukhova et al, 2003; Lutgens et al, 
2006, Kitamoto et al; 2007).  An inhibitor of cathepsin S inhibits atherosclerotic plaque 
burden in Apo-E knockout mice (Samokhin et al, 2010).  This data is summarised in table 1.5. 
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Table 1.5  Effects of manipulation of Cathepsins in atherosclerosis  
 
Cathepsin Setting Mechanism Observation Reference 
S LDL-R deficient mouse Cathepsin S deficiency Smaller plaques, less 
intimal thickening, 
reduced adverse plaque 
content 
Sukhova et al, 2003 
L LDL-R knock-out mouse Cathepsin L deficiency 
 
Reduced atherosclerotic 
burden 
Reduced plaque lipid 
content 
Reduced matrix 
breakdown 
Kitamoto et al, 2007 
S ApoE deficient mouse Renin-angiotensin-
aldosterone pathway 
blockade with 
Olmesartan 
Reduced plaque 
macrophage content 
Halted plaque 
progression 
Sasaki et al, 2010 
S ApoE knock-out mouse Drug inhibitor of 
cathepsin S 
Reduced plaque burden Samokhin et al, 2010 
K ApoE knock-out mice Disrupted cathepsin K 
gene 
Limits plaque 
progression 
41.8% reduced plaque 
area 
Plaque fibrosis 
Reduced macrophage 
foam cell formation 
Lutgens et al, 2006 
LDL-R: Low Density Lipoprotein Receptor; ApoE: Apolipoprotein 
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1.3.4.3 ADAM and ADAMTS 
More recently, the ‘a disintegrin and metalloprotease’ (ADAM) and ‘ADAM with 
thrombospondin motifs’ (ADAMTS) family of proteases have been identified as important 
enzymes in extracellular matrix protein turnover (Salter et al, 2010).  They have much greater 
substrate specificity than MMPs.  Their altered regulation has been implicated in a variety of 
disorders including cancer, arthritis and atherosclerosis (Jönsson-Rylander et al, 2005).  
Although data regarding their role in plaque pathophysiology is currently limited, they have 
been found to be released by plaque macrophages, and promote matrix and fibrous cap 
remodelling which predisposes to plaque rupture (Wågsäter et al, 2008). 
 
1.3.4.4 CD40 ligand pathway 
The MCP-1/CCR2 and CD40/CD40 ligand (CD40L) systems appear to be interlinked in 
atherogenesis. The immune response-mediating factor CD40L and its receptor CD40 have 
been implicated in the initiation of atheroma formation and plaque progression and 
destabilisation (Schönbeck & Libby, 2001).  Stimulation of the CD40 induces production of 
inflammatory cytokines, chemokines, MMPs and tissue factor by macrophages which impair 
the collagen structure within the plaque and promote its destabilisation and rupture (Mach et 
al, 1998).  Blockade of MCP-1 was shown to reduce immunohistochemically-detectable 
CD40 and CD40L expression within plaques of hypercholesterolaemic ApoE-knockout mice 
(Inoue, 2002). 
 
1.3.4.5 Neopterin 
Neopterin is a pteridine derivative produced via the guanosine triphosphate pathway.  It is 
produced by activated macrophages upon stimulation by IFNγ released by T-lymphocytes, 
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and may have a role as a pro-oxidant.  Neopterin is a marker of activated 
monocytes/macrophages, and serum levels are raised in ACS (Sugioka et al, 2010).  More 
recently, immunohistochemical techniques demonstrated significantly higher content of 
neopterin-rich macrophages in coronary atherectomy samples of unstable plaques in humans 
following ACS.  This suggests that neopterin content correlates with plaque instability 
(Adachi et al, 2007).    
 
1.3.5 Monocytes and angiogenesis 
Monocytes play pivotal roles in the processes of angiogenesis and intimal and plaque 
neovascularisation, which are further important mechanisms related to plaque progression and 
destabilisation (Ribatti et al, 2008).  In vitro models of angiogenesis and gene expression 
studies in humans (Zawada et al, 2011) and the ability of TIE-2 expressing monocytes in 
mouse to induce a capillary network (De Palma et al, 2005) suggest a prominent role for the 
Mon2/intermediate subset in this process.  As a plaque develops, the central core becomes 
hypoxic due to impaired diffusion of oxygen from the arterial lumen through the thickened 
intima.  Upregulated monocyte expression of pro-angiogenic factors including VEGF and 
fibroblast growth factor (FGF)-2 (Murdoch et al, 2007) stimulates proliferation of endothelial 
cells, as well as mobilisation and homing of bone marrow-derived endothelial progenitors 
(Lambert et al, 2008).  This promotes neovascularisation of the plaque from the adjacent 
adventitia.  Hence, the angiogenic process sets up a vicious cycle whereby new vessels 
produced under the influence of monocytes concurrently provide an additional route for their 
enhanced entry into plaques.   
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Thus, although the initial effect of monocytes is beneficial, aiming to improve tissue 
perfusion, this therapeutic effect may become pathological. Progressive hypoxia and 
enhanced plaque vascularity promotes ongoing accumulation of inflammatory cells including 
monocytes via the neo-vessels, and the fragile network of neovessels predisposes to intra-
plaque haemorrhage (Virmani et al, 2005).  These processes contribute to atheroma 
progression and ultimately plaque destabilisation. 
 
As vulnerable plaques contain increased number of vasa-vasorum, inhibition of this process of 
neovascularisation may represent a potential therapeutic target aiming to reduce the risk of 
plaque rupture.  For example, angiostatin (an anti-angiogenic molecule) inhibits intraplaque 
angiogenesis and thus reduces accumulation of intraplaque monocytes and macrophages, 
which appears to promote plaque stability (Moulton et al, 2003).  However more data is 
needed to explore this concept. 
 
1.3.6 Monocytes and apoptosis 
The LPS receptor CD14 mediates recognition and phagocytosis of apoptotic cells by 
monocytes (Devitt et al, 1998).  This is inherently a biologically protective mechanism, which 
may attenuate atherosclerosis in early plaques.  However, it also perpetuates atherogenesis via 
the inflammatory reactions it causes.  Incomplete apoptotic cell clearance in mature plaques 
may lead to an enhanced proinflammatory response and further apoptotic signals for 
endothelial cells, smooth muscle cells and leukocytes within atherosclerotic plaques (Tabas, 
2005), leading to plaque destabilisation and rupture. 
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1.3.7 Conclusions 
Cells of the monocyte-macrophage lineage are key contributors to the complex process of 
initiation and propagation of atherosclerotic plaques.  They are clearly implicated in plaque 
destabilisation via a number of complex inter-linked mechanisms.  Importantly, monocytes 
may be involved in the pathogenesis of atherosclerosis, including plaque destabilisation 
locally at the site of atheroma, and also whilst in circulation. 
 
Plaque destabilisation and rupture is clearly an active process rather than a passive 
phenomenon.  Therefore, modulation of monocytes and the pathways via which they are 
activated and exert their effects may be viable therapeutic targets in the treatment of 
atherosclerosis and the prevention of plaque progression and destabilisation.  Heterogeneity of 
human monocytes may allow for specific targeting of pathological pathways whilst sparing 
beneficial roles, thus avoiding the adverse effects associated with indiscriminate monocyte 
inhibition.  Further functional characterisation of the specific human monocyte subsets in 
atherosclerosis and their contributions to disease progression and repair is of fundamental 
importance in this regard. 
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CHAPTER 2 
 
AIMS AND HYPOTHESES 
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The overall aim of this thesis was to provide a detailed phenotypic comparison of differences 
between the three human monocyte subsets in the setting of CAD and MI, which has not been 
done before.  Particular emphasis was placed on the ‘Mon2’/’Intermediate’ and 
‘Mon3’/’Nonclassical’ subsets which have hitherto been grouped together as a single 
population, and hence little is known about their individual characteristics in these settings.  
Based on our previous observations demonstrating marked differences between subsets in 
healthy subjects, I hypothesised that the Mon2 subset exhibits distinct changes compared to 
Mon1 and Mon3. 
 
Emphasis was placed on examining expression of monocyte surface markers associated with 
monocyte activation, inflammation, repair and angiogenesis, and also aggregates with 
platelets.  I also sought to explore associations between monocyte subset parameters and 
cytokines, markers of fibrinolysis, MCP-1 and residual LV ejection fraction (EF) in the 
recovery phase following STEMI which is the most important determinant of long-term 
prognosis. 
 
In chapter 4, the focus was placed on investigating differences in expression of surface 
receptors implicated in inflammatory and reparative responses in CAD by comparing with 
healthy subjects.  Additionally, the functional status of monocyte subsets was investigated via 
measurement of intracellular inhibitory κB kinase (IKK) (a marker of activation of the NFκB 
pathway).  Monocyte interactions with platelets were examined, and associations between 
monocyte characteristics and plasma markers of inflammation and fibrinolysis were explored. 
As monocyte subsets have been proposed to play different roles in the pathogenesis of CAD, I 
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hypothesised that there are significant differences in these subset characteristics between 
healthy subjects and those with CAD. 
 
In chapter 5, my aim was to investigate the dynamic changes of the three human monocyte 
subsets and their associations with MPAs in STEMI, from the acute to the recovery phase.  I 
hypothesised that the Mon2 subset exhibits distinct dynamic changes following STEMI 
compared to Mon1 and Mon3, and that these changes differ from healthy subjects or those 
with stable CAD.  I also hypothesised that these changes are related to the degree of 
myocardial damage and to changes in inflammatory cytokines and MCP-1.  Finally I 
hypothesised that the dynamic changes in monocyte subsets acutely after STEMI are related 
to LVEF in the recovery phase. 
 
My objective in chapter 6 was to assess numbers of TLR4 expressing monocytes in each of 
the three human subsets in STEMI and NSTEMI, their expression of TLR4, and relations to 
markers of monocyte pro-inflammatory activation, myocardial damage, inflammatory 
cytokines and LVEF in the recovery phase.  I hypothesized that there are distinct differences 
in TLR4 parameters between patients with MI compared with CAD controls, and that there 
are dynamic changes between the acute phase of MI and the recovery phase.   
 
In chapter 7, my aim was to focus on the associations of monocyte subsets with surface 
markers implicated in reparative processes following STEMI.  The numbers of CXCR4+, 
CD34+ and KDR+ cells attributed to the three human monocyte subsets were assessed, along 
with monocyte expression of CD204 and CD163.  Their associations with biological and 
physiological parameters related to myocardial damage and recovery following MI were 
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assessed.  I hypothesised that the number of CXCR4+ monocytes, CD34+/KDR+ cells and 
expression of monocyte scavenger receptors is changed in patients following STEMI. 
Additionally, I hypothesised that these changes are attributable to specific monocyte subsets 
and are associated with biomarkers of inflammation and LVEF in the recovery phase after 
STEMI. 
 
My aim in chapter 8 was to examine expression of ICAM-1r, VCAM-1r and IL-6 receptor 
(IL6r) on individual subsets in patients with MI and to assess dynamics of monocyte 
expression of these receptors during the acute and recovery phases after STEMI which has not 
been described.  I also explored possible associations between these receptors and markers of 
systemic inflammation, myocardial damage and cardiac functional recovery following 
STEMI.  Having observed significant differences in expression of these receptors between the 
three monocyte subsets in healthy humans, I hypothesised that there are marked differences in 
their expression in the setting of MI. 
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CHAPTER 3 
 
METHODS AND MATERIALS 
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3.1 SUBJECT SELECTION 
 
3.1.1 ST elevation and non-ST elevation myocardial infarction patients 
Patients with STEMI admitted to Sandwell and West Birmingham Hospitals (SWBH) NHS 
Trust meeting the study criteria (see 3.1.1.1 and 3.1.3) were recruited between November 
2009 and November 2010.  Patients were recruited from both the City Hospital and Sandwell 
General Hospital sites within the Trust.  The cardiology Consultants within the Trust work on 
both sites, including undertaking PPCI for STEMI.  All operators adhere to the Trust policy 
on management of patients with STEMI, and hence there is little variation in practice and 
management of patients with STEMI. 
 
Patients with NSTEMI meeting the study criteria (see 3.1.1.1 and 3.1.3) were recruited from 
SWBH and Heart of England NHS Foundation Trust between November 2009 and May 2011 
(Birmingham Heartlands Hospital, Solihull Hospital and Good Hope Hospital). 
 
3.1.1.1 Inclusion criteria 
STEMI was diagnosed according to the ESC definition; patients presenting with symptoms of 
cardiac ischaemia with persistent ST-segment elevation or presumed new left bundle branch 
block (LBBB) on ECG (Van de Verf et al, 2008). 
 
NSTEMI was diagnosed according to the ESC definition; patients presenting with symptoms 
of cardiac ischaemia, new ECG changes compatible with cardiac ischaemia other than 
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persistent ST-segment elevation or presumed new LBBB, and dynamic changes in biomarkers 
of myocyte necrosis (troponins) (Bassand et al, 2007).  
 
3.1.1.2 Time points 
The counts of the 3 monocyte subsets and MPAs were measured at 4 time points following 
STEMI: day 1 (during the first 24 hours after PPCI), day 3, day 7 and day 30. A proportion of 
patients did not complete follow-up due to withdrawal of consent or death.  
 
3.1.2 Control groups 
Two age- and sex-matched control groups were studied: 
 
3.1.2.1 Stable coronary artery disease 
‘Disease controls’ were recruited, with angiographically proven CAD and no episodes of 
hospital admissions or instability for ≥3 months.  Additionally, none of the CAD patients had 
a history of prior STEMI, LV systolic impairment or heart failure. Patients with stable CAD 
were identified from out-patient clinics and cardiac rehabilitation services at SWBH.  The 
‘disease control’ group was chosen in order to allow comparison with the STEMI group and 
examine changes in study parameters related to the onset of and recovery from MI on a 
background of CAD.  
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3.1.2.2 Healthy controls 
Healthy subjects were identified as people with no evidence of cardiovascular disease on 
history taking and routine clinical examination, with no disqualifying exclusion criteria (see 
3.1.3).  The healthy control group was chosen in order to allow comparison with the ‘disease 
control’ group and examine differences in study parameters related to the presence of stable 
CAD and its associated risk factors.  
 
3.1.3 Exclusion criteria 
Exclusion criteria comprised factors that could affect monocyte count (infectious disease, 
inflammatory disorders and their treatment (including steroids and non-steroidal anti-
inflammatory drugs), cancer, haemodynamically significant valvular heart disease, atrial 
fibrillation, renal failure and hormone replacement therapy.  Additionally, no STEMI patients 
had a history of previous STEMI, LV systolic impairment or heart failure.  All subjects were 
asked to refrain from extreme physical exertion for at least 1 hour prior to blood sampling 
(Shantsila et al, 2012) (3.3.2). 
 
3.1.4 Patient management 
This study was purely observational and there were no alterations in patient management.  All 
study patients received standard treatment according to contemporary guidelines (Van de Verf 
et al, 2008; Bassand et al 2007).  All patients with STEMI were treated with PPCI.  The 
SWBH NHS Trust is very experienced in the management of patients with STEMI and has 
been undertaking PPCI for STEMI since 2005.  The Trust’s median ‘door-to-balloon’ (DTB) 
time which indicates the time between admission to the hospital accident and emergency 
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department and restoration of coronary artery blood flow was 68 minutes (IQR 50-91 
minutes) at the time of this study  (Kong et al, 2009).  The national standard median DTB 
time is ≤90 minutes. 
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3.2 FLOW CYTOMETRY 
 
3.2.1 Equipment & software 
Flow cytometry was undertaken using the BD FACSCalibur flow cytometer (Becton 
Dickinson, Oxford, UK [BD]).  VenturiOne, Version 3.1 software (Applied Cytometry, 
Sheffield, UK) was used for data analysis. 
 
3.2.2 Absolute count of monocytes, monocyte subsets and monocyte platelet aggregates 
We have published a paper utilising the flow cytometry protocols and methodology used in 
this thesis to further characterize and describe the three monocyte subsets in healthy humans 
(Shantsila et al, 2011) identified using contemporary nomenclature (Ziegler-Heitbrock et al, 
2010. 
 
3.2.2.1 Monocytes and monocyte subsets 
Mouse anti-human monoclonal fluorochrome-conjugated antibodies anti-CD16-Alexa Fluor 
488 (clone DJ130c, AbD Serotec, Oxford, UK), anti-CD14-PE (clone MфP9, BD), anti-
CD42a-PerCP (clone Beb1, BD) and anti-CCR2-APC (clone 48607, R&D) were mixed with 
50μl of ethylene diamine tetra-acetic acid (EDTA)-anticoagulated whole blood in TruCount 
tubes (BD) which contain a precise number of fluorescent count beads.  Following incubation 
for 15 minutes, red blood cells were lysed using 450μl of lysing solution® (BD) for 15 
minutes.  Subsequently the sample was diluted in 1.5 ml of phosphate buffered saline (PBS) 
and immediately analysed by flow cytometry. 
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Definitions of CD14, CD16 and CCR2 positivity were made using appropriate isotype 
controls (Ziegler-Heitbrock et al, 2010).  Monocyte subsets were defined as CD14++CD16-
CCR2+ (‘Mon1’), CD14++CD16+CCR2+ (‘Mon2’) and CD14+CD16++CCR2- (‘Mon3’) 
(Shantsila et al, 2011). 
 
The gating strategies employed to discriminate monocytes into the three subsets are illustrated 
in figure 3.1.  Monocytes were firstly selected by a gating strategies based on forward scatter 
versus side scatter (figure 3.1, panel a).  Granulocytes were excluded by CD14 expression 
versus side scatter (figure 3.1, panel b).  CD16+CD14- natural killer lymphocytes were 
excluded from CD16+ monocytes based on ungated CD14 versus CD16 expression (figure 
3.1, panel, c).  Mon1 are identified as CD14++CD16- cells (figure 3.1, panel e).  The CD16+ 
cells (figure 3.1, panel e) are separated into Mon 2 and Mon 3 based on their expression of 
CCR2 (figure 3.1, panel g). 
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Figure 3.1 Gating strategies and definition of the three monocyte subsets 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The monocyte region is selected based on the forward scatter (FSC) versus side scatter (SSC) 
plot (a).  Exclusion of granulocytes by CD14 expression versus SSC (b).  Exclusion of 
CD16+CD14- natural killer lymphocytes from CD16+ monocytes (c).  Monocytes (e) are 
defined as cells that correspond to the gate ‘Monos’ in panel (a) and ‘Mon’ in panel (b) and 
do not correspond to natural killer lymphocytes in panel (c).  In panel (e) Mon 1 are identified 
as CD14++CD16- cells (green box).  CD14+CD16+ cells (e, blue box) are discriminated 
based on their expression of CCR2 (g) into Mon 2 (CCR2+, red box) and Mon 3 (CCR2-, 
yellow box).  Panel (h) demonstrates CCR2 expression by the Mon1 subset.  Panels (d) and 
(f) demonstrate the location of Mon3 (d, yellow box) and Mon2 (f, red box) respectively on 
the CD14 versus CD16 plot. 
 
  
a 
b c 
d 
e f 
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The absolute count of monocytes (cells/μl) was obtained by calculating the total number of 
monocytes proportional to the number of count beads in the TruCount tube according to the 
manufacturer’s recommendations.  The count of each subset and their relative proportions of 
the absolute monocyte count were defined according to the gating strategy described above in 
3.2.2.1.   
 
3.2.2.2 Monocyte platelet aggregates 
MPAs were defined as events positive to both the monocyte markers described in 3.2.2.1 and 
the platelet marker CD42a (glycoprotein IX).  The total MPA count and MPA count 
associated with each monocyte subset was calculated based on the number of count beads as 
described in 3.2.2.1.  Thus, MPAs associated with Mon1 are CD14++CD16-CCR2+CD42a+, 
MPAs associated with Mon 2 are CD14++CD16+CCR2+CD42a+ and MPAs associated with 
Mon 3 are CD14+CD16++CCR2-CD42a+.   
 
3.2.3 Expression of surface antigens on monocyte subsets 
For the analysis of expression of surface antigens (summarised in table 3.1) by monocytes and 
the three subsets, 100μl of whole blood was incubated with mouse anti-human monoclonal 
fluorochrome-conjugated antibodies for 15 minutes in the dark.  Subsequently red blood cells 
were lysed with 2ml of BD lysing solution® for 10 min, followed by washing in PBS and 
immediate analysis by flow cytometry.  The three monocyte subsets were defined as 
CD14++CD16– monocytes (‘Mon1’), CD14++CD16+ monocytes (‘Mon2’) and 
CD14+CD16++ monocytes (‘Mon3’) in accordance with contemporary guidelines (Ziegler-
Heitbrock et al, 2010) using anti-CD16-Alexa Fluor 488 (clone DJ130c, AbDSerotec, Oxford, 
UK) and anti-CD14-PerCP-Cy5.5 (clone M5E2, BD) antibodies. 
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PE-conjugated antibodies were used against TLR4 (clone 285219, R&D), ICAM-1 receptor 
(integrin β2/CD18) (clone 212701, R&D Systems Europe Ltd, Abingdon, UK [R&D]), 
CXCR4 (SDF-1 receptor) (clone 12G5, R&D), CD34 (clone 8G12, BD) and VEGF receptor 1 
(clone 49560, R&D).  APC-conjugated antibodies were used against IL6r (clone 17506, 
R&D), VCAM-1 receptor (integrin α4/CD49d) (clone 7.2R, R&D), CD163 (clone 215927, 
R&D), KDR (VEGF receptor 2) (clone 89106, R&D) and CD204 (clone 351520, R&D). 
Monoclonal antibodies for CD204 were conjugated to APC using the LLAPC-XL conjugation 
kit [Innova Biosciences, UK]. 
 
Table 3.1 Summary of monocyte markers, fluorochromes and antibodies 
Surface antigen Fluorochrome Antibody 
TLR4 PE clone 285219, R&D 
ICAM-1 receptor 
(integrin β2/CD18)  
PE clone 212701, R&D 
CXCR4 
(SDF-1 receptor) 
PE clone 12G5, R&D 
CD34 PE clone 8G12, BD 
VEGF receptor 1 PE clone 49560, R&D 
IL6 receptor APC clone 17506, R&D 
VCAM-1 receptor 
(integrin α4/CD49d) 
APC clone 7.2R, R&D 
CD163 APC clone 215927, R&D 
KDR 
(VEGF receptor 2 
APC clone 89106, R&D 
CD204 APC clone 351520, R&D 
conjugated to APC using LLAPC-XL 
conjugation kit [Innova Biosciences, UK] 
 
 
3.2.4 Assessment of activation of the nuclear factor κ B pathway 
Stimulation of monocyte surface receptors (including TLRs and CD14) by a variety of stimuli 
leads to activation of the NFκB pathway.  Specific inhibitory κB kinases promote 
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phosphorylation and disintegration of IκBs.  Subsequently cytoplasmic NFκB is translocated 
into the nucleus where it binds to the promoter region of various genes which activates their 
transcription.  These genes include cytokines (including TNF-α and IL-1β), cyclooxygenase-
2, inducible nitric oxide (NO)-synthase and MMPs (Yamamoto et al, 2004; Hayden et al 
2004). 
 
The IKK complex consists of two catalytic subunits, IKKα and IKKβ.  IKKβ is 20-fold more 
active than IKKα, and plays an essential role in activation of the NFκB pathway activation 
mediated by lipopolysaccharides, TNFα, or IL-1 (Hu et al, 1999; Mercurio et al, 1997).  As 
the activated form of NFκB (translocated into nuclei) is identical to the resting cytoplasmic 
form, measurement of total NFκB level within a cell is not informative.  The assessment of 
NFκB in isolated nuclei is problematic as it necessitates multistep procedures including cell 
isolation and preparation which are thought to contribute to artificial activation (Ritchie, 
1998).  In this study, direct measurement of intracellular levels of IKKβ was used as a 
surrogate cytoplasmic marker of activation of the NFκB pathway, thereby aiming to assess 
activation of monocytes which has been associated with changes in phenotype and function. 
 
Intracellular level of IKKβ in monocytes was measured from whole blood.  100μl of blood 
was incubated with monoclonal mouse anti-human antibodies against CD16-Alexa Fluor 488 
(clone DJ130c, AbD Serotec, Oxford, UK) and CD14-PerCP-Cy5.5 (clone M5E2, BD) for 15 
minutes.  Red blood cells were then lysed with 2ml of BD PharmLyse™ for 10 minutes 
followed by washing in staining buffer. The resulting pellet was resuspended in 
Fixation/Permeabilization solution (BD) for 20 minutes.  Following centrifugation the pellet 
was resuspended in 2 ml of BD Perm/Wash™ buffer for 10 minutes. After further 
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centrifugation, the pellet was incubated for 30 minutes with monoclonal mouse anti-human 
APC-conjugated antibodies (LL-APC-XL conjugation kit [Innova Biosciences, UK]) against 
IKKβ (clone 10A9B6, Abcam, Cambridge, UK), washed and resuspended in 200μl of 2% 
PBS/2% paraformaldehyde solution (PharmFix, BD) and immediately analysed by flow 
cytometry.  
 
3.2.5 Plasma markers 
Plasma levels of IL-1β, IL-6, IL-10 and MCP-1 were measured by cytometric bead array 
technology.  The BD FACSCalibur flow cytometer was used for data acquisition, with FCAP 
Array v2.0.2 software (Burnsville, Minnesota, USA) for data analysis.  Commercially 
available reagent sets, Human IL-1β Flex Set, Human IL-6 Flex Set, Human IL-10 Flex Set 
and Human MCP-1 Flex Set (all from BD) were used according to the manufacturer’s 
recommendations. 
 
3.2.6 Reproducibility of assay results 
Intra-assay variability is a measure of the ability of an assay to give the same result when the 
same sample is tested multiple times.  Intra-assay reproducibility was assessed during 
development of the Standard Operating Procedure (SOP) for studying monocytes in the 
preparatory stages for this project.  An SOP is a fundamental requirement for all laboratory 
investigations in the Atherosclerosis Thrombosis and Vascular Biology Unit of the University 
Of Birmingham Department Of Medicine at City Hospital, Birmingham where this project 
was conducted.  All SOPs must be evaluated and ‘signed off’ by the department’s Consultant 
Clinical Scientist, Dr Andrew Blann, before they may be used in research projects.  The SOP 
for this project is SOP 201 “Monocyte subsets, monocyte platelet aggregates by flow 
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cytometry” (see appendix 3).  This SOP was developed by Dr Eduard Shantsila with Dr Luke 
Tapp and Dr Ben Wrigley. 
The intra-assay reproducibility of the methods was assessed on six samples of blood; one set 
of three from a healthy male (subject A) and second set of three from a woman with a history 
of renal and ovarian cancer (subject B) (table 3.2). 
 
Table 3.2  Mean intra-assay coefficients of variation (%) for monocyte subset and monocyte 
platelet aggregate. 
 
     Subject A Subject B Mean 
Total Mon 0.6 0.4 0.5 
Mon1 0.9 1.4 1.15 
Mon2 10.6 9.9 10.25 
Mon3 3.9 4.7 4.3 
Total MPA 3.2 4.5 3.85 
MPA1 3.4 5.2 4.3 
MPA2 14.1 9.7 11.9 
MPA3 8.2 6.8 7.5 
Median intra assay coefficient of variation 4.6% 
Total Mon, total monocyte count; Mon1, CD14++CD16-CCR2+ monocytes; Mon2, 
CD14++CD16+CCR2+ monocytes; Mon3, CD14+CD16++CCR2- monocytes; MPA, 
monocyte platelet aggregates; Total MPA, total MPA count; MPA1, MPAs associated with 
Mon1; MPA2, MPAs associated with Mon2; MPA3, MPAS associated with Mon 3; CV, 
coefficient of variability. 
 
Similarly, assessments of intra-assay reproducibility were made for an example monocyte 
surface marker CCR2 (median CV 4.1%) and IKKβ (median CV 5.3%).  The reproducibility 
of each surface marker used in the study was not assessed as the core protocol is identical 
other than different antibodies being used in each tube.  
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The CVs for the assays used in this study are low.  This suggests that the assays are sound and 
that differences measured subsequently in my study are genuine and due to real changes in the 
parameters measured in the disease settings evaluated. 
 
The acknowledgement that reproducibility is limited by measurement error along with 
extrinsic variables including diurnal variation and exercise status should be considered a 
limitation of this study.     
 
My ability to perform the assays required for this study was assessed and approved by Dr 
Andrew Blann prior to commencing subject recruitment.  The other operators involved in 
processing some laboratory samples in this study (Dr Ben Wrigley and Dr Burack Pamukcu) 
were assessed and approved in a similar manner.    
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3.3 BLOOD SAMPLING AND STORAGE 
 
As part of the preparatory work for this thesis, I undertook experiments to determine the 
optimal conditions under which blood samples should be collected, stored and processed.  I 
hypothesized that total monocyte count, monocyte subset count and MPAs would be affected 
by physical exercise and that there would be diurnal variation in their numbers.  I also 
hypothesized that monocyte and MPA parameters would be affected by the time delay 
between taking the sample and processing.  
 
3.3.1 Effect of exercise 
The effects of a Bruce protocol exercise test was assessed on 12 healthy volunteers (age 35.3 
± 7.6 years, 8 male) with no evidence of cardiovascular disease.  Venous blood samples were 
taken pre- and post exercise.  Total monocyte count and Mon1 increased significantly 15 
minutes after ceasing exercise, followed by a significant reduction by 1 hour.  Mon2 and 
Mon3 followed similar dynamic changes, but only the reduction in Mon3 count at 1 hour post 
exercise reached statistical significance.  The proportions of the overall monocyte population 
contributed to by each subset were not affected by exercise.  The total MPA count and MPAs 
associated with Mon1 decreased significantly 15 minutes post exercise, with a further 
significant reduction at 1 hour compared to pre-exercise.  The number of MPAs associated 
with Mon2 also decreased significantly by 1 hour.  No changes in MPAs associated with 
Mon3 were apparent.  Additionally, Mon1 expression of CD14 decreased significantly 1 hour 
post exercise.  No such changes were observed for the Mon2 or Mon3 subset.  CD16 and 
CCR2 expression was not affected by exercise (Shantsila et al, 2012).  Having observed these 
effects on monocyte subsets and MPAs, participants in my study were asked to refrain from 
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strenuous exertion for at least 1 hour prior to sample collection in order to minimise the effect 
of exercise on monocyte parameters.    
 
3.3.2 Effect of diurnal variation 
Diurnal variation in monocyte parameters was assessed in 16 healthy volunteers (age 36.0 ± 
8.7 years, 7 male) with no evidence of cardiovascular disease on examination or history-
taking.  Samples were taken five times at six hourly intervals over a 24 hour period (06.00, 
12.00, 18.00, 00.00 and 06.00).  The number and proportion of Mon2 was observed to 
undergo significant diurnal variation.  These values peaked at 18.00 and reached their nadir at 
06.00.  There were no significant variations in total monocyte count, or count of Mon1 or 
Mon 3.  Expression of CCR2 by Mon2 exhibited the same pattern.  There was no variation in 
expression of CD14 or CD16 (Shantsila et al, 2012).  Given these observations on the effects 
of exercise on monocyte parameters, the increase noted during the daytime may be 
attributable to a generally higher level of background physical activity.  It was logistically 
impossible to plan to undertake sample collection at the same time each day.  However, the 
majority of samples were collected from all subject groups between 09.00 and 12.00.  The 
remaining influence of diurnal variation on monocyte parameters should be considered as a 
limitation of my study.       
 
3.3.3 Effect of delay in sample preparation 
The effect of time delay on monocyte and MPA parameters between sample collection and 
processing was assessed in 12 healthy volunteers with no evidence of cardiovascular disease.  
Following venesection, the sample was processed immediately and then repeated at 1, 2 and 4 
hours after collection whilst being stored at ambient room temperature.  The count and 
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proportions of monocyte subsets was not affected by a delay of up to 2 hours before sample 
processing.  By 4 hours, significant changes had become apparent; the proportion of Mon2 
increased, the proportion of Mon1 decreased and Mon 3 counts increased.  The expression of 
CD14 and C16 by Mon1 increased significantly by 2 hours and significantly further by 4 
hours.  Expression of CCR2 was not affected by a delay in sample preparation.  MPAs 
appeared more sensitive to a delay in sample processing.  MPA count increased significantly 
at 2 hours followed by a further significant increase at 4 hours.  This trend was apparent for 
all three monocyte subsets (Shantsila et al, 2012).  In order to minimise the effect of time 
delay between sample collection and processing on monocyte parameters in my study, all 
samples were analysed within 1 hour of venesection.     
 
3.3.4 Plasma storage 
Plasma was separated by centrifugation and stored at –70oC for batched analysis at the end of 
my study. 
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3.4 ENZYME-LINKED IMMUNOSORBENT ASSAYS 
 
Enzyme-linked immunosorbent assay (ELISA) of citrated plasma was used to quantify 
plasma levels and activity of fibrinolytic parameters. All measurements were performed using 
recognized high quality ZYMUTEST kits (Hyphen Bio-Med, Neuville-sur-Oise, France 
distributed by Quadratech Ltd, Epsom, UK); tissue type plasminogen activator (tPA) antigen 
(Cat. No. RK011A), plasminogen activator inhibitor type 1 (PAI-1) antigen (Cat. No. 
RK012A), PAI-1 Activity (Cat. No. RK019A) and urokinase type plasminogen activator 
(uPA) antigen (Cat. No. RK013A).  All measurements were performed according to the 
manufacturer’s recommendations. 
 
3.5 LABOROATORY MEASUREMENTS 
 
Routine haematology (full blood count) and biochemistry (urea and electrolytes, troponin) 
tests were conducted by the clinical pathology laboratories at SWBH NHS Trust.
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3.6 ASSESSMENT OF LEFT VENTRICULAR FUNCTION 
 
All patients underwent echocardiographic assessment of LVEF by Simpson’s method 6 weeks 
after STEMI as part of their routine care (Van de Werf et al, 2008).  The scans were 
undertaken by British Society of Echocardiography accredited echocardiographers blinded to 
the study results (Lang et al, 2005). 
 
  
3.7 POWER CALCULATION 
 
Based on our previous work (Shantsila et al, 2011), the calculated minimum number of 
participants required to achieve 80% power to detect a difference of 0.5 standard deviations in 
mean monocyte count between the study groups was n=35 for the cross-sectional study and 
n=25 for the longitudinal study in STEMI patients.  For additional confidence, and in 
anticipation of the potential for subjects to drop-out of the longitudinal study, I aimed to 
recruit 50 STEMI patients and 40 subjects in each control group.    
 
 
3.8 STATISTICAL ANALYSIS 
 
Following a test of statistical normality, normally distributed continuous data are expressed as 
mean [standard deviation, SD].  Non-normally distributed continuous data are expressed as 
median [interquartile range].  Cross-sectional data were analysed by one way analysis of 
variance (ANOVA) and follow-up data were analysed by repeated measures ANOVA.  The 
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Kruskal-Wallis or Friedman test was used for non-normally distributed data.  A post-hoc 
Tukey test was performed to assess inter-group differences, where appropriate.  Arithmetic 
(log or inverted) transformation of non-normally distributed variables was performed prior to 
post-hoc analysis of ANOVA.  Statistical significance of differences between monocyte 
subsets was determined by independent sample T-test for normally distributed variables, and 
by Mann-Whitney test for non-normally distributed variables.  Correlations between study 
parameters were assessed using Pearson’s method (for normally distributed parameters) or 
Spearman’s method (for non-normally distributed parameters).  Univariate and multivariate 
linear regression analyses were used to establish predictive value of the study parameters for 
LVEF at 6 weeks in STEMI patients.  A p-value of <0.05 was considered statistically 
significant.  In order to minimise the possibility of finding a significant association by chance 
due to the multiple comparison effect, the Bonferroni adjustment of  p value was used using 
the formula: p[significant] = 0.05/number of comparisons per a receptor in an analysis where 
appropriate.  SPSS18 (SPSS, Inc, Chicago, Illinois, USA) software was used to perform 
statistical analyses. 
 
Formal training in statistical methodology was undertaken as part of the curriculum for MD 
students of the University of Birmingham working in the University of Birmingham 
Department of Medicine at City Hospital, Birmingham.  This was taught by Dr Andrew Blann 
who is a Trust Statistician for SWBH NHS Trust and Dr Deirdre Lane.  
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3.9 ETHICAL CONSIDERATIONS 
 
This study was performed in accordance with the Helsinki declaration.  Ethical approval was 
granted by the Coventry Research Ethics Committee (reference number 09/H1210/11) and 
approval was obtained from the Research & Development departments at SWBH NHS Trust 
and Heart of England NHS Foundation Trust.  All participants provided written informed 
consent. 
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CHAPTER 4 
 
MONOCYTE SUBSETS IN CORONARY ARTERY DISEASE 
 
 
 
 
 
 
 
 
 
 
Contributory publication: Monocyte subsets in coronary artery disease and their associations 
with markers of inflammation and fibrinolysis.  Shantsila E, Tapp LD, Wrigley BJ, Pamukcu 
B, Apostolakis S, Montoro-Garcia S, Lip GY.  Atherosclerosis 2014; 234(1): 4-10.  
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Abstract 
 
The diverse roles of monocytes in atherogenesis are attributed to the existence of distinct 
monocyte sub-populations.  Scarce data are available regarding changes in phenotype and 
functional status of human monocyte subsets in patients with CAD, especially when evaluated 
as three subsets. 
 
Monocyte subset surface expression of receptors implicated in inflammation and repair and 
their activation status (intracellular IKKβ) was assessed by flow cytometry in 53 patients with 
CAD and compared to 50 age- and sex-matched healthy subjects.  Monocyte subsets were 
defined as CD14++CD16–CCR2+ (Mon1), CD14++CD16+CCR2+ (Mon2), and 
CD14+CD16++CCR2– (Mon3).  Plasma levels of inflammatory cytokines (by FACSArray) 
and fibrinolytic factors (by ELISA) were measured in CAD. 
 
Compared to HC, CAD was associated with lower expression of CD14 on Mon1 (p=0.02) and 
Mon3 (p=0.036), lower expression of CD16 on Mon1 (p=0.002) and Mon2 (p=0.001), higher 
expression of IL6 receptor on Mon1 (p=0.025) and Mon2 (p=0.015), higher expression of 
CXCR4 on Mon3 (p=0.003), and higher expression of CD34 on all subsets (all p<0.007).  
There were no significant differences in levels of intracellular IKKβ.  Monocyte CD163 
expression correlated negatively with IL6 levels (p<0.01 for all subsets).  IL1β levels 
correlated positively with CD42a expression on Mon1 aggregated with platelets (r=0.36, 
p=0.009).  Expression of VEGFR1 correlated positively with uPA levels on Mon1 (r=0.51, 
p=0.003) and Mon2 (r=0.44, p=0.012), and VEGFR1 expression on Mon2 correlated 
positively with PAI-1 antigen levels (r=0.47, p=0.006). 
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The marked differences observed in subset phenotype in CAD supports the presence of 
unique roles for the three human monocyte subsets in CAD pathogenesis. 
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4.1 INTRODUCTION 
 
4.1.1 Monocytes in coronary artery disease 
Monocyte-derived ‘foam’ cells have been established as a hallmark and key pathogenic 
feature of atherosclerosis, a disease of inflammatory aetiology (Gerrity, 1981).  High total 
monocyte count is a strong predictor of increased risk of CAD or MI (Hristov & Weber, 
2004; Woollard & Geissmann, 2010; Shantsila & Lip, 2009; Maekawa et al, 2002).  However 
the roles of monocytes in atherosclerosis are diverse, including involvement in inflammatory 
responses, the regulation of thrombogenic status (eg via tissue factor expression and the 
modulation of fibrinolysis) and also physiologically beneficial processes related to scavenging 
of redundant or pathological substances, angiogenesis and repair (Panizzi et al, 2010; Dresske 
et al, 2006; Nahrendorf et al 2007; Shantsila et al, 2012). 
 
4.1.2 Monocyte subsets in coronary artery disease 
This diversity of monocyte functions has been partly attributed to the existence of different 
monocyte subsets with specific phenotypic and functional properties (Geissmann et al, 2003; 
Auffray et al, 2009; Shantsila & Lip, 2009; Cros et al, 2010; Zawada et al, 2011).  Specific 
monocyte subsets have been shown to be differentially involved in the pathogenesis and 
outcomes of a range of diseases including heart failure (Wrigley et al, 2013) and stroke (Urra 
et al, 2009) (Table 1.3). 
 
Evidence supporting functional diversity of monocyte subsets in atherogenesis has primarily 
been derived from animal experiments (Swirski et al, 2007; Combadiere et al, 2008; Tacke et 
al, 2007).  Experimental work in mice suggests that in the pathogenesis of MI, ‘classical’ Ly-
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6C
high
 monocytes contribute to inflammation, phagocytic and proteolytic processes, whilst 
‘non-classical’ Ly-6Clow monocytes are involved in myocardial healing, recovery and 
angiogenesis (Nahrendorf et al, 2007).  However, there is limited published data describing 
the phenotypic and functional characteristics of human monocyte subsets in CAD.  Marked 
differences in monocyte subset phenotype and the pathogenesis of atherosclerosis between 
rodents and humans preclude direct translation of data between species.  Also, variation in the 
definition of subpopulations and methodological differences between published papers 
renders comparison between studies problematic. 
 
In humans, an increased number of CD14
dim
CD16
+
 monocytes was observed in 
hypercholesterolaemic patients, and an increased number of CD14+CD16+ monocytes was 
found in patients with CAD (Rothe et al, 1996; Schlitt et al, 2004).  In stable CAD a negative 
correlation was found between CD14
low
CD16
+
 monocyte count and cumulative risk factor 
score, cigarette smoking, family history of CAD and history of hypertension (Hristov et al, 
2010).  However, the majority of available data describes human monocytes as two subsets 
(CD14+CD16- and CD14+CD16+) where CD16+ monocytes are considered as a single 
subset, pre-dating the recently published consensus nomenclature which describes three 
subsets (Ziegler-Heitbrock et al, 2010) (section 1.2.1).  The hitherto poorly characterised 
CD14++CD16+ subset has been the focus of much recent interest.  An association was noted 
between this subset and adverse cardiovascular outcomes in patients with chronic kidney 
disease (Rogacev et al, 2011) and a cohort of high cardiovascular risk patients referred for 
coronary angiography (Rogacev et al, 2012).  However, there is very little data regarding the 
three monocyte subsets in the setting of stable CAD. 
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4.2 AIMS AND HYPOTHESES 
 
The aim of this study was to provide a detailed phenotypic comparison of differences between 
the three human monocyte subsets in patients with CAD and healthy subjects defined 
according to contemporary nomenclature (Ziegler-Heitbrock et al, 2010; Shantsila et al, 
2011).  The focus was placed on investigating differences in expression of surface receptors 
implicated in inflammatory and reparative responses between groups.  Additionally, the 
functional status of monocyte subsets was investigated via measurement of intracellular 
IKKβ, a marker of activation of the NFκB pathway.  Monocyte interactions with platelets 
were examined, and associations between monocyte characteristics and plasma markers of 
inflammation and fibrinolysis were explored. 
 
As monocyte subsets have been proposed to play different roles in the pathogenesis of CAD, I 
hypothesised that there would be significant differences in subset characteristics between 
healthy subjects and those with CAD. 
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4.3 METHODS AND MATERIALS 
 
4.3.1 Coronary artery disease subjects 
53 patients were recruited with angiographically proven stable CAD and normal LVEF from 
SWBH NHS Trust as described in section 3.1.2.1. 
 
4.3.2 Control group 
50 age and sex-matched healthy controls (HC) were recruited as described in section 3.1.2.2.  
Exclusion criteria comprised factors which may affect monocyte numbers (section 3.1.3). 
 
4.3.3 Sample collection 
All subjects were asked to refrain from extreme physical exertion for at least 1 hour prior to 
sample collection (section 3.3.1).  Peripheral venous blood samples were collected from all 
participants and processed by flow cytometry within 60 minutes (section 3.2).  Plasma was 
separated by centrifugation and stored at –70oC for batched ELISA analysis (section 3.4). 
 
Routine haematology and biochemistry investigations were undertaken by the hospital 
laboratory (section 3.5). 
 
4.3.4 Flow cytometry 
Flow cytometric analysis was performed as described in section 3.2.  Briefly, the absolute 
count of monocytes and counts of the three monocyte subsets and associated MPAs were 
performed, as described in section 3.2.2.  The three monocyte subsets were defined as 
CD14++CD16-CCR2+ (Mon1), CD14++CD16+CCR2+ (Mon2) and CD14+CD16++CCR2- 
82 
 
(Mon3) in keeping with contemporary nomenclature (Shantsila et al, 2011; Ziegler-Heitbrock 
et al, 2010).  Expression of surface antigens on monocyte subsets was measure as described in 
section 3.2.3. 
 
Intracellular level of IKKβ was measured as described in section 3.2.4.  
 
Plasma levels of IL-1β, IL-6, IL-10 and MCP-1 were measured by cytometric bead array 
technology as described in section 3.2.5. 
 
 
4.3.5 Enzyme-linked immunosorbent assays 
ELISA of citrated plasma was used to quantify levels and activity of fibrinolytic parameters 
as described in section 3.4.  
 
4.3.6 Statistical analysis 
Statistical analyses were performed as described in chapter 3.8.  Statistical significance of 
differences between monocyte subsets was determined by independent sample T-test for 
normally distributed variables, and by Mann-Whitney test for non-normally distributed 
variables.  Correlations between monocyte parameters and inflammatory and fibrinolytic 
markers in CAD were assessed using Pearson’s method (for normally distributed variables) 
and Spearman’s method (for non-normally distributed variables). 
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4.4 RESULTS 
 
4.4.1 Subject demographics 
The study groups were well matched for age, sex, body mass index, blood pressure and renal 
function (Table 4.1).  Healthy subjects included significantly less cigarette smokers.  Among 
patients with CAD, 28 (53%) had a history of hypertension, 9 (17%) had diabetes mellitus, 
and 24 (46%) had a history of previous MI.  The CAD patients received the following 
background pharmacological treatment: aspirin 46 (87%), clopidogrel 23 (43%), prasugrel 2 
(4%), statins 47 (89%), angiotensin converting enzyme inhibitors/angiotensin receptor 
antagonist 41 (77%), beta-blockers 38 (72%), calcium channel blockers 15 (28%).  
 
Table 4.1 Demographic and clinical characteristics, leukocyte counts and plasma 
inflammatory cytokines in the study groups 
 CAD 
(n=53) 
Healthy controls 
(n=50) 
p value 
Age, years 64 [12] 61 [14] 0.22 
Male, n (%) 38 [72] 33 [66] 0.53 
Systolic BP, mm Hg 134 [16] 128 [17] 0.35 
Diastolic BP, mm Hg 72 [10] 75 [4] 0.38 
Body mass index, kg/m
2
 29 [5] 27 [4] 0.26 
Creatinine, μmol/l 88 [20] 77 [14] 0.17 
Smoking, n (%) 19 [36] 2 [4] <0.001 
Leukocytes, x10
3
 per µl 6.4 [1.9] 5.9 [1.3] 0.23 
Neutrophils, x10
3
 per µl 3.9 [1.4] 3.5 [1.4] 0.25 
Lymphocytes, x10
3
 per µl 1.8 [0.6] 1.8 [0.6] 0.94 
Platelets, x10
3
 per µl 235 [71] 263 [67] 0.089 
Monocytes, per µl 567 [171] 508 [182] 0.095 
MPA, per µl 74 [53-104] 62 [37-90] 0.061 
Interleukin 1β, pg/ml 0.64 [0.11-0.75] 0.52 [0.3-0.75] 0.45 
Interleukin 6, pg/ml 2.1 [1.2-3.1] 1.7 [0.8-2.7] 0.098 
Interleukin 10, pg/ml 0.13 [0.07-1.26] 0.83 [0.13-1.63] 0.009 
MCP-1, pg/ml 52 [28-107] 107 [63-170] <0.001 
BP: blood pressure, CAD: coronary artery disease, MCP-1: monocyte-chemoattractant 
protein-1, MPA: monocyte-platelet aggregates. Data are presented as mean [SD] or median 
[IQR] for normally and non-normally distributed variables. 
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4.4.2 Leucocytes and inflammatory cytokines 
There was no significant difference in leukocyte levels between the groups, although there 
was a trend towards higher monocyte count and lower platelet count in CAD (Table 4.1). 
Subjects with CAD had significantly lower plasma IL10 and MCP-1 levels than controls 
(p=0.009, and p<0.001, respectively), with a trend towards higher IL6 concentrations.  There 
was no difference in IL1β levels between the groups. 
 
4.4.3 Monocyte subset characteristics 
There were similar numbers of the Mon1 and Mon2 subsets and their aggregates with 
platelets in the groups. MPA number associated with the Mon3 subset was higher in CAD 
(p=0.03), with a non-significant trend observed in Mon3 count (Table 4.2). 
 
CAD was associated with lower expression of CD14 on Mon1 and Mon3 (p=0.02, and 
p=0.036, respectively), and lower expression of CD16 on Mon1 and Mon2 (p=0.002, and 
p=0.001, respectively).  Patients with CAD had significantly higher expression of IL6 
receptor on Mon1 (p=0.025) and Mon2 (p=0.015), CXCR4 on Mon3 (p=0.003), and CD34 on 
all three subsets as compared to HC (p=0.007 for Mon1, p=0.002 for Mon2, and p<0.001 for 
Mon3) (Figure 4.1).  There were no significant differences in other monocyte parameters 
including levels of intracellular IKKβ (Table 4.2).
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Table 4.2 Characteristics of monocyte subsets in the study subjects 
 Mon1 Mon2 Mon3 
 CAD Healthy p 
value 
CAD Healthy p 
value 
CAD Healthy p 
value 
Count, per μl 469 [149] 423 [160] 0.15 30 [18-48] 29 [10-51] 0.52 54 [39-79] 49 [35-62] 0.094 
MPA, per μl 60 [41-81] 48 [28-74] 0.11 6 [3-10] 5 [3-8] 0.22 8 [5-11] 7 [4-9] 0.030 
CCR2, MFI 148 [43] 147 [51] 0.94 115 [33] 106 [33] 0.16 15 [3] 15 [2] 0.37 
CD14, MFI 1268  [342] 1423 [312] 0.02 1287 [391] 1281 [495] 0.95 141 [44] 158 [36] 0.036 
CD16, MFI 9 [3] 10 [3] 0.002 49 [14] 59 [16] 0.001 142 [60] 143 [61] 0.89 
TLR4, MFI 5.8 [1.7] 5.7 [2.0] 0.70 9.2 [7-13] 10 [6-16] 0.47 3.9 [1.2] 3.9 [1.5] 0.88 
IL6R, MFI 70 [16] 62 [20] 0.025 64 [14] 55 [20] 0.015 35 [23] 32 [12] 0.40 
Integrin β2, MFI 33 [15] 38 [18] 0.23 60 [24] 66 [30] 0.28 29 [15] 28 [12] 0.78 
Integrin α4, MFI 11 [5] 11 [4] 0.80 23 [9] 24 [11] 0.55 36 [14] 36 [12] 0.83 
CXCR4, MFI 17 [13] 14 [3.2] 0.13 26 [17] 21 [8] 0.069 9 [6] 6 [2] 0.003 
CD34, MFI 2.2 [0.3] 2.0 [0.2] 0.007 2.1 [0.5] 1.8 [0.3] 0.002 2.0 [0.4] 1.6 [0.3] <0.001 
VEGFR1, MFI 6.3 [1.6] 6.8 [1.8] 0.28 13.3 [4.7] 15.2 [6.4] 0.13 4.2 [1.5] 4.0 [1.8] 0.55 
VEGFR2, MFI 3.3 [1.0] 3.4 [1.4] 0.78 4.4 [1.9] 4.4 [2.3] 0.95 3.5 [0.9] 3.9 [0.8] 0.57 
CD163, MFI 142 [60] 136 [50] 0.57 236 [90] 222 [76] 0.42 16 [12-22] 14 [9-24] 0.55 
CD204, MFI 12 [8-23] 9 [7-13] 0.13 30 [14-61] 30 [19-100] 0.43 32 [19-73] 38 [23-71] 0.46 
IKKβ, MFI 68 [17] 67 [13]  0.78 75 [20] 74 [16] 0.95 64 [15] 64 [10] 0.95 
Mon1, CD14++CD16-CCR2+ monocytes; Mon2, CD14++CD16+CCR2+ monocytes; Mon3, CD14+CD16++CCR2– monocytes; CAD, 
coronary artery disease; IL6R, interleukin 6 receptor; MFI, median fluorescent intensity; MPA, monocyte-platelet aggregates (associated with 
individual monocyte subsets); TLR4, toll-like receptor 4; VEGFR, vascular endothelium growth factor receptor. Data are presented as mean [SD] 
or median [IQR] for normally and non-normally distributed variables respectively. 
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Figure 4.1 CD34 expression by monocyte subsets in subjects with coronary artery disease 
and healthy controls 
 
Mon1, CD14++CD16-CCR2+ monocytes; Mon2, CD14++CD16+CCR2+ monocytes; Mon3, 
CD14+CD16++CCR2– monocytes; CAD, coronary artery disease; MFI, median fluorescent 
intensity.  Red bars represent mean and standard deviation.  Horizontal lines indicate 
significant differences between groups.   
 
p=0.007 p=0.002 p<0.001 
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4.4.4 Correlations between expression of monocyte receptors and intracellular IKKβ 
levels 
In this analysis a p value <0.0167 was considered significant, based on the Bonferroni 
adjustment for multiple testing.  Significant correlations were found between intracellular 
IKKβ levels and monocyte parameters as follows: for Mon1 with expression of CXCR4 
(r=0.54, p=0.003), CD34 (r=0.54, p=0.003), VEGFR1 (r=-0.51, p=0.003) and CD42a 
expression on aggregates with platelets (r=0.43, p=0.007); for Mon2 with expression of 
VEGFR1 (r=-0.51, p=0.006) (Table 4.3).  
 
4.4.5 Correlations between expression of monocyte surface receptors, plasma cytokines 
and monocyte chemoattractant protein-1 
In this analysis a p value <0.0125 was considered significant based on the Bonferroni 
adjustment for multiple testing.  CD163 expression by all monocyte subsets correlated 
negatively with IL6 levels (r=-0.50, p<0.001 for Mon1, r=-0.41, p=0.004 for Mon2, r=-0.41, 
p=0.004 for Mon3) (Table 4.3).  MCP-1 levels correlated positively with expression of TLR4 
on Mon1 (r= 0.47, p=0.001) and Mon2 (r=0.52, p<0.001) and VEGFR1 on Mon2 (r=0.44, 
p=0.004) and negatively with CD204 expression on Mon1 (r=-0.64, p<0.001) and Mon2 (r=-
0.57, p<0.001).  Also, IL1β levels correlated positively with CD42a expression on Mon1 
aggregated with platelets (r=0.36, p=0.009) (Table 4.3). 
 
4.4.6 Correlations between expression of monocyte receptors and plasma fibrinolytic 
factors 
In this analysis a p value <0.0125 was considered significant based on the Bonferroni 
adjustment for multiple testing.  Plasma uPA levels correlated positively with VEGFR1 
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expression on Mon1 (r=0.51, p=0.003) and Mon2 (r=0.44, p=0.012).  VEGFR1 expression on 
Mon2 correlated with positively with PAI-1 antigen levels (r=0.47, p=0.006). IL6R 
expression on Mon2 correlated negatively with PAI-1 antigen (r=-0.45, p=0.005) and PAI-1 
activity (r=-0.47, p=0.004) (Table 4.3). 
 
Table 4.3 Correlations between expression of monocyte receptors, intracellular IKKβ levels, 
inflammatory and fibrinolytic markers 
 
 r p value 
Correlations with intracellular IKKβ levels 
CXCR4 (Mon1) 0.54 0.003 
CD34 (Mon1) 0.54 0.003 
VEGF receptor 1 (Mon1) -0.51 0.003 
VEGF receptor 1  (Mon2) -0.51 0.006 
CD42a (Mon1) 0.43 0.007 
Correlations with inflammatory markers 
Plasma interleukin-6 levels 
CD163 (Mon1) -0.50 <0.001 
CD163 (Mon2) -0.41 0.004 
CD163 (Mon3) -0.41 0.004 
Plasma MCP-1 levels 
TLR4 (Mon1) 0.47 0.001 
TLR4 (Mon2) 0.52 <0.001 
CD204 (Mon1) -0.64 <0.001 
CD204 (Mon2) -0.57 <0.001 
VEGF receptor 1 (Mon2) 0.44 0.004 
Plasma interleukin-1β levels 
CD42a (Mon1) 0.36 0.009 
Correlations with fibrinolytic factors 
Plasma uPA levels 
VEGF receptor 1 (Mon1) 0.51 0.003 
VEGF receptor 1 (Mon2) 0.44 0.012 
Plasma PAI-1 antigen levels 
VEGF receptor 1 (Mon2) 0.47 0.006 
Interleukin-6 receptor (Mon2) -0.45 0.005 
Plasma PAI-1 activity 
Interleukin-6 receptor (Mon2) -0.47 0.004 
VEGFR, vascular endothelium growth factor; MPA, monocyte-platelet aggregates; TLR4, 
toll-like receptor 4; PAI-1, plasmin activator inhibitor-1; uPA, urokinase type plasminogen 
activator
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4.5 DISCUSSION 
 
This study observed multiple significant novel changes in human monocyte phenotype in 
patients with CAD compared to healthy subjects, which are attributable to specific monocyte 
subsets.  A significant up-regulation of IL6R expression on Mon1 and Mon2 subsets was 
found.  There was significant up-regulation of CXCR4 expression on Mon3, with a similar 
trend for Mon2.  A significant increase in CD34 expression was observed on all monocyte 
subsets. 
 
In a recently published meta-analysis, Sarwar et al provided compelling evidence of a causal 
relationship between the pro-inflammatory IL6 pathway and risk of coronary artery disease.  
A genotype linked to accelerated shedding of the IL6r into the circulation (Asp358A1a) was 
associated with potent atheroprotective properties, independent of traditional cardiovascular 
risk factors (Sarwar et al, 2012).  This was associated with reduced levels of downstream 
mediators of the IL6 pathway and disruption of IL6-driven inflammatory responses.  Their 
findings imply that it is not IL6r shed into the circulation, but that left on effector cells which 
is of major importance, but data on cells that up-regulate expression of IL6r in CAD were not 
provided.  Thus the observations in this study support the data of Sarwar and colleagues, that 
patients with CAD express higher IL6r levels, and suggest that Mon1 and Mon2 may be those 
effector cells responsible for IL6r-mediated atherogenesis (Sarwar et al, 2012).  This is also in 
accordance with the recent finding of an independent association between CD14++CD16+ 
monocyte count and future risk of cardiovascular events in a large prospective cohort study of 
patients at high cardiovascular risk (Rogacev et al, 2012).  The observations in my study 
suggest what one of the mechanisms underlying this association may be.  Although limited 
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methodologically by the assessment of CD16+ monocytes as a single population, the findings 
that statin drugs lower the proportion of the CD16+ subset (population with higher expression 
of IL6r in my study) may explain the potential therapeutic pathway of this class of drug in 
lowering cardiovascular risk (Imanishi et al, 2010). 
 
Although the CXCL12 (Stromal cell-derived factor-1)/CXCR4 axis is thought to play a 
critical role in vascular repair and remodelling, its role in atherogenesis and post-infarct 
recovery is controversial, with conflicting data (Zernecke et al, 2008).   Mobilisation of 
CXCR4+ cells has been shown to mediate the benefit of treatment with macrophage-colony 
stimulating factor (M-CSF) in reduction of LV dysfunction and accelerated neointima 
formation following vascular injury in mice (Morimoto et al, 2007; Shiba et al 2007).  
Additionally, inhibition of the CXCL12/CXCR4 axis in mice exacerbated atherogenesis 
(Zernecke et al, 2008).  However, CAD risk alleles at rs1746048 and rs501120 have been 
associated with higher plasma levels of CXCL12 (Mehta et al, 2011; Liehn et al, 2011).  This 
discrepancy may be partly due to the fact that both inflammatory and progenitor cells are 
CXCR4+ and are both recruited by this pathway.  My finding of a significantly higher 
expression of CXCR4 by Mon3 in CAD compared to HC suggests that these ‘non-classical’ 
monocytes may be a subset with enhanced CXCR4-dependent mobilisation to tissues in CAD, 
in keeping with their ‘patrolling’ behaviour (Cros et al, 2010). 
 
This study found a significant increase in CD34 expression by all three monocyte subsets in 
CAD.  This may reflect a compensatory mechanism attempting to enhance angiogenic 
processes in response to likely low-grade ischaemia in stable CAD.  Indeed, potent angiogenic 
potential related to CD34+ cells has been observed in animal models (Shantsila et al, 2007; 
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Harraz et al, 2001).  Of interest, in a cohort of subjects of South Asian origin (a high risk 
population for CAD and it’s complications) no difference in CD34+ monocyte counts was 
found between patients with CAD and healthy subjects.  Ethnicity was independently 
predictive of CD34+ monocyte levels in heart failure subjects, with lower values seen in 
South Asian subjects that in Caucasians (Shantsila et al, 2012). 
 
In this study I observed significant reductions in CD14 expression on Mon1 and Mon3, and 
CD16 expression on Mon1 and Mon2 in patients with CAD compared to HC.  Although a 
reduction in CD16 expression on Mon1 (described as CD16- cells) may appear paradoxical, it 
may reflect that some of these cells do in fact express very low levels of the CD16 (~14-fold 
lower expression that Mon3, and ~5-6 fold lower expression than Mon2 in this study).  This 
low-level expression may not be reliably discriminated using isotype-control samples, but 
may be detectable by measuring MFI.  Lower density of these receptors, which have been 
implicated in inflammatory reactions, may reflect their enhanced release into circulation or 
the partial suppression of inflammatory signalling previously observed in monocytes from 
patients with stable CAD (Schirmer et al, 2009).  
 
No significant differences were seen in monocyte expression of the other receptors tested 
between CAD and HC in this study.  This may be related to the comprehensive contemporary 
medical therapy prescribed to patents with CAD and their subsequent stable status.  This is 
supported by the lack of differences in IKKβ expression between study groups, in contrast to 
the significant up-regulation (especially the Mon2 subset) seen in patients with STEMI 
(discussed in chapter 5).  
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Whilst the role of the NFκB pathway in induction of synthesis of inflammatory cytokines, 
MMPs and other biological molecules in monocytes is well established (Pamukcu et al, 
2011), this study shows for the first time an association between monocyte activation and 
increased surface expression of receptors associated with angiogenesis, repair and 
remodelling (CXCR4, CD34 and VEGFR1) on monocyte subsets in stable CAD.  This 
suggests a more complex role of the NFκB system in monocyte responses to tissue injury. The 
positive correlation observed between IKKβ levels in the Mon 1 subset and CD42 expression 
on their aggregates with platelets (a measure of platelet load on monocytes) provides further 
support to the growing evidence on the role that interaction with platelets plays in regulation 
of monocyte activity (Simon et al, 1993; van Gils et al, 2008; Kuckleburg et al, 2011). 
 
This study also reinforces the anti-inflammatory properties of the haptoglobin scavenger 
receptor CD163, as expression on all monocyte subsets was found to correlate negatively with 
plasma IL6 levels.  Additionally, the positive correlations between VEGFR1 expression on 
Mon1 and Mon2 with uPA levels and the negative correlation between IL6r expression on 
Mon2 and plasma PAI-1 level may reflect a role of fibrinolytic enzymes in the regulation of 
expression and cleavage of these receptors, in accordance with previous data reporting links 
between monocytes and the fibrinolytic system (Shantsila et al, 2012).  
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4.6 LIMITATIONS 
 
This study is limited by its cross-sectional design, and any clinical relevance of the findings 
should be assessed in prospective and ideally interventional studies.  As with all 
contemporary human studies, I was limited to analysing monocytes in peripheral venous 
blood, and direct extrapolation of these findings into physiological processes within 
atherosclerotic plaques and the myocardium should be made with caution. 
 
Robust mechanistic implications cannot be inferred from this purely observational data.  
These mechanisms should be explored in future experiments.  The differences and similarities 
observed between study groups may be partly attributable to the medication taken by CAD 
patients rather than the presence of CAD per se.  Thus my findings may only be relevant to 
patients receiving such treatment.  An examination of the effects individual medications exert 
on the observations made in this study would be of interest. 
 
Although the majority of samples were collected between 09.00 and 12.00 hours, it was 
logistically impossible to collect all samples at the same time each day.  The remaining 
influence of diurnal variation on monocyte parameters should be considered as a limitation 
(Shantsila et al, 2012).       
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4.7 CONCLUSIONS 
 
There are multiple significant differences in monocyte phenotype in patients with CAD, 
which are differentially attributable to individual monocyte subsets.  There appears to be a 
complex interplay between monocyte activity, phenotype, plasma cytokines and fibrinolytic 
factors.  The findings of this study support accumulating data describing the presence of 
diverse roles of human monocyte subsets in the pathogenesis of CAD, with specific emphasis 
on the CD14++CD16+ subset.  This data suggests potential mechanisms which may underlie 
the recently reported associations between this ‘intermediate’ subset and prognosis in CAD.  
Further research into the heterogeneity of human monocyte populations in CAD may 
ultimately allow for cell-specific therapeutic strategies for modulation of atherosclerosis.  
CD14++CD16+ ‘intermediate’ monocytes and their relations with the IL6r may be a 
promising target. 
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CHAPTER 5 
 
MONOCYTE SUBSETS AND MONOCYTE PLATELET 
AGGREGATES IN ST-ELEVATION MYOCARDIAL 
INFARCTION 
 
 
 
 
 
 
 
 
 
Contributory publication: The CD14++CD16+ monocyte subset and monocyte-platelet 
interactions in patients with ST-elevation myocardial infarction.  Tapp LD, Shantsila E, 
Wrigley BJ, Pamukcu B, Lip GY.  J Thromb Haemost 2012; 10(7): 1231-41. 
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Abstract 
 
Monocytes contribute to both myocardial damage and repair by virtue of subset heterogeneity.  
The hitherto unknown dynamic changes and relations to LVEF of the three human monocyte 
subsets and their aggregates with platelets (MPAs) following STEMI were studied. 
 
The three monocyte subsets defined as CD14++CD16-CCR2+ (Mon1), 
CD14++CD16+CCR2+ (Mon2) and CD14+CD16++CCR2- (Mon3) and their contributions to 
MPAs were analysed by flow cytometry in 50 patients with STEMI, 40 patients with stable 
CAD and 40 healthy subjects.  Parameters were measured within 24 hours of PPCI (day1) and 
on days 3, 7 and 30.  Monocyte activation status was assessed by measuring the NFĸB 
pathway.  LVEF was measured by echocardiography 6 weeks after STEMI.  Correlations 
between monocyte subsets and MPAs with plasma cytokines (by FACSArray) and troponin 
were assessed. 
 
On day 1, marked differences in subset dynamics were observed, with a prominent (2.5 fold) 
increase in Mon2 (p < 0.0001) but no changes in Mon3.  Significant increases in Mon2 CD14 
(P = 0.002) and CCR2 (p < 0.0001) expression, and a reduction in CD16 expression (p = 
0.001) were seen.  NFĸB pathway activity increased most prominently in Mon2 (p = 0.007). 
Mon2 count correlated with peak troponin (r = 0.31, p = 0.044) and plasma IL6 (r = 0.65, p < 
0.0001) and IL-10 (r = 0.34, p = 0.017).  Mon1 correlated with IL-6 (r = 0.55, p < 0.0001).  
Reduced Mon2 expression of CD16 on day 1 was independently predictive of higher LVEF (b 
= -0.37, p = 0.013) at 30 days.  The increase in MPA count following STEMI persisted at 1 
month. 
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The Mon2 ‘intermediate’ subset has unique dynamic and phenotypic characteristics following 
STEMI and significant correlations with troponin, plasma cytokines and convalescent LV 
function were observed.  The persistent increase in MPA count 30 days after STEMI may 
reflect monocyte subset functional activity.  
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5.1 INTRODUCTION 
 
5.1.1 Monocytes in myocardial infarction 
The underlying pathophysiological mechanisms contributing to MI include vascular 
inflammation, plaque rupture, coronary artery thrombosis and occlusion resulting in 
myocardial necrosis (chapter 1.1).  Monocytes are an essential component of the innate and 
adaptive immune systems and have been implicated in many inflammatory diseases including 
CAD and atherosclerosis (Woollard et al, 2010; Hristov et al, 2010, Hristov et al, 2011).  
Following MI, monocytosis has been associated with impaired myocardial recovery and 
unfavourable prognosis (Maekawa et al, 2002; Panizzi, et al 2010).  However, unique 
characteristics of monocytes also suggest an intimate role in cardiovascular repair processes 
(Dresske et al, 2006; Nahrendorf et al, 2007).  This functional diversity is thought to result 
from heterogeneity of monocyte subpopulations (Geissmann et al, 2003; Auffray et al, 2009, 
Shantsila et al, 2009; Zawada et al, 2011).  
 
5.1.2 Monocyte subsets in myocardial infarction 
Evidence supporting the hypothesis of monocyte functional diversity in MI in vivo is 
supported by the findings of sequential mobilisation of monocyte subsets, firstly in mouse 
(Nahrendorf et al, 2007) and more recently in humans (Tsujioka et al, 2009).  Sequential 
mobilisation of subsets is thought to be due to the orchestrated release of subset-specific 
chemokines. In the mouse model of MI, the Ly-6C
high
 monocyte subset predominated within 
the myocardium during phase I after MI (peak level on day 3) and was found to exhibit 
phagocytic, proteolytic and inflammatory activity.  In contrast, the Ly-6C
low
 monocyte subset 
predominated in phase II after MI (peak on day 7) and was implicated in myocardial healing 
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and recovery processes, including anti-inflammatory properties, promotion of myofibroblast 
accumulation, angiogenesis and collagen deposition (Nahrendorf et al, 2007).  In humans, the 
CD14+CD16- and CD14+CD16+ monocyte subsets peaked in the circulation on days 3 and 5 
respectively after MI (Tsujioka et al, 2009).  A negative correlation was found between the 
peak level of the CD14+CD16- monocyte subset following MI and convalescent LVEF at 6 
months assessed by cardiovascular MRI (Tsujioka et al, 2009).  These studies illustrate the 
diverse and contrasting functions of monocytes and their subsets in homeostasis and the 
pathophysiology of MI.  Further evaluation of monocyte subset biology and a greater 
understanding of their specific roles in MI may allow the development of novel therapeutic 
interventions specifically targeted towards inhibiting detrimental processes whilst selectively 
sparing beneficial roles. 
 
CD16+ positive monocytes remain the most poorly characterised as they have historically 
been evaluated as a single population, including the paper by Tsujioka and colleagues 
(Tsujioka et al, 2009).  However, more recently they have been shown to comprise two 
distinct subsets of CD14++CD16+ and CD14+CD16++ cells and there is emerging 
phenotypic, functional and genetic evidence suggestive of distinct roles for each subset (Cros 
et al, 2010; Zawada et al, 2011; Shantsila et al, 2011; Auffray et al, 2007; Rogacev et al, 
2010; Wong et al 2011) (chapter 1.2). 
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5.2 AIMS AND HYPOTHESES 
 
Our research group described marked phenotypic differences between the three human 
monocyte subsets in healthy subjects (Shantsila et al, 2011), but their characteristics in MI 
have not been studied.  My objective in this study was to investigate their dynamic changes 
and associations with MPAs in STEMI, from the acute to the recovery phase, with particular 
emphasis on the hitherto poorly characterised Mon2 subset.  Based on the accumulating data 
suggesting its unique characteristics (Cros et al, 2010; Rogacev et al, 2010; Wong et al, 2011; 
Shantsila et al, 2011; Zawada et al, 2011) I hypothesised that the Mon2 subset would exhibit 
distinct dynamic changes following STEMI compared to Mon1 and Mon3, and that these 
changes would differ from monocyte numbers in healthy people and those with stable CAD.  I 
hypothesised that these changes may be related to the degree of myocardial damage and to 
changes in inflammatory cytokines and MCP-1.  Finally I hypothesised that the dynamic 
changes in monocyte subsets acutely after MI is related to convalescent LVEF, which is the 
most important determinant of long-term prognosis following STEMI. 
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5.3 METHODS AND MATERIALS 
 
5.3.1 ST elevation myocardial infarction patients 
50 consecutive patients diagnosed with STEMI fulfilling the study criteria were recruited 
from SWBH NHS Trust between November 2009 and November 2010 (sections 3.2.1.1 and 
3.1.3).  The diagnosis of STEMI was made according to the universal definition (Thygesen et 
al, 2007) (chapter 1.1.3).  All patients were treated successfully with PPCI and managed 
according to the contemporary ESC guidelines (Van de Verf et al, 2008) (chapter 1.1.5).  The 
three monocyte subsets and MPAs were evaluated at 4 time points following STEMI: day 1 
(during the 24 hours after PPCI), day 3, day 7 and day 30. 
 
5.3.2 Control groups 
For a cross-sectional comparison, STEMI patients were compared to two age- and sex-
matched control groups: (i) 40 ‘disease controls’ with stable CAD (chapter 3.1.2.1) and (ii) 40 
‘healthy controls’ (HC) (chapter 3.1.2.2).  Exclusion criteria are summarised in chapter 3.1.3.  
No STEMI patients had a history of previous MI, LV dysfunction or heart failure.   
 
5.3.3 Sample collection 
All subjects were asked to refrain from extreme physical exertion for at least 1 hour prior to 
sample collection (chapter 3.3.1).  Peripheral venous blood samples were collected from all 
participants and processed by flow cytometry within 60 minutes (chapter 3.2).  Plasma was 
stored at –70oC for batched ELISA analysis (chapter 3.4). 
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Routine haematology and biochemistry investigations were undertaken by the hospital 
laboratory (chapter 3.5). 
 
 
5.3.4 Flow cytometry 
Flow cytometric analysis was as described in chapter 3.2.  Briefly, monocyte subsets were 
defined as CD14++CD16–CCR2+ (Mon1), CD14++CD16+CCR2+ (Mon2) and 
CD14+CD16++CCR2– (Mon3) in accordance with contemporary nomenclature (Ziegler-
Heitbrock et al, 2010; Shantsila et al, 2011) (chapter 1.2). 
 
Intracellular level of IKKβ was measured as described in chapter 3.2.4.  
 
Plasma levels of IL-1β, IL-6, IL-10 and MCP-1 were measured by cytometric bead array 
technology as described in chapter 3.2.5. 
 
5.3.5 Assessment of left ventricular function 
Patients underwent echocardiographic assessment of convalescent LVEF by Simpson’s 
method 6 weeks after STEMI (chapter 3.6). 
  
5.3.6 Statistical analysis 
Statistical analyses were performed as described in chapter 3.8.  T-test (for normally 
distributed parameters) or Mann-Whitney test (for non-normally distributed parameters) was 
performed to compare study parameters between patients with stable CAD and 30 day values 
in STEMI patients.  Correlations between monocyte parameters and levels of troponin and 
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plasma markers on day 1 after STEMI were assessed using Pearson’s method (for normally 
distributed parameters) or Spearman’s method (for non-normally distributed parameters). 
Univariate and multivariate linear regression analyses were performed to assess the predictive 
value of the study parameters for convalescent LVEF 6 weeks after STEMI.  In the 
longitudinal analysis, only STEMI patients who completed follow-up were included. 
 
 
5.4 RESULTS 
 
5.4.1 Patient characteristics 
50 patients with STEMI (57.5 [11.7] years, 86% male), 40 patients with stable CAD (60.4 
[10.8] years, 83% male) and 40 healthy volunteers (59.5 [13.4] years, 80% male) were 
recruited (Table 5.1).  Thirty three STEMI patients completed follow-up.  Two patients died; 
1 on day 1 due to a retroperitoneal bleed from the femoral artery puncture and the second on 
day 2 from respiratory failure having suffered a cardiac arrest due to ventricular fibrillation on 
day 1, complicated by aspiration pneumonia.  One patient developed recurrent non ST-
elevation MI attributed to a different culprit coronary artery lesion than that implicated in 
their index STEMI and underwent a second PCI.  Fourteen withdrew consent.  The principle 
reasons for withdraw of consent were logistical difficulties in attending follow-up 
appointments and unwillingness to continue with the blood tests required for this study in 
addition to the frequent blood tests needed for routine care post-MI.  Only 2 patients dropped 
out due to feeling too unwell to attend follow-up.   
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Table 5.1 Demographic and clinical characteristics of study patients 
 
 STEMI 
(n=50) 
Stable CAD 
(n=40) 
HC 
(n=40) 
p value 
Demographic and clinical characteristics 
 
Age, years 57.5 [11.7] 60.4 [10.8] 59.5 [13.4] 0.50 
Male, n (%) 43 (86) 33 (83) 32 (80) 0.75 
BP systolic, mmHg 132 [18] 133 [15] 128 [17] 0.74 
BP diastolic, mmHg 78 [14] 75 [9] 75 [4] 0.74 
Body mass index, kg/m
2
 30.0 [6.1] 28.8 [4.7] 26.7 [3.8] 0.25 
Smoking, n (%) 29 (58) 17 (43) 1 (3) <0.0001 
Stroke, n (%) 3 (6) 5 (13) - 0.25 
Hypertension, n (%) 24 (48) 20 (50) - 0.67 
Diabetes, n (%) 16 (32) 8 (20) - 0.25 
COPD, n (%) 3 (6) 3 (8) - 0.73 
Creatinine, μmol/l 91.7 [18.5] 89.5 [17.9] 78.8 [15.2] 0.26 
Glomerular filtration rate, ml/min 75.1 [15] 73.0 [14] 83.5 [9] 0.26 
Platelets, per μl 263 [98] 226 [69] 252 [67] 0.14 
Medications at time of recruitment 
 
Aspirin, n (%) 50 (100) 36 (90) - 0.10 
Clopidogrel or prasugrel, n (%) 50 (100) 30 (75) - <0.0001 
Statin, n (%) 48 (96) 34 (85) - 0.23 
ACE inhibitor or ARA, n (%) 45 (90) 29 (73) - 0.082 
Diuretic, n (%) 2 (4) 5 (13) - 0.12 
Beta-blocker, n (%) 35 (70) 27 (68) - 0.91 
Calcium channel blocker, n (%) 8 (16) 11 (28) - 0.14 
ACE, angiotensin converting enzyme; ARA, angiotensin receptor antagonist; BP, blood 
pressure; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; HC, 
healthy control; STEMI, ST-elevation myocardial infarction. 
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5.4.2 Monocyte subsets 
5.4.2.1 Comparison with control groups 
Counts of the Mon1 and Mon2 subsets were significantly higher on day 1 after STEMI 
compared to both control groups (p<0.0001 for all).  There was a particularly prominent (over 
2.5-fold) increase in Mon2 count.  No difference was seen in Mon3 count.  However, in stable 
CAD subjects, the proportion of Mon3 was 56% higher than Mon2.  In contrast, the reverse 
pattern was seen on day 1 following STEMI, where Mon 2 predominated; the Mon 2 
proportion was 47% higher compared to Mon3 (Table 5.2, Figure 5.1).  
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Table 5.2 Study parameters on day 1 after ST elevation myocardial infarction, compared with 
controls 
 
 STEMI 
(n=50) 
Stable CAD 
(n=40) 
HC 
(n=40) 
p value 
Monocyte subsets 
 
Total monocytes, per μl 946 [378]*† 599 [165] 506 [192] <0.0001 
Mon1, per μl 765 [322]*† 494 [146] 422 [169] <0.0001 
Mon2, per μl 112 [98.9]*† 40.3 [26.3] 31.9 [25.3] <0.0001 
Mon3, per μl 67.5 [35.8] 63.9 [32.5] 52.0 [28.4] 0.074 
Mon1, % 80.9 [8.9] 82.3 [5.8] 83.0 [7.7] 0.41 
Mon2, % 11.3 [8.2]*† 6.92 [4.1] 6.41 [5.1] <0.0001 
Mon3, % 7.69 [4.4]*† 10.8 [3.9] 10.6 [4.5] 0.001 
Monocyte platelet aggregates 
 
MPA, per μl 146 [78.4]*† 82.0 [28.6] 65.4 [36.5] <0.0001 
MPA (with Mon1), per μl 111 [61.2]*† 65.5 [24.7] 52.7 [31.8] <0.0001 
MPA (with Mon2), per μl 16.2 
[7.2-26.4]*† 
8.0 
 [3.7-9.8] 
5.6 
[2.5-8.6] 
<0.0001 
MPA (with Mon3), per μl 10.0 
[5.8-13.1]† 
7.4 
[5.3-11.1] 
6.6 
[4.2-8.5] 
<0.0001 
MPA (with Mon1), % 13.5  
[11.1-17.4] 
12.6  
[9.6 - 17.6] 
11.4  
[6.8 – 16.7] 
0.088 
MPA (with Mon2), % 19.4 
[14.9-23.1] 
20.4 
[14.0-26.4] 
21.2  
[12.7-35.4] 
0.65 
MPA (with Mon3), % 14.5 
[12.1-17.9] 
12.7 
[10.0-14.8] 
12.0  
[9.7-14.5] 
0.011 
MPA (with Mon1), MFI 40.1 
[38.1-44.7]* 
40.9 
[37.7-45.1] 
37.7  
[36.3-42.8] 
0.059 
MPA (with Mon2), MFI 52.2 
[44.9-71.3]† 
73.8 
[54.6-106] 
89.5  
[57.6-114] 
<0.0001 
MPA (with Mon3), MFI 
 
55.3 
[48.3-68.6] 
54.6 
[48.2-62.6] 
54.5  
[46.4-62.5] 
0.47 
Surface expression of monocyte markers 
 
CCR2 (Mon1), MFI 170 [51.6] 155 [45.0] 149 [47.5] 0.13 
CCR2 (Mon2), MFI 159 [57.2]*† 121 [34.1] 106 [34.9] <0.0001 
CCR2 (Mon3), MFI 15.3 [2.4] 15.9 [2.6] 15.0 [2.1] 0.23 
CD14 (Mon1), MFI 1315 [461] 1339 [268] 1472 [296] 0.11 
CD14 (Mon2), MFI 1626 [527]* 1388 [329] 1286 [516] 0.003 
CD14 (Mon3), MFI 195 [98.5]* 146 [37.4] 160 [38.4] 0.002 
CD16 (Mon2), MFI 39.8 
[36.7-48.6]† 
55.6 
[40.7-61.9] 
61.0 
[48.4-67.7] 
<0.0001 
CD16 (Mon3), MFI 130 
[87.2-174] 
143 
[108-198] 
149 
[89.3-201] 
0.22 
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Monocyte intracellular IKKβ 
 
IKKβ (Mon1), MFI 79.5 [18.1]*† 68.6 [16.3] 67.9 [12.6] 0.004 
IKKβ (Mon2), MFI 90.9 [22.0]*† 76.2 [19.4] 76.6 [14.0] 0.002 
IKKβ (Mon3), MFI 76.1 [14.]1*† 64.3 [14.2] 65.7 [10.4] <0.0001 
Inflammatory cytokines and MCP-1 
 
Interleukin 1β, pg/ml 0.5 [0.58] 0.6 [0.54] 0.4 [0.4] 0.41 
Interleukin 6, pg/ml 10.8  
 [4.8-18.0]* 
2.3  
[1.4-3.4] 
1.7  
[0.7-2.7] 
<0.0001 
Interleukin 10, pg/ml 0.2  
[0.1-1.2] 
0.1 
[0.1-1.4] 
0.8  
[0.1-1.7] 
0.44 
MCP-1, pg/ml 60.2 [39.2]* 73.3 [53.8]‡ 122 [76.7] <0.0001 
 
CAD, coronary artery disease; HC, healthy control; MCP-1, monocyte chemoattractant 
protein 1; MPA, monocyte-platelet aggregates; MFI, median fluorescent intensity; STEMI,  
ST-elevation myocardial infarction; Mon1, CD14++CD16-CCR2+ (‘classical’) monocytes ;  
Mon2, CD14++CD16+CCR2+ (‘intermediate’) monocytes ; Mon3, CD14+CD16++CCR2- 
(‘non-classical’) monocytes. *p<0.05 STEMI vs. stable CAD (p=0.054 for CD14 (Mon2), 
MFI), †p<0.05 STEMI vs. healthy controls (p=0.055 for MPAs with Mon1, p=0.052 for 
CD14 (Mon3), MFI).  ‡ p<0.05 stable CAD vs. healthy controls 
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Figure 5.1 Longitudinal changes in monocyte subset counts compared with control groups. 
p=0.039 
p<0.0001 
p<0.0.001
1 
p<0.0001 
p<0.0001 
p<0.0001 
p<0.0001 
p<0.0001 
p<0.0001 
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Numbers of Mon1 (upper), Mon2 (middle) and Mon3 (lower) per µl were measured in 
healthy controls and stable coronary artery disease (CAD) patients.  This was compared with 
ST elevation myocardial infarction (STEMI) patients measured within 24 hours of primary 
PCI (day 1) and on days 3, 7 and 30.  Red bars represent mean and standard deviation.  
Horizontal bars illustrate significant differences with individual p values. Mon1, 
CD14++CD16-CCR2+ (‘classical’) monocytes ;  Mon2, CD14++CD16+CCR2+ 
(‘intermediate’) monocytes ; Mon3, CD14+CD16++CCR2- (‘non-classical’) monocytes.   
 
 
5.4.2.2 Longitudinal changes in ST elevation myocardial infarction 
The peak Mon1 and Mon2 counts were observed on day 1 after STEMI, with comparable 
values seen on day 3.  The total monocyte count and Mon1 count decreased significantly by 
day 30 (p<0.0001 for both), where they reached levels not significantly different to those 
observed in stable CAD (p=0.072 and p=0.086, respectively).  Mon2 count reduced earlier 
(by day 7), and on day 30 was similar to values seen in stable CAD (p=0.35).  No significant 
dynamic changes were seen in Mon3 levels.  The relative proportions of Mon2 and Mon3 had 
returned to levels similar to stable CAD by day 30 (Table 5.3).   
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Table 5.3 Dynamics of study monocyte parameters during 30 day follow-up after ST elevation myocardial infarction and relation to values in 
stable coronary artery disease 
N=33 (27 for IKKβ) Day 1 Day 3 Day 7 Day 30 p value CAD p value‡ 
Monocyte subsets 
 
Monocytes, per μl 994 [66.2] 967 [71.0] 861 [70.3] 670 [32.4]*† <0.0001 599 [165] 0.072 
Mon1, per μl 810 [57.7] 785 [58.5] 712 [62.9] 557 [31.3]*† <0.0001 494 [146] 0.086 
Mon2, per μl 108 [16.0] 105 [15.9] 73.6 [13.1]† 45.3 [5.6]*† <0.0001 40.3 [26.3] 0.35 
Mon3, per μl 72.2 [7.1] 77.1 [10.1] 75.1 [5.7] 67.3 [4.3] 0.55 63.9 [32.5] 0.65 
Mon1, % 81.4 [1.6] 81.3 [1.6] 82.1 [1.6] 82.4 [1.3] 0.81 82.3 [5.8] 0.99 
Mon2, % 10.9 [1.4] 10.5 [1.2] 8.58 [1.4] 7.36 [1.1]*† 0.002 6.92 [4.1] 0.63 
Mon3, % 7.61 [0.8] 8.23 [0.8] 9.37 [0.7] 10.3 [0.6]*† 0.001 10.8 [3.9] 0.53 
Monocyte-platelet aggregates 
 
MPA, per μl 157 [15.1] 148 [13.0] 136 [11.6] 107 [7.21]*†‡ <0.0001 82.0 [28.6] 0.003 
MPA (with Mon1), per μl 123 [11.7] 113 [10.6] 109 [10.4] 87.4 [6.65]*†‡ 0.001 65.5 [24.7] 0.004 
MPA (with Mon2), per μl 18.0 [6.2-26.2 ] 14.1 [6.8-24.3] 10.6 [7.5-17.6] 8.70 [4.6-17.1]*† 0.006 7.95 [3.7-9.8] 0.069 
MPA (with Mon3), per μl 10.3 [4.6-13.2] 9.50 [5.8-14.1] 11.3 [8.7-16.3] 8.50 [5.8-12.0] 0.10 7.40 [5.3-11.1] 0.50 
MPA (with Mon1), % 14.1 [11.0-17.6] 15.1 [12.6-18.0] 15.1 [12.2-18.4] 14.9 [10.5-18.3] 0 38 12.6 [9.6 - 17.6] 0.16 
MPA (with Mon2), % 19.7 [14.7-26.3] 20.3 [15.3-25.6] 22.0 [17.2-28.5] 22.2 [15.6-34.2] 0.11 20.4 [14.0-26.4] 0.15 
MPA (with Mon3), % 13.8 [12.3-16.8] 15.2 [11.8-18.5] 15.6 [12.9-19.7] 12.8 [10.7-14.9]† 0.001 12.7 [10.0-14.8] 0.61 
MPA (with Mon1), MFI 39.7 [37.9-43.7] 41.3 [37.6-44.5] 42.1 [38.4-45.8] 39.0 [36.9-41.4] 0.10 40.9 [37.7-45.1] 0.23 
MPA (with Mon2), MFI 50.1 [44.7-71.8] 56.0 [45.8-74.7] 59.4 [48.9-111] 62.0 [49.0-77.4] 0.078 73.8 [54.6-106] 0.076 
MPA (with Mon3), MFI 55.0 [48.1-65.0] 54.3 [48.6-58.6] 56.3 [51.0-63.6] 54.3 [49.6-60.3] 0.85 54.6 [48.2-62.6] 0.77 
Surface expression of monocyte markers 
 
CCR2 (Mon1), MFI 173 [8.6] 177 [10.1] 166 [8.3] 144 [4.5]*† 0.003 155 [45.0] 0.27 
CCR2 (Mon2), MFI 157 [10.5] 142 [8.4] 136 [8.5] 114 [4.2]* <0.0001 121 [34.1] 0.36 
CCR2 (Mon3), MFI 15.6 [0.4] 17.2 [0.4]* 14.9 [0.3]† 15.0 [0.3]† <0.0001 15.9 [2.6] 0.082 
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CD14 (Mon1), MFI 1394 [79.7] 1338 [77.5] 1315 [49.8] 1330 [53.8] 0.76  1339 [268] 0.81 
CD14 (Mon2), MFI 1687 [98.2] 1489 [96.3] 1381 [64.4]* 1382 [58.6] 0.001 1388[329] 0.93 
CD14 (Mon3), MFI 192 [15.8] 223 [15.0]* 143 [8.1]*† 145 [7.1]*† <0.0001 146 [37.4] 0.86 
CD16 (Mon2), MFI 40.3 [37.3-55.7] 43.8 [38.5-58.5] 46.5 [37.3-60.7] 51.5 [37.1-63.1] 0.46 55.6  [40.7-61.9] 0.71 
CD16 (Mon3), MFI  128 [83.4-177] 116 [88.1-191] 125 [95.4-173] 144 [98.3-194] 0.71 143 [108-198] 0.48 
Monocyte intracellular IKKβ 
 
IKKβ (Mon1), MFI 80.4 [3.3] 72.6 [3.7] 69.4 [3.4] 61.8 [3.1]* 0.002 68.6 [16.3] 0.13 
IKKβ (Mon2), MFI 92.8 [4.3] 80.4 [4.4] 76.0 [3.5]* 73.8 [4.2]* 0.003 76.2 [19.4] 0.66 
IKKβ (Mon3), MFI 76.6 [2.5] 70.9 [2.8] 68.6 [2.8] 62.8 [2.8]* 0.003 64.3 [14.2] 0.71 
Inflammatory cytokines and MCP-1 
 
  
Interleukin 1β, pg/ml 0.6 [0.6] 0.8 [0.6]* 0.8 [0.7]* 0.8 [0.7] 0.005 0.6 [0.5] 0.16 
Interleukin 6, pg/ml 10.2 [4.8-18.1] 5.3 [2.9-10.6] 3.3 [2.2-5.9] *† 1.8 [1.1-2.6] *† <0.0001 2.3 [1.4-3.4] 0.20 
Interleukin 10, pg/ml 0.2 [0.1-1.2] 0.3 [0.1-1.3] 0.9 [0.2-1.3]* 0.5 [0.1-0.9] 0.023 0.1 [0.1-1.4] 0.52 
MCP-1, pg/ml 64.1 [39.8] 55.4 [30.5] 41.3 [26.3]*† 58.3 [52.5] 0.024 73.3 [53.8] 0.27 
CAD, coronary artery disease; MFI, median fluorescent intensity; MCP-1, monocyte chemoattractant protein; MPA, monocyte-platelet aggregates; 
Mon1, CD14++CD16-CCR2+ (‘classical’) monocytes; Mon2, CD14++CD16+CCR2+ (‘intermediate’) monocytes; Mon3, CD14+CD16++CCR2- 
(‘non-classical’) monocytes. *p<0.05 vs. day 1, †p<0.05 vs. day 3, ‡day 30 vs. stable CAD 
 
112 
 
5.4.3 Monocyte-platelet aggregates 
5.4.3.1 Comparison with control groups 
The total MPA count and MPAs associated with the Mon1 and Mon2 subsets were 
significantly higher on day 1 after STEMI compared with both control groups (p<0.0001 for 
all) (Table 5.2, Figure 5.3).  MPAs associated with the Mon3 subset were increased in number 
on day 1 after STEMI compared to HC (p=0.008) (Table 5.3).  There was a trend towards a 
higher proportion of Mon1 aggregated with platelets on day 1 after STEMI compared with 
HC (p=0.055).  There was no observed difference in the proportion of the Mon2 subset 
aggregated with platelets (p=0.65).  There was a trend towards a higher percentage of the 
Mon3 subset aggregated with platelets on day 1 after STEMI (p=0.011), but post-hoc analysis 
did not reach significance.  
 
The number of platelets aggregated with the Mon1 subset (as indicated by MPA MFI) was 
increased on day 1 after STEMI compared with stable CAD (p=0.041).  The number of 
platelets aggregated with the Mon2 subset was decreased in STEMI compared with HC 
(p=0.001) (Tables 5.2 and 5.3).  The percentage of the Mon2 subset aggregated with platelets 
(19.4 [14.9-23.1]) on day 1 after STEMI was significantly higher than the percentage of 
aggregates with the Mon1 subset (13.5 [11.1-17.4]) (p<0.001). 
 
 
5.4.3.2 Longitudinal changes in ST elevation myocardial infarction 
After STEMI, the total number of MPAs and MPAs associated with Mon1 and Mon2 were 
reduced on day 30 (p=0.005 vs. day 1 and day 3 for total MPAs; p=0.011 and p=0.055 vs. day 
1 and day 3 for Mon1; p=0.001 and p=0.019 vs. day 1 and day 3 for Mon2 respectively). At 
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day 30, total MPA count and MPAs associated with Mon1 remained significantly higher 
compared to stable CAD (p=0.003 and p=0.004, respectively).  MPAs associated with Mon2 
followed a similar but non-significant trend (p=0.069).  The number of MPAs associated with 
Mon3 on day 1 after STEMI were increased compared to HC (p=0.008), but there was no 
significant longitudinal change during follow-up.  The number of platelets aggregated with 
Mon1 (as indicated by MPA MFI) was increased in STEMI compared with stable CAD 
(p=0.041) and remained unchanged during follow-up (Table 5.3). 
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Figure 5.2  Longitudinal changes in monocyte-platelet aggregate number following ST 
elevation myocardial infarction compared with control groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total MPA count per µl (upper left) and MPAs associated with Mon1 (lower left), Mon2 
(upper right) and Mon3 (lower right) were measured in healthy controls and stable coronary 
artery disease patients.  Comparisons were made with STEMI patients measured within 24 
hours of primary PCI (day 1) and on days 3, 7 and 30.  Data are presented as median and 
interquartile range.  Horizontal bars show significant differences between the groups at 
p<0.05 level.  MPA, monocyte platelet aggregates; CAD, coronary artery disease; STEMI, ST 
elevation myocardial infarction; Mon1, CD14++CD16-CCR2+ (‘classical’) monocytes; 
Mon2, CD14++CD16+CCR2+ (‘intermediate’) monocytes; Mon3, CD14+CD16++CCR2- 
(‘non-classical’) monocytes; healthy, healthy control 
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5.4.4 Monocyte expression of CCR2, CD14 and CD16 
5.4.4.1 Comparison with control groups 
CCR2 expression by the Mon2 subset was significantly increased on day 1 after STEMI 
compared with both control groups (p<0.0001 for both) (Table 5.3). 
 
In comparison with stable CAD, patients on day 1 after STEMI had increased expression of 
CD14 by the Mon2 (p=0.002) and Mon3 subsets (p=0.02). 
 
Expression of CD16 by the Mon2 subset was reduced on day 1 after STEMI compared with 
healthy controls (p=0.001). 
 
5.4.4.2 Longitudinal changes in ST elevation myocardial infarction 
The significant elevation in CCR2 expression by Mon2 on day 1 after STEMI had reduced 
significantly by day 30 (p<0.0001) (Table 5.2).  CCR2 expression by the Mon1 subset, 
although not significantly increased at admission, reduced by day 30 (p=0.013).  Following 
STEMI, CCR2 expression by the Mon3 subset increased by day 3 (p=0.007), followed by 
reduced expression at subsequent time points (Table 5.3). 
 
The elevation in CD14 expression by Mon 2 on day 1 after STEMI had reduced significantly 
by day 7 (p=0.009).  The elevation in CD14 expression by Mon3 seen on day 1 after STEMI 
continued to increase on day 3 (p=0.048) followed by a reduction by day 7 (p=0.008 vs. day 
1, and p<0.0001 vs. day 3). 
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No significant longitudinal changes in monocyte CD16 expression were seen (Tables 5.2 and 
5.3). 
 
5.4.5 Intracellular monocyte inhibitory κB kinases levels 
5.4.5.1 Comparison with control groups 
The intracellular level of IKKβ was significantly increased in all three monocyte subsets on 
day 1 after STEMI (most prominent increase in Mon2) compared with stable CAD and HC 
(p=0.018 and p=0.015 for Mon1, p=0.007 and p=0.012 for Mon2, p<0.0001 and p<0.0001 for 
Mon3, respectively) (Table 5.2).  There was a significant negative correlation between the 
percentage of Mon1 with IKKβ levels (r=-0.40, p=0.008). A similar non-significant trend was 
observed for Mon2 (r=-0.26, p=0.094).  There was no such association seen for Mon3 (r= -
0.20, p=0.20). 
 
5.4.5.2 Longitudinal changes in ST elevation myocardial infarction 
The elevation in IKKβ level in all three monocyte subsets observed on day 1 after STEMI did 
not persist.  IKKβ levels in Mon1 and Mon3 reduced significantly by day 30 (p=0.003 and 
p=0.01, respectively).  A reduction in IKKβ levels in Mon2 was observed earlier, by day 7 
(p=0.02).  By day 30, IKKβ levels in all three monocyte subsets were similar to those in stable 
CAD (Table 5.3). 
 
5.4.6 Inflammatory cytokines and monocyte chemoattractant protein-1 
5.4.6.1 Comparison with control groups 
Plasma IL-6 levels were significantly increased in patients on day 1 after STEMI compared to 
both stable CAD and healthy controls (p<0.0001 vs. both groups) (Table 5.2). 
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Patients on day 1 after STEMI and patients with stable CAD had lower plasma levels of 
MCP-1 than healthy controls (p<0.0001 and p=0.001, respectively). 
 
No differences in plasma IL-1β and IL-10 levels were observed between STEMI patients on 
day 1 and control groups (p=0.41 and p=0.44, respectively). 
 
5.4.6.2 Longitudinal changes in ST elevation myocardial infarction 
During follow-up, the elevated plasma IL-6 level observed on day 1 after STEMI had reduced 
significantly by day 7 (p=0.001 for day 7 vs. day 3and p<0.0001 for day 30 vs. day 7) (Table 
5.3). 
 
In STEMI patients, the plasma MCP-1 level which was lower on day 1 compared to HC 
reduced further on day 7 (p=0.002 vs. day 1 and p=0.031 vs. day 3) and on day 30 had 
returned to levels not significantly different to stable CAD. 
 
Having been unchanged on day 1 after STEMI, plasma IL-1β level was increased on day 3 
(p=0.035 vs. day 1), and plasma IL-10 level had increased significantly by day 7 (p=0.033 vs. 
day 1). 
 
On day 30, all plasma cytokine levels and MCP-1 values were similar to those observed in 
stable CAD. 
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5.4.6.3 Relations between monocyte subsets, plasma cytokines and monocyte 
chemoattractant protein 1 
Plasma IL-6 levels in patients on day 1 after STEMI correlated positively with counts of 
Mon1 (r=0.55, p<0.0001), Mon2 (r=0.65, p<0.0001), total MPAs (r=0.44, p=0.002), MPAs 
associated with the Mon1 subset (r=0.41, p=0.004) and MPAs associated with the Mon2 
subset (r=0.55, p<0.0001).  Plasma IL-10 level correlated positively with the Mon2 subset 
count (r=0.34, p=0.017).  No other significant correlations were observed for IL-10, and there 
were no significant correlations seen between plasma IL-1β or MCP-1 levels and monocyte or 
MPA count. 
 
5.4.7 Relations of monocyte subsets and monocyte platelet aggregates to peak troponin 
level and left ventricular ejection fraction at 6 weeks after ST elevation myocardial 
infarction 
The median peak troponin T value after STEMI was 2.50μg/l (interquartile range 1.19-
5.50μg/l).  Peak troponin level correlated negatively with LVEF measured 6 weeks after 
STEMI (r= -0.51, p=0.002), Mon2 count on day 1 (r=0.31, p=0.044), number of platelets on 
Mon2 on day 1 (r=-0.41, 0.01), CCR2 expression by Mon2 on day 1 (r=0.30, 0.056), and 
CD14 expression by Mon2 on day 1 (r=0.34, p=0.032).  In contrast to Mon2, no correlations 
were observed between Mon1 count and peak troponin level (r = 0.11, p=0.49) or LVEF at 6 
weeks (r = -0.08, p=0.62). 
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5.4.8 Monocyte subsets and monocyte platelet aggregates as predictors of left 
ventricular ejection fraction at 6 weeks after ST elevation myocardial infarction 
Mean LVEF 6 weeks after STEMI was 54.1±14.6%.  In a univariate regression analysis, 
significant predictors of LVEF at 6 weeks were age, peak troponin level, Mon2 count on day 
1, the number of MPAs associated with Mon2 on day 1, Mon2 expression of CCR2 and 
CD14 on day 1, and Mon3 expression of CD14 on day 1.  After adjustment for age, the 
number of MPAs associated with Mon2, and Mon3 expression of CD14 remained 
independent predictors of LVEF at 6 weeks.  None of these parameters remained independent 
predictors of LVEF at 6 weeks after additional adjustment for peak troponin level.  Lower 
expression of CD16 by the Mon2 subset, measured as MFI (which was not a significant 
predictor of LVEF in the univariate analysis) was an independent predictor of higher LVEF 
at 6 weeks after adjustment for age and peak troponin level (Table 5.4). 
 
Table 5.4 Regression analysis of the predictive value of monocyte parameters for left 
ventricular ejection fraction 
 B±SE β p value 
Univariate analysis 
Age, years -0.45±0.19 -0.36 0.023 
Mon2, per μl -0.47±0.02 -0.30 0.055 
MPA with Mon2, per μl -0.20±0.09 -0.34 0.03 
MPA with Mon1, MFI 0.55±0.26 0.32 0.044 
CCR2 (Mon2), MFI -0.09±0.04 -0.32 0.044 
CD14 (Mon2), MFI -0.01±0.004 -0.31 0.053 
CD14 (Mon3), MFI -0.06±0.02 -0.38 0.015 
Adjusted for age, troponin level 
CD16 (Mon2), MFI -0.49±0.18 -0.37 0.013 
B, regression coefficient; SE, standard error; β, adjusted regression coefficient; MFI, median 
fluorescent intensity; MPA, monocyte-platelet aggregates; Mon1, CD14++CD16-CCR2+ 
(‘classical’) monocytes ;  Mon2, CD14++CD16+CCR2+ (‘intermediate’) monocytes ; Mon3, 
CD14+CD16++CCR2- (‘non-classical’) monocytes 
 
120 
 
5.5 DISCUSSION 
 
The diverse functions attributed to monocytes is likely to stem from the presence of subsets 
with heterogeneous functions (Geissmann et al, 2003; Auffray et al, 2007; Auffray et al, 2009; 
Shantsila et al, 2009; Cros et al, 2010; Zawada et al, 2011; Rogacev et al, 2010; Wong et al, 
2011).  In this study I have described for the first time the differential dynamics of the three 
human monocyte subsets in venous blood after STEMI, defined according to the 
contemporary classification (Ziegler-Heitbrock et al, 2010).  Particular emphasis was placed 
on the differences between the two types of CD16+ monocytes (Mon2 and Mon3), hitherto 
described as a single subset.  Comparisons have been made between day 1 after STEMI and 
subjects with stable CAD and healthy subjects. 
 
5.5.1 Monocyte subsets 
The novel observation of a dramatically higher number of the Mon2 subset on day 1 
compared to controls is particularly striking.  This contrasts with a less prominent (54%) 
increase in number of the Mon1 subset and no change in Mon3 subset number. 
Proportionally, Mon2 predominates over Mon3 on day 1 after STEMI, with the reverse 
pattern seen on day 30 and in subjects with stable CAD.  The observation of no change in 
number of Mon3 during 30 days after STEMI supports the recently proposed hypothesis that 
this subset has substantially different physiological roles compared to the more ‘typical’ 
functions of the Mon1 and Mon2 subsets, such as ‘patrolling’ the endothelium (Auffray et al 
2007; Cros et al, 2010).  Van der Laan and colleagues recently found that 40% of monocytes 
within the necrotic core during the proliferative phase after MI (5-14 days) are CD14+CD16+ 
cells) (van der Laan et al, 2013).  This is clearly a much higher proportion than the total 
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proportion of Mon2 + Mon3 (ie total of CD14+CD16+ cells) seen in my study, which stayed 
remarkably similar at each time point after STEMI: 18.5% on day 1, 18.7% on day 3, 18.0% 
on day 7, 17.7% on day 30 (17.7% in stable CAD) (Table 5.3).  This suggests that 
CD14+CD16+ cells may be selectively recruited into the myocardium after MI, although it 
should be noted that all subjects in the van der Laan study had died after MI suggesting a 
more severe and extensive burden of necrosis than in my cohort where the mean EF at 6 
weeks was 54.1%.  Moreover, CD16+ cells were considered as a single population which is a 
significant limitation (van der Laan et al, 2013).  As I observed a marked increase then 
decrease in Mon2 subset number in venous blood after STEMI but no longitudinal change in 
Mon3 number, one may speculate that the CD14+CD16+ cells within the necrotic core may 
be of the Mon2 subset.  Furthermore, as the number of monocytes in the spleen in the early 
phase after MI (3-12 hours) is significantly reduced (van der Laan et al, 2013), these Mon2 
may have been liberated from a splenic reservoir.  Alternatively, they may also be liberated 
from the bone marrow, as our previous work demonstrated that all three monocyte subsets are 
present in bone marrow, which contained relatively higher proportions of Mon2 than found in 
circulation (Shantsila et al, 2011).  My observation of a significant elevation of Mon2 count 
on days 1 and 3 followed by a significant reduction on day 7 and return to levels comparable 
to controls at day 30 (compared to total monocyte and Mon1 counts which remained elevated 
on day 7) is in accordance with the findings of Nahrendorf and colleagues in mice, where 
levels of both the Ly-6C
high
 and Ly-6C
low
 subsets in circulation were higher during phase I 
than phase II.  The significant reduction in Mon2 number on day 7 in my study is in keeping 
with the observed increased capacity for Ly-6C
low
 monocytes to migrate into the myocardium 
at this stage in mice (Nahrendorf et al, 2007).  
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Data supporting the hypothesis that the Mon2 subset has unique properties are supported by 
the findings of specific and highly significant changes in their phenotype after STEMI in this 
study, including increases in CD14 and CCR2 expression and reduction in CD16 expression. 
In contrast, the only significant phenotypic change observed in the other monocyte subsets 
after STEMI was an increase in CD14 expression by Mon3.  Although the NFκB pathway 
appeared to be more active in all 3 monocyte subsets after STEMI when compared to controls 
(defined by an increased intracellular IKKβ level), the highest level of this key transcriptional 
factor was observed in the Mon2 subset, thus suggesting a prominent increase in their 
functional activity. 
 
Our research group and others have shown that both the Mon1 and Mon2 subsets can 
produce high levels of pro-inflammatory cytokines in healthy subjects.  However, a unique 
feature of the Mon2 subset is the ability to produce high levels of the anti-inflammatory 
cytokine IL-10 (Cros et al, 2010; Shantsila et al, 2011).  In this study, I found that the Mon1 
count on day 1 after STEMI correlates significantly with plasma levels of the pro-
inflammatory cytokine IL-6, whilst Mon2 subset count correlates with levels of both IL-6 
and IL-10. 
 
As this study was purely observational in its approach, it is difficult to speculate on the exact 
biological roles of the changes in monocyte parameters seen.  However, the vast majority of 
dynamic changes observed corresponded to the Mon 2 subset.  For example, the only 
significant correlations between monocyte parameters and peak troponin level were with 
Mon2 number and characteristics.  Additionally, univariate regression analysis showed that 
most monocyte-associated predictors of LVEF at 6 weeks were related to the Mon2 subset, 
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including the count of Mon2 and count of MPAs associated with Mon2.  Furthermore, the 
only parameter in this study that independently predicted LVEF at 6 weeks following STEMI 
after adjustment for age and peak troponin level was CD16 expression by Mon2 (lower CD16 
expression predicted better LVEF).  These findings suggest a close relationship between 
numerous Mon2 subset characteristics and the degree of myocardial damage and recovery 
following STEMI.  This is in accordance with recent data relating the Mon2 subset to 
cardiovascular prognosis (Rogacev et al, 2010; Rogacev et al, 2012), and suggests a more 
selective relationship between specific monocyte subsets and prognosis than absolute 
monocytosis per se.  The observations made in this study lend support to the literature which 
suggests a specific role for the Mon2 subset in the pathophysiology of MI.  There are several 
similarities between Mon2 and the potentially reparative and angiogenic monocytes described 
in experimental studies (De Palma et al, 2005; Morimoto et al, 2007; Shantsila et al, 2011).  
This suggests that further research into the reparative potential of the Mon2 subset may be of 
interest. 
  
Several observations in this study contrast with those reported in humans by Tsujioka and 
colleagues (Tsujioka et al, 2009).  Firstly, they observed no difference in CD14+CD16- 
monocyte count, but a significantly lower CD14+CD16+ count respectively after STEMI 
compared with stable angina subjects.  They also described the sequential mobilisation of 
two monocyte subsets in circulation following STEMI, with peak CD14+CD16- monocyte 
count on day 2.6 and peak CD14+CD16+ monocyte count on day 4.  However, the trends 
described did not reach statistical significance and should therefore be interpreted with 
caution.  Additionally, in direct contrast to mouse data, Tsujioka and colleagues did not find 
a relationship between CD16+ monocyte count and myocardial recovery and outcome 
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following STEMI (Nahrendorf et al, 2007; Tsujioka et al, 2009).  These discrepancies 
between our findings are likely to arise from methodological differences.  These include 
variation in definitions of monocyte subsets, gating strategies, and counting the two CD16+ 
monocyte subsets (Mon2 and Mon3 in this study) together as a single subset (Tsujioka et al, 
2009).  These differences make comparisons between our findings difficult.  As I discussed 
in section 5.2, my aim was to evaluate monocytes after STEMI using the contemporary 
definition of three subsets, which has not been previously undertaken (Ziegler-Heitbrock et 
al, 2010).    
 
It remains unclear whether the differentiation of human monocytes into specific subsets is 
already complete in the bone marrow or whether this maturation occurs in the circulation and 
tissues as has been demonstrated in mice.  The Mon1 subset has been reported to show some 
degree of CD16 expression after stimulation (Passacquale et al, 2011).  The changes in 
phenotype observed may reflect their differentiation towards the Mon2 subset or maturation 
into CD16+ macrophages.  Our previous work demonstrated that all three monocyte subsets 
are present in bone marrow, which contained relatively higher proportions of Mon2 than 
found in circulation (Shantsila et al, 2011).  A rapid release of the Mon2 subset from bone 
marrow into the circulation may explain the dramatic increase in Mon2 count on day 1 after 
STEMI in this study.  Further research is required to answer these questions about monocyte 
phenotypic differentiation.  
 
5.5.2 Monocyte platelet aggregates 
The finding of a significant (~80%) rise in MPA count on day 1 after STEMI is in accordance 
with previous findings (Furman et al, 2001).  However, this study demonstrates for the first 
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time that the increase in MPA count persists at 30 days after STEMI, despite ongoing potent 
dual antiplatelet therapy, and after the monocyte count has returned to a level comparable to 
stable CAD.  Although the pathophysiological implications of this observation are unclear, it 
is in accordance with the accumulating data describing the important regulatory role platelets 
have in modulating the functional activity of monocytes.  Aggregation of monocytes with 
platelets up-regulates expression of surface receptors to adhesion molecules which promotes 
monocyte migration to tissues (Simon et al, 1993; van Gils et al, 2008; Kuckleburg et al, 
2011). 
  
Although the increase in MPA count observed in this study was partly attributable to an 
increase in total monocyte count, there was also a strong trend towards an increased 
proportion of the Mon1 subset aggregated with platelets after STEMI, which persisted 
throughout follow-up.  Given the potent antiplatelet therapy used after STEMI, these results 
suggest that monocyte-platelet interactions may involve mechanisms beyond simple platelet 
aggregation.  The finding that aggregation of the Mon1 subset with platelets was associated 
with a reduced IKKβ level provides indirect evidence of the regulatory role of platelet 
interactions on monocytes functional activity.  The effect of platelets on monocytes is 
complex.  Certain monocyte functions may be activated by interaction with platelets whereas 
others are inhibited. Moreover, the net effects on monocytes may also depend on the 
activation status of the platelets, which is dependent upon other factors.  
 
These observations on monocyte-platelet interactions after STEMI may be related to the 
dynamic changes found in circulating CD16+ monocytes in this study and that of Tsujioka 
and colleagues, together with the circulating and myocardial levels of Ly6C
low
 monocytes in 
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mice (Nahrendorf et al, 2007; Tsujioka et al, 2009).  Although the absolute number of the 
Mon3 subset was unchanged after STEMI, the proportion of Mon3 aggregated with platelets 
was increased on day 1 and peaked on day 7.  Similarly to healthy subjects, Mon2 following 
STEMI had the highest (over 20%) proportion of aggregation with platelets seen in the three 
monocyte subsets.  The number of platelets per one Mon2 (as reflected by MFI) was 
significantly reduced on day 1, when the number of Mon2 peaked; however, the reverse trend 
was seen on day 7, when Mon2 count reduced significantly.  Current evidence suggests that 
(i) CD16+ monocytes may  promptly migrate to tissues following  activation, (ii) formation of 
MPAs promotes monocyte migration and (iii) mouse ‘equivalents’ of human CD16+ 
monocytes predominate in the myocardium but not in circulation on day 7 after MI 
(Nahrendorf et al, 2007; Cros et al, 2010; Kuckleburg et al, 2011).  Therefore, this raises the 
possibility that from day 7 onwards, levels of Mon2 and Mon3 in circulation may not directly 
reflect their level in the myocardium, due to platelet-mediated migration through the 
endothelium.  However, my aim in this study was purely to characterise the three monocyte 
subsets in peripheral blood.  Assessment of myocardial levels of the three human monocyte 
subsets following STEMI would be very informative and of great interest.  
 
5.5.3 Comparison of healthy subjects and stable coronary artery disease 
I did not observe any differences at all between monocyte subset count or proportion, or their 
association with MPAs between healthy subjects and patients with CAD.  This suggests that 
the presence of CAD, the co-existing risk factors and co-morbidities associated with CAD and 
the medication used in its treatment do not affect these monocyte parameters, and the 
differences observed were related to the pathophysiological processes of STEMI.  
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5.6 LIMITATIONS 
 
My study aimed to characterise the dynamic changes in the three human monocyte subsets in 
peripheral blood following STEMI in a real-world setting and explore relationships with 
convalescent LVEF.  Mouse data suggests that monocyte counts and activity in circulation 
may not reflect their accumulation and functionality within the myocardium (Nahrendorf et al 
2007).  Hence, any extrapolation of my findings towards suggestions of how monocyte 
subsets may migrate into and accumulate in tissues is purely speculative and hypothesis 
generating.  Mechanistic conclusions cannot be drawn from the observational approach of this 
study. 
 
It is not possible to distinguish whether the changes observed in expression of surface markers 
following STEMI reflect activation of monocyte subsets or the process of their differentiation 
into other subsets.  Further studies would be required to explore the significance of an 
increase in individual subset number, changes in expression of surface markers and whether 
these represent selective expansion or transformation between subsets. 
 
Correlations were made between monocyte subset counts and certain cytokines.  However, 
this does not confirm to what extent if any these cytokines were secreted by the respective 
monocyte subset. 
 
Although statistically significant, the correlations observed between monocyte parameters, 
peak troponin level and convalescent LVEF are not strong and any pathological implications 
based upon them should be made with caution.  However, strong correlations may perhaps not 
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be expected as the pathophysiological mechanisms underlying development of 
atherosclerosis, myocardial infarction and the ensuing recovery processes involve multiple 
cell types and are complex.  
 
Although the number of subjects recruited exceeded the minimum number derived from the 
power calculation, the relatively small sample size and short follow-up in this study precludes 
evaluation of the impact of individual monocyte subsets and associated MPAs on clinical 
outcomes other than LVEF.  The remarkable success of PPCI delivered expeditiously in 
restoring coronary blood flow is highlighted by the low 30 day mortality rate (n=2, 4%) and 
relatively minor impairment of LVEF recorded at 6 weeks after STEMI (54.1±14.6%).  This 
suggests that the average ‘magnitude’ of myocardial infarction suffered by a patient in this 
study is relatively small.  This is undoubtedly important for patients, as convalescent LV 
systolic function is the most important determinant of long-term prognosis.  The observations 
made in this study may have been more striking, and perhaps trends detected may have 
become significant, if repeated in a cohort of patients with relatively larger degrees of 
myocardial damage.    
 
There was a higher proportion of cigarette smokers in STEMI subjects compared to controls, 
and a higher proportion treated with clopidogrel or prasugrel.  These factors may influence 
cross-sectional comparisons of MPAs. 
 
Of the 50 patients with STEMI recruited, 33 completed follow up at 30 days.  The principle 
reasons for withdraw of consent (n=14) were logistical difficulties in attending follow up 
appointments and unwillingness to continue with the blood tests required for this study in 
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addition to the frequent blood tests needed for routine care post-MI rather than being too 
unwell.  Hence, the patients who withdrew consent are unlikely to differ pathophysiologically 
from those who completed follow-up. 
 
It was logistically impossible to plan to undertake sample collection at the same time each 
day.  However, the majority of samples were collected from all subject groups between 09.00 
and 12.00.  The remaining influence of diurnal variation on monocyte parameters is likely to 
be minimal but should be considered as a limitation (Shantsila et al, 2012). 
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5.7 CONCLUSIONS 
 
This study describes for the first time the dynamic differences between the three human 
monocyte subsets, as defined according to contemporary nomenclature, following STEMI.  
Many significant dynamic and phenotypic differences were found, especially related to the 
CD14++CD16+ Mon2 subset.  The count of the Mon2 subset increased dramatically after 
STEMI and correlated significantly with peak troponin level, plasma cytokines and 
convalescent LVEF.  All monocyte subsets exhibited evidence of functional activation, but 
this was most prominent in Mon2 following STEMI.  The increase in MPA count persisted 30 
days after STEMI despite potent dual antiplatelet therapy.  These findings are in accordance 
with data supporting distinct functional differences between the two CD16+ monocytes 
subsets.  This confirms that these subsets should be analysed separately in future studies in 
order to fully understand their specific role. 
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CHAPTER 6 
 
TOLL-LIKE RECEPTOR 4 EXPRESSION BY MONOCYTE 
SUBSETS IN MYOCARDIAL INFARCTION 
 
 
 
 
 
 
 
 
 
 
Contributory publication: TLR4 expression on monocyte subsets in myocardial infarction.  
Tapp LD, Shantsila E, Wrigley BJ, Montoro-Garcia S, Lip GY.  J Intern Med 2013; 273(3): 
294-305. 
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Abstract 
 
Monocyte TLR4 has been implicated in the pathogenesis of atherosclerosis, and increased 
levels observed following MI.  This study aimed to assess the numbers of TLR4+ monocytes 
in the three human subsets following MI, their expression of TLR4 and their associations with 
markers associated with monocyte activation and inflammation, myocardial damage and post-
MI cardiac contractility. 
The three monocyte subsets were defined as CD14++CD16-CCR2+ (Mon1), 
CD14++CD16+CCR2+ (Mon2) and CD14+CD16++CCR2- (Mon3).  Monocyte surface 
expression of TLR4 and the number of TLR4-expressing monocytes was assessed by flow 
cytometry of venous blood in 50 patients with STEMI, 48 with NSTEMI and 40 controls with 
stable CAD.  Parameters were measured on days 1, 3, 7 and 30 post-MI in STEMI patients.  
Plasma inflammatory cytokine levels were assessed using cytometric bead array. 
There were significant increases in counts of TLR4+ Mon1 and Mon2 in STEMI and TLR4+ 
Mon2 in NSTEMI compared with CAD.  Monocyte TLR4 expression was similar between 
groups, and did not change during follow-up in STEMI.  Plasma IL6 levels correlated 
positively with TLR4+ Mon2 count (r = 0.54, P < 0.001), but negatively with TLR4 
expression by Mon2 (r = -0.33, P = 0.021). 
Following acute MI, TLR4 expression by individual human monocyte subsets is unchanged.  
The increase in TLR4+ Mon1 and Mon2 count after STEMI and TLR+ Mon2 count after 
NSTEMI is due to an increase in monocyte subset number and not to changes in TLR4 
133 
 
expression.  Monocyte count but not TLR4 expression correlates positively with plasma IL6 
level.  TLR4 expression may not be a reliable marker of monocyte activation after MI.  
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6.1 INTRODUCTION 
 
6.1.1 Toll-like receptor 4 
TLR4 is a member of the pattern recognition receptor family.  It is involved in innate 
immunity via bacterial endotoxin-induced inflammatory responses, but it has also been 
implicated in the pathogenesis of atherosclerosis (Edfeldt et al, 2002).  The role of TLR4 in 
cardiovascular disease may be attributed to responsiveness to host ligands, such as HSP 
released during myocardial damage, fibronectin, and reactive oxidative species (Vabulas et al, 
2002; Asehnoune et al, 2004).  Whilst the biological roles of TLR4-mediated pathways 
represent an anti-bacterial defense mechanism, its chronic stimulation or acute up-regulation 
in the setting of atherosclerotic CAD may be detrimental, by facilitating excessive 
inflammation, leukocyte accumulation and release of MMPs (Xu et al, 2001).  TLR4 over-
expression by monocytes in acute MI, both in the circulation and in ruptured plaques, has 
been associated with high levels of inflammatory cytokines, including IL-6 (Ishikawa et al, 
2008).  Conversely, inhibition of TLR4 in mouse models of MI attenuated the inflammatory 
process and was associated with smaller infarct size (Nakamura et al, 2007).  
 
6.1.2 Toll-like receptor 4 and monocyte subsets 
However, most published work on human monocyte TLR4 over-expression is in vitro, in 
isolated monocytes which may influence monocyte phenotype.  Moreover, examination of the 
whole monocyte pool does not take into account the presence of distinct monocyte subsets 
(chapter 1.2).  Even in the most recently published study considering monocyte subsets 
separately, ‘classical’ CD14++CD16– monocytes were compared with CD14+CD16+ 
monocytes; i.e. CD14++CD16+ (‘Mon2’ Intermediate’) and CD14+CD16++ (‘Mon3’ 
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‘Nonclassical’) cells were grouped together as a single cell population (Kashiwagi et al, 
2012).  Hence, little is known about TLR4 parameters and their relationships in monocytes 
defined as three subsets according to contemporary nomenclature (Ziegler-Heitbrock et al, 
2010; Shantsila et al 2011) in healthy subjects or in the setting of MI. 
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6.2 AIMS AND HYPOTHESES 
 
In this study, my objective was to assess numbers of TLR4+ monocytes in each of the three 
human subsets in patients with STEMI and NSTEMI, their expression of TLR4, and relations 
to markers of monocyte pro-inflammatory activation, myocardial damage, inflammatory 
cytokines and convalescent post-MI cardiac contractility.  Parameters of monocyte TLR4 
expression in patients with MI were compared with matched subjects with stable CAD.  As 
our research group has previously observed marked differences in monocyte subsets in 
healthy subjects (Shantsila et al, 2011), I hypothesized that there would be distinct differences 
in TLR4 parameters between patients with MI versus healthy subjects and that there would be 
dynamic changes between the acute phase of MI and the recovery phase.   
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6.3 METHODS AND MATERIALS 
 
6.3.1 Study population 
Fifty consecutive subjects with STEMI admitted to SWBH Hospitals NHS Trust and 48 with 
NSTEMI admitted to SWBH NHS Trust or Heart of England NHS Foundation Trust were 
recruited between November 2009 and May 2011 (chapter 3.1).  MI was diagnosed according 
to the consensus universal definition (Thygesen et al, 2007) (chapter 1.1.3).  All STEMI 
patients underwent PPCI (chapter 1.1.5.1.2).  All study patients received standard treatment 
according to the contemporary ESC guidelines (Bassand et al, 2007; Van de Werf et al, 2008).  
STEMI patients and NSTEMI patients were compared to an age- and sex-matched group with 
stable CAD (n=40) (chapter 3.1.2.1).  Exclusion criteria are described in chapter 3.1.3.  
 
 
6.3.2 Blood sample collection 
In STEMI patients, blood samples were collected at 4 time points: day 1 within 24 hours of 
MI (after PPCI), day 3, day 7 and day 30 (section 3.1.1.2).  A proportion of STEMI patients 
did not complete follow-up due to withdrawal of consent, re-infarction or death (chapter 
5.4.1). 
 
In NSTEMI patients, blood samples were collected on day 1, before PCI.  All patients had 
received loading doses of dual anti-platelet therapy (aspirin plus clopidogrel) and low-
molecular weight heparin prior to venesection (chapter 1.1.6). 
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All subjects were asked to refrain from extreme physical exertion for at least 1 hour prior to 
sample collection (section 3.3.1).  Peripheral venous blood samples were collected from all 
participants and processed by flow cytometry within 60 minutes (chapter 3.2).  Plasma was 
separated by centrifugation and stored at –70oC for batched ELISA analysis (chapter 3.4). 
 
Routine haematology and biochemistry investigations were undertaken by the hospital 
laboratory (chapter 3.5). 
 
6.3.3 Flow cytometry 
Flow cytometric analysis was performed as described in chapter 3.2.  The three monocyte 
subsets were defined as CD14++CD16-CCR2+ (Mon1), CD14++CD16+CCR2+ (Mon2) and 
CD14+CD16++CCR2- (Mon3) in keeping with contemporary nomenclature (Shantsila et al, 
2011; Ziegler-Heitbrock et al, 2010). 
 
Monocyte surface TLR4 expression by each subset was analysed as described in chapter 
3.2.3., quantified as MFI, using appropriate isotype controls to establish cut-off levels for 
positivity in keeping with current consensus guidance (Ziegler-Heitbrock et al, 2010) (figure 
6.1). 
 
Intracellular level of IKKβ was measured as described in chapter 3.2.4.  
 
Plasma levels of IL-1β, IL-6, IL-10 and MCP-1 were measured by cytometric bead array 
technology as described in chapter 3.2.5. 
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Figure 6.1 Assessment of Toll-like receptor 4 expression by monocyte subsets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Top figures, definition of monocyte subsets based on their CD14, CD16, and CCR2 
expression; bottom figures, TLR4 expression is quantified for individual monocyte subsets. 
Mon1, CD14++CD16–CCR2+ monocytes; Mon2, CD14++CD16+CCR2+ monocytes; Mon3, 
CD14+CD16++CCR2– monocytes; TLR4, toll-like receptor 4 
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6.3.4 Assessment of left ventricular function 
Patients underwent echocardiographic assessment of convalescent LVEF by Simpson’s 
method 6 weeks after STEMI (chapter 3.6) 
 
6.3.5 Statistical analysis 
Statistical analyses were performed as described in chapter 3.8.  Univariate and multivariate 
linear regression analyses were used to establish predictive value of the study parameters for 
LVEF at 6 weeks in STEMI patients. 
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6.4 RESULTS 
 
6.4.1 Subject characteristics 
50 patients with STEMI (mean age [standard deviation] 58 [12] years, 86% male), 48 patients 
with NSTEMI (mean age 60 [12] years, 83% male) and 40 patients with stable CAD (mean 
age 60 [11] years, 83% male) were recruited.  Demographic and clinical details are 
summarised in table 6.1.  The study groups were well matched for most demographic and 
clinical parameters, and most medications.  Glycoprotein IIbIIIa inhibitors were administered 
to 96% of STEMI patients but only 10% of NSTEMI subjects.  Patients with MI had higher 
rates of clopidogrel/prasugrel (100%) usage that subjects with stable CAD (75%, p<0.001 for 
both STEMI and NSTEMI).  Thirty three STEMI patients completed follow-up (chapter 
5.4.1).  Twenty seven STEMI patients had data on TLR4 expression at all four time-points; 
the remainder could not be analysed due to logistical difficulties in sourcing anti-TLR4 
antibodies midway through the project.  Despite this factor, the number of patients with data 
on TLR exceeded the minimum required from the power calculation.  
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Table 6.1 Subject demographics, clinical characteristics and medication 
 
 STEMI 
(n=50) 
NSTEMI 
(n=48) 
Stable CAD 
(n=40) 
p value 
Demographic and clinical characteristics 
Age, years 57.5 [11.7] 60.6 [12.4] 60.4 [10.8] 0 .58 
Male, n (%) 43 (86) 39 (83) 33 (83) 0.96 
BP systolic, mmHg 132 [18] 137 [17] 133 [15] 0.56 
BP diastolic, mmHg 78 [14] 82 [10] 75 [9] 0.15 
Body mass index, kg/m
2
 30 [6] 28 [6] 29 [5] 0.46 
Smoking, n (%) 29 (58) 27 (57) 17 (43) <0.001 
Stroke, n (%) 3 (6) 2 (4) 5 (13) 0.27 
Hypertension, n (%) 24 (48) 27 (57) 20 (50) 0.65 
Diabetes, n (%) 16 (32) 14 (30) 8 (20) 0.50 
Creatinine, μmol/l 91.7 [18.5] 92.3 [27.0] 89.5 [17.9] 0.51 
Platelets, per μl 263 [98] 247 [58] 233 [56] 0.35 
Medications at time of recruitment 
Aspirin, n (%) 50 (100) 47 (100) 36 (90) 0.075 
Clopidogrel or prasugrel, n (%) 50 (100) 47 (100) 18 (45) <0.001 
Glycoprotein IIbIIIa inhibitor 48 (96) 5 (11) - <0.001 
Statins, n (%) 50 (100) 47 (100) 34 (85) 0.063 
ACE inhibitor or ARA, n (%) 45 (90) 39 (83) 29 (73) 0.22 
Diuretics, n (%) 2 (4) 2 (4) 5 (13) 0.17 
Beta-blockers, n (%) 35 (70) 34 (72) 27 (68) 0.97 
Calcium channel blockers, n (%) 8 (16) 13 (28) 11 (28) 0.27 
 
ACE, angiotensin converting enzyme; ARA, angiotensin receptor antagonist; BP, blood 
pressure; CAD, coronary artery disease; STEMI, ST-elevation myocardial infarction; 
NSTEMI, Non-ST-elevation myocardial infarction.  [SD].  (%). 
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6.4.2 Cross-sectional comparison of monocytes, monocyte subsets and Toll-like receptor 
4 parameters 
Mirroring our previous observations following STEMI, there were significant but numerically 
less prominent increases in Mon1 and Mon2 subset count and no change in Mon3 subset 
count following NSTEMI (Figure 6.2) (Tapp et al, 2011). Also, patients with NSTEMI 
showed a trend similar (but not statistically significant) to that observed following STEMI, 
with a reduced relative proportion of Mon3 but increased relative proportion of Mon2, so that 
Mon2 predominated over Mon3 in STEMI and NSTEMI in contrast to stable CAD (Figure 
6.2) (Tapp et al, 2011). 
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Figure 6.2 Counts and percentage of individual monocyte subsets in the study groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mon1, CD14++CD16–CCR2+ monocytes; Mon2, CD14++CD16+CCR2+ monocytes; Mon3, 
CD14+CD16++CCR2– monocytes; CAD, coronary artery disease; STEMI, ST-elevation 
myocardial infarction; NSTEMI, non ST-elevation myocardial infarction; p, p value.  Boxes 
represent 25
th
, 50
th
 and 75
th
 centiles. Whiskers represent 5
th
 and 95
th
 centiles.  Horizontal lines 
represent significant differences between groups. 
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There was a significant increase in TLR4+ Mon1 and Mon2 subset count in STEMI and 
TLR4+ Mon2 count only in NSTEMI (Table 6.2, Figure 6.3).  There was no difference in 
TLR4 expression on any monocyte subset (neither percentage, nor MFI) despite the study 
being powered to detect even small (20%) changes (Table 6.2). 
 
 
Table 6.2 Toll-like receptor 4 expressing monocytes and monocyte subsets in the study 
groups 
 
 
STEMI 
(n=50) 
NSTEMI 
(n=48) 
CAD 
(n=40) 
p value 
STEMI 
vs. CAD 
p value 
NSTEMI 
vs. CAD 
TLR4+ Monocytes, per µl 130 [68-190] 102 [52-162] 80 [39-145] 0.008 0.315 
TLR4+ Mon1, per µl 82 [43-140] 60 [32-106] 54 [25-110] 0.034 0.690 
TLR4+ Mon2, per µl 25 [13-49] 21 [11-36] 13 [8.7-19] 0.005 0.015 
TLR4+ Mon3, per µl 6.3 [3.8-12] 8.4 [4.0-13] 8.3 [4.9-12] 0.193 0.591 
TLR4+ Mon1, % 12 [7-18] 9.7 [5.3-17] 12 [6.8-20] 0.952 0.518 
TLR4+ Mon2, % 39 [23-56] 47 [28-61] 40 [30-57] 0.554 0.640 
TLR4+ Mon3, % 11 [7-18] 13 [6.9-22] 16 [9.5-20] 0.102 0.630 
TLR4 (Mon1), MFI 6.4 [2.0] 5.9 [2.2] 6.0 [1.7] 0.36 [82%]* 0.93 [81%]* 
TLR4 (Mon2), MFI 10.1 [4.8] 10.7 [5.1] 10.3 [4.8] 0.83 [52%]* 0.80 [50%]* 
TLR4 (Mon3), MFI 4.0 [1.7] 4.1 [1.7] 3.9 [0.8] 0.85 [75%]* 0.71 [81%]* 
CAD, coronary artery disease; MFI, median fluorescent intensity; Mon, monocytes; Mon1, 
CD14++CD16–CCR2+ monocytes; Mon2, CD14++CD16+CCR2+ monocytes; Mon3, 
CD14+CD16++CCR2– monocytes; NSTEMI, non ST-elevation myocardial infarction; 
STEMI, ST-elevation myocardial infarction; TLR4, Toll-like receptor 4.  Data expressed as 
median [interquartile range] or mean [standard deviation] *Statistical power (1-β) to detect a 
minimum 20% changes in TLR4 expression. 
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Figure 6.3 Toll-like receptor 4 expressing monocytes in the study groups 
 
Mon1, CD14++CD16–CCR2+ monocytes; Mon2, CD14++CD16+CCR2+ monocytes; Mon3, 
CD14+CD16++CCR2– monocytes; TLR4, toll-like receptor 4; CAD, coronary artery disease;  
STEMI, ST-elevation myocardial infarction; non-STEMI, non ST-elevation myocardial 
infarction; p, p value (horizontal lines).  Red bars represent mean and standard deviation. 
 
p=0.034 
p=0.69 
p=0.005 
p=0.015 
p=0.19 
p=0.59 
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6.4.3 Longitudinal changes in Toll-like receptor 4 expression by monocyte subsets after 
STEMI 
There was no change in TLR4 expression during follow up in STEMI (Table 6.3). 
 
Table 6.3 Monocyte TLR4 expression during follow-up in patients with ST-elevation 
myocardial infarction 
 
 Day 1 Day 3 Day 7 Day 30 p value 
TLR4 (Mon1), MFI 5.9 [5.0-7.0] 5.5 [4.6-7.4] 5.7 [4.9-6.9] 5.1 [4.1-6.2] 0.17 
TLR4 (Mon2), MFI 9.7 [7-13] 10 [7-16] 8.9 [7-15] 7.5 [5-15] 0.44 
TLR4 (Mon3), MFI 3.6 [2.9-4.6] 4.1 [3.4-4.9] 4.5 [3.4-5.5] 3.8 [2.9-5.1] 0.29 
MFI, median fluorescent intensity; Mon1, CD14++CD16–CCR2+ monocytes; Mon2, 
CD14++CD16+CCR2+ monocytes; Mon3, CD14+CD16++CCR2– monocytes; TLR4, Toll-
like receptor 4.  Data expressed as median [interquartile range]. 
 
 
6.4.4 Correlations with monocyte Toll-like receptor 4 parameters 
On day 1 following STEMI, troponin level correlated positively with TLR4+ Mon2 subset 
count (r=0.31, p=0.044) but not with TLR4 expression on Mon2 (nor any other subset). 
Plasma IL6 level correlated positively with TLR4+ Mon2 count (r=0.54, p<0.001), but 
negatively with TLR4 expression on Mon2 (r=-0.33, p=0.021).  No significant association 
was found between TLR4–related monocyte parameters and convalescent LVEF 6 weeks 
after STEMI.  No significant correlation was found between monocyte TLR4 expression and 
their IKKβ level. 
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6.5 DISCUSSION 
 
This study shows for the first time that MI is associated with increased numbers of TLR4+ 
monocytes, but not with higher TLR4 expression by individual monocyte subsets.  Moreover 
the increase in TLR4+ monocytes is only attributed to specific human monocyte subsets 
(Mon1 and Mon2 in STEMI and Mon2 only in NSTEMI).  This suggests that TLR4 
expression may not be a reliable marker of monocyte activation in MI.  
 
Given that these findings contradict some previously published data on monocyte TLR4 
expression in MI (as summarised in Table 6.3), the possible reasons for this merit discussion.  
Although all studies point towards increases in TLR4+ monocyte parameters, there is marked 
heterogeneity between these studies.  For example the proportion of monocytes expressing 
TLR4 in comparable STEMI cohorts varies from 6% to about 80%; in the present study 12% 
of ‘classical’ monocytes (Mon1) expressed TLR4 in STEMI.  Similar variations are also seen 
in control samples (Azeredo et al, 2010; Xie et al, 2010; Methe et al, 2005).  These 
discrepancies are likely to reflect differences in methodological approaches used and 
populations tested.  The lowest proportions of TLR+ expressing monocytes are seen in studies 
which analysed fresh whole blood samples when compared to protocols based on prolonged 
sample processing (including density centrifugation, adhesion to plastic or immune-magnetic 
separation, and often in vitro culture) (Table 6.3).  As there is consistent evidence of 
monocyte activation in STEMI, and their high responsiveness to external stimuli results in 
prompt TLR4 up-regulation, it is likely that monocyte TLR4 expression may be increased by 
sample processing.  Monocytes following STEMI may potentially be more sensitive in this 
regard due to their activated state (Satoh et al, 2006).  
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Another confounding factor is related to variations in the definition of TLR4-expressing 
monocytes by flow cytometry.  Monocytes do not form a separate cluster of TLR4-expressing 
cells, but rather show a continuous spectrum of cells with varying TLR4 expression.  With the 
exception of the Mon2 subset, this expression is rather low.  In these circumstances definition 
of ‘TLR4-positivity’ critically depends on the cut-off value used.  This is reflected in the  
lower proportion of TLR4+ cells in studies employing isotope controls (aiming to account for 
non-specific binding) compared to the studies using ‘sham’ controls (Xie et al, 2010).  As 
TLR4 is functionally a co-receptor for CD14 which is a key part of the innate immune system, 
continuous low level expression of TLR4 would perhaps be expected rather than variable or 
inducible expression.  Thus, TLR4 is likely to be expressed on all monocytes (at least Mon1 
and Mon2), but in such low levels that its expression may be difficult to discriminate from 
isotype controls.  Accordingly, the assessment of monocyte TLR4 expression may be 
preferable via MFI rather than percentage of TLR4+ cells.  Lastly, several studies used 
healthy volunteers as controls, which makes drawing conclusions on whether differences 
observed are purely due to MI or other co-morbidities, cardiovascular risk factors and their 
treatments problematic. 
 
Of interest, there appears to be a general trend towards lower monocyte TLR4 expression in 
more recent studies, which might indicate that more effective contemporary medical therapy 
underlies the relatively low TLR4 expression seen.  This may partly explain the lack of 
significant differences in monocyte TLR4 expression between the groups in this study. 
Virtually all STEMI patients and a fraction of NSTEMI patients received platelet glycoprotein 
IIbIIIa inhibitors and all were on potent dual antiplatelet therapy (aspirin plus clopidogrel or 
prasugrel).  Given that monocyte-platelet interactions play significant roles in regulation of 
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monocyte phenotype and activity, the use of such antiplatelet therapy may influence 
monocyte TLR4 expression (Shantsila & Lip, 2009). 
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Table 6.4  Published data on Toll-like receptor 4 expression in myocardial infarction 
 
Study 
Study patients 
[mean age] 
Controls 
[mean  age] 
Source of sample, 
Sample processing 
TLR4 measure Findings 
Mon 
counts 
Other findings 
Limitations 
Kashiwagi 
et al, 2012  
22 MI  
(17 STEMI) 
[67] 
27 CAD 
[65] 
PB and CA blood, 
Fresh whole blood 
TLR4+ Mon % for 
Mon1and all CD16+ 
Mon [Mon2 + Mon3]  
↑in MI (~6% for Mon1 and ~15% for 
CD16+ Mon) vs. CAD (~2% for Mon1 
and ~4% for CD16+ Mon). 
↑in CA lesion site than in PB (CD16+ 
Mon only). 
TLR4 Mon% in MI ↓ by day 12. 
NA, 
CD16+ 
Mon ↓ in 
STEMI 
vs. CAD  
Plasma TNFα and CRP positively 
correlated with TLR4 expression on 
Mon (all subsets together).  
Mon2 and Mon3 analysed together. 
Yonekawa 
et al, 2011 
20 STEMI,  
7 NSTEMI 
[53] 
NA PB and CA thrombi, 
DC, negative IM 
selection on CD14+ 
cells 
Mon TLR4 MFI MRP8/14 enhanced Mon TLR4 
expression in thrombi, but not in PB 
NA  
Sheu 
et al, 2008 
43 STEMI 
[62] 
20 HC 
[62] 
PB 
DC, 2 h in culture, 
detached by scrapping, 
further 24h incubation 
with or without LPS 
Mon TLR4 MFI ↑in MI with MACE (3.6 [0.9]) vs. MI 
without MACE (2.1 [0.7]) vs. HC (1.2 
[0.3]). 
NA TLR4 increased after incubation with 
LPS in all groups. 
High TLR-4 expression was the most 
independent predictor of 30-day 
MACE. 
Very low MFI, no FC figure 
Xie 
et al, 2010 
70 STEMI 
[60] 
32 CAD 
[57]  
PB 
Fresh whole blood 
TLR4+ Mon % 
(defined by sham 
controls, not IC) 
↑ in MI (80 [11]) vs. CAD 60 [16]. 
 
NA Positive correlation between TLR4 and 
TNFα/MMP-9. 
Not clear how monocytes were defined. 
All treatments were withdrawn 12 h 
prior to blood sampling. 
Wyss 
et al, 2010 
35 ACS  
(26 STEMI) 
[~57] 
10 without 
CAD 
[61] 
CA thrombi, aortic 
blood. 24 h in vitro 
incubation, lysed by 
osmotic shock 
Mon TLR4 MFI ↑ in coronary artery thrombi (78 [64–
85] vs. aortic blood (65 [57–70]). ↑ in 
ACS vs. controls (47 [40–49]). 
NA Proportion of related to total leukocyte 
count was 47% in coronary artery 
thrombi vs. 20% in aortic blood. 
Ishikawa 
et al, 2008 
62 STEMI 
[64] 
20 CAD 
[65] 
PB, CA blood, solid 
plaque samples 
Mon TLR4 mRNA 
Mon TLR4 MFI 
↑ in STEMI vs. CAD in PB 
↑in coronary artery blood plaques vs. 
NA TLR4 expression responded to 
stimulation with HSP70. 
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DC, adhesion to plastic 
dishes 
Plaque Mon TLR4+ 
levels 
PB High Mon TLR4 expression predicted 
cardiac events at 6 months. 
Satoh 
et al, 2006 
52 STEMI 
[65] 
20 HC 
[62] 
PB 
DC, adhesion to plastic 
dishes, detached by 
incubation in cold PBS. 
Mon TLR4 mRNA 
Mon TLR4 MFI 
↑ in STEMI (2.64[0.17] RU) vs. HC 
(0.37 [0.06] RU). ↑ in STEMI 
(6.15[0.31] RU) vs. HC (1.08 [0.09]). 
Both measures ↓by day 14 (still ↑ vs. 
HC)   
665 [40] 
in 
STEMIN
A in HC 
Circulating HSP70 levels were 
positively correlated 
with Mon TLR4 MFI in MI 
Satoh 
et al, 2006 
65 STEMI 
[65] 
20 HC 
[61] 
As above 
 
Intracellular Mon 
TLR4 MFI, Mon 
TLR4 mRNA 
Both ↑ in STEMI - remained ↑ at 14 
days STEMI onset.  
↑ in those with HF vs. no HF 
NA  After incubation with LPS TLR4 
increased in MI. LPS-stimulated TLR4 
correlated with IL6/TNFα.  
Methe 
et al, 2005 
28 STEMI 
[62] 
20 CAD 
[60] 
PB 
DC, positive IM 
selection of CD14+ 
cells 
TLR4+ Mon %, Mon 
TLR4 mRNA, RU 
 
↑in STEMI (78 [14]) vs. CAD (33 [5]) 
↑in STEMI (1.82 [0.33]) vs. CAD (0.96 
[0.19]) 
NA A strong correlation between TLR4+ 
Mon % and B7-1 expression/IL-12 
secretion across all patient groups 
Shiraki 
et al, 2006 
21 with MI or 
UA 
[NA] 
79 CAD 
[NA] 
PB 
Paraformaldehyde-
fixed, lysed whole 
blood 
Ratio of Mon TLR4 
MFI to IC MFI 
↑in ACS vs. CAD NA No correlation between hsCRP and 
TLR4 
 
Mon, monocyte, Mon1; CD14++CD16–CCR2+ monocytes; Mon2, CD14++CD16+CCR2+ monocytes; Mon3, CD14+CD16++CCR2– 
monocytes; CAD, coronary artery disease; CRP, C-reactive protein; hsCRP, high sensitivity CRP; HC, healthy controls; HSP, heat shock 
proteins; IC, isotype control; IL, interleukin; LPS, lipopolysaccharide; MFI, mean or median fluorescent intensity; MI, myocardial infarction; 
MRP, myeloid related protein; NA, not available; RU, relative units; STEMI, ST-elevation myocardial infarction; TLR4, Toll-like receptor 4; 
TNF α, tumour necrosis factor α; ↑, increased; ↓, decreased; PB, peripheral blood; CA, coronary artery; MACE, major adverse clinical events; 
ACS, acute coronary syndrome; mRNA, messenger ribonucleic acid; FC, flow cytometry; MMP-9, matrix metalloproteinase 9; HF, heart failure; 
DC, density centrifugation; UA, unstable angina; IM, immune-magnetic.
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The diversity of monocyte subsets in terms of phenotype, function and pathophysiological 
implications in cardiovascular disease is increasingly recognised.  Following MI in humans, 
only the Mon1 and Mon2 subset increase in number, but not Mon3, with the most prominent 
changes being seen in Mon2 (over 2.5-fold increase in STEMI) (chapter 5; Tapp et al, 2011).  
This study shows that in humans with MI managed according to contemporary guidelines and 
with monocytes defined as 3 distinct subsets, there is an increase in TLR4+ expressing Mon1 
and Mon2 in STEMI and TLR4+ Mon2 in NSTEMI due to an increase in number of these 
monocyte subsets, but this is not due to a change in TLR4 expression per se. 
 
The relative clinical importance of monocyte count rather than their individual level of TLR4 
expression is suggested by the correlation observed between peak troponin level and TLR4+ 
Mon2 subset count (similarly to the previously reported correlation with total Mon2 subset 
count), but not with TLR4 expression on any subset (chapter 5; Tapp et al, 2011).  Of interest, 
plasma IL6 level correlated positively with TLR4+ Mon2 number, but negatively with TLR4 
expression on Mon2.  This observation is in agreement with previous data describing the 
association of this subset with high IL6 levels.  In contrast, the negative association with 
TLR4 expression by other monocytes may reflect partial loss of TLR4 from activated 
monocytes, indicating that TLR4 expression may not be a reliable marker of monocyte 
activation in STEMI.  This possibility is also supported by the lack of any observed 
correlation between monocyte TLR4 expression and a marker of NFκB activation 
(intracellular IKKβ) as well as the lack of association between monocyte TLR4 expression 
and convalescent LVEF 6 weeks post STEMI. 
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Finally, as illustrated in Figure 6.3 and Table 6.2, in STEMI (and to a smaller degree in 
NSTEMI) there is an increase in the proportion of Mon2 with high TLR4 expression and a 
decrease in proportion of Mon3 with lower TLR4 expression.  Accordingly an MI-related 
increase in TLR4 expression by CD16+ monocytes analysed together (i.e. Mon2 and Mon3 
considered as a single population) may be partly due to an  increase in proportion of Mon2 
rather than a true increase in TLR4 expression per se (Kashiwagi et al, 2012).  
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6.6 LIMITATIONS 
 
The study is descriptive in its nature, with monocyte functional activity assessed only by 
intracellular IKKβ levels in peripheral venous blood.  Thus it is not possible to provide any 
mechanistic insight into TLR4 related monocyte pathways or into their roles within the 
myocardium. 
 
Also, given that certain amounts of surface TLR4 could be shed into circulation, surface 
TLR4 expression may not be a comprehensive parameter of monocyte TLR4 production.  
Intracellular TLR4 mRNA measurement could be of additive value in this regard.  In aiming 
to obtain a snapshot of monocyte TLR4 expression as close to the in vivo state as possible (by 
expeditious processing of fresh whole blood samples), the more prolonged sample processing 
time required for monocyte (subsets) isolation and RNA extraction was avoided. 
 
It was logistically impossible to plan to undertake sample collection at the same time each 
day.  However, the majority of samples were collected from all subject groups between 09.00 
and 12.00.  The remaining influence of diurnal variation on monocyte parameters should be 
considered as a limitation of my study (Shantsila et al, 2012).  
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6.7 CONCLUSIONS 
 
Following acute MI treated according to contemporary guidelines, monocyte TLR4 
expression by individual subsets is unchanged.  The number of TLR4+ Mon1 and Mon2 
subsets increases in STEMI as does the number of TLR+ Mon2 in NSTEMI.  However, there 
is no change in their surface expression of TLR4.  Monocyte count but not their TLR4 
expression correlates positively with plasma IL6 levels.  This suggests that TLR4 expression 
may not be a reliable marker of monocyte activation in MI. 
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CHAPTER 7 
 
CXCR4 POSITIVE AND ANGIOGENIC MONOCYTES IN 
MYOCARDIAL INFARCTION 
 
 
 
 
 
 
 
 
 
 
Contributory publication: CXCR4 positive and angiogenic monocytes in myocardial 
infarction.  Shantsila E, Tapp LD, Wrigley BJ, Montoro-Garcia S, Lip GY.  Thromb Haemost 
2013; 109(2): 255-62. 
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Abstract 
 
There are limited data on the role of human monocytes in cardiac repair.  The aim of this 
study was to evaluate the dynamic alterations of monocytes with reparative and angiogenic 
potential, and expression of scavenger receptors by monocytes in patients following MI, with 
specific reference to the three human monocyte subsets defined as CD14++CD16-CCR2+ 
(Mon1), CD14++CD16+CCR2+ (Mon2) and CD14+CD16++CCR2- (Mon3). 
 
CXCR4+ monocytes, CD34+ / KDR+ monocytes with angiogenic potential and monocyte 
expression of CD204 and CD163 were quantified by flow cytometry in 50 patients with 
STEMI and 40 controls with stable CAD.  Parameters were measured on days 1, 3, 7 and 30 
after STEMI.  Plasma levels of inflammatory cytokines were assessed on day 1 by cytometric 
bead array. 
 
The number of CXCR4+ and KDR+ monocytes were increased following STEMI, being most 
prominently associated with the Mon1 and Mon2 subsets (both p=0.002).  The number of 
CXCR4+ Mon1 and Mon2 after STEMI reduced significantly by day 30 (p=0.009 and 
p<0.001 respectively).  Expression of the pro-reparative scavenger receptor CD163 by Mon3 
was reduced on day 1 after STEMI (p=0.008), but later on other subsets with lowest levels on 
day 3 post-STEMI (p<0.001 for Mon1, p=0.02 for Mon2).  
 
IL-6 levels correlated positively with counts of Mon2-derived CXCR4+ (r=0.63, p<0.001) 
and KDR+ cells (r=0.55, p<0.001) and negatively with Mon2 expression of CD204 (r=-0.29, 
p=0.044).  IL1β levels correlated positively with counts of KDR+ Mon1 (r=0.34, p=0.016) 
159 
 
and Mon2 (r=0.36, p=0.010).  IL-10 concentration correlated positively with levels of 
CXCR4+ Mon2 (r=0.36, p=0.010) and negatively with KDR+ Mon3 (r=-0.29, p=0.039) and 
Mon2 expression of CD204 (r=-0.28, p=0.046). 
 
No significant association was found between MCP-1 and any monocyte parameter.  Peak 
troponin level correlated positively with counts of CXCR4+ Mon2 (r=0.35, p=0.022).  Low 
number of CXCR4+ Mon2 and low CD163 expression by Mon2 were associated with higher 
LVEF six weeks after STEMI. 
 
The Mon2 subset appears to have the most prominent changes in characteristics of the 
‘reparative’ monocytes following STEMI.  The association of reparative monocytes with both 
pro and anti-inflammatory cytokines indicates a complex interplay of these cells in the post-
STEMI setting. 
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7.1 INTRODUCTION 
 
7.1.1 The myocardium following infarction 
Despite prompt coronary artery recanalisation and successful restoration of normal blood flow 
by PPCI in patients with MI, the injured myocardium undergoes complex healing and 
reparative processes.  Myocardial salvage and preservation of cardiac contractility is rarely 
complete.  This leads to scaring of the infarcted area, compensatory structural changes in non-
infarcted segments and only partial recovery of the vascular bed.  The process of angiogenesis 
after MI aims to improve myocardial perfusion via the formation of new capillaries, and is 
orchestrated by a number of growth factors (Lee et al, 2004).   
 
The mechanisms underlying cardiac repair following MI are incompletely understood.  These 
reparative processes are thought to involve several types of cells which respond to various 
tissue signals including chemokines that regulate cellular migration via interactions with their 
specific chemokine receptors.  Most such chemokines are not expressed in normal 
myocardium but may be up-regulated and secreted by the heart following MI (Rijken & 
Lijnen, 2009). 
 
7.1.2 The CXCL12/CXCR4 axis following myocardial infraction 
CXCL12 (Stromal cell-derived factor-1) and its main receptor CXCR4 are thought to play a 
unique role in myocardial biology, with actions including a reparative potential.  The 
CXCL12/CXCR4 axis may be rapidly activated following MI.  This promotes several 
reparative mechanisms including angiogenesis and enhanced regenerative capacity of 
progenitor cells.  However there is conflicting data as the CXCL12/CXCR4 axis has also been 
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associated with detrimental effects on the injured myocardium.  Reduced post-MI scaring 
seen in CXCR4-deficient mice compared to wild type animals was associated with reduced 
myocardial infiltration of neutrophils and proinflammatory monocytes but earlier and more 
prevalent infiltration of ‘reparative’ monocytes.  Interestingly, CXCR4 deficiency was not 
associated with worse post-MI contractility despite impaired neoangiogenesis (Liehn et al, 
2011).  These observations suggest that the net effect of the CXCL12/CXCR4 is finely 
balanced and may depend upon differential influences on individual cell types under different 
physiological conditions, both temporally and spatially (eg cardiovascular growth and 
development compared with post-MI).  Thus, the CXCL12/CXCR4 axis represents a potential 
therapeutic target for enhancing cardiovascular recovery.  As the majority of data in this area 
has been conducted in mice and rats, further research is required to explore the roles of 
CXCR4 expressing cells in humans. 
 
7.1.3 Scavenger receptors following myocardial infarction 
The role of monocytes in reparative processes may also be related to their activity mediated 
by scavenger receptors, such as CD204 (scavenger receptor class A type I) and CD163 
(haptoglobin receptor).  CD204 is involved in lipid accumulation (by macrophages) and 
atherogenesis.  There are emerging data to implicate this receptor in reparative processes 
including clearance of apoptotic cells, attenuation of oxidative stress and inflammation, and 
myocardial remodelling (Kobayashi et al, 2007; Tsujita et al, 2007; Todt et al, 2008; Chen et 
al, 2010; Hu et al, 2011).  CD163 is also implicated in a range of reparative processes in 
various tissues, and its expression has been linked with attenuated inflammatory properties of 
monocytes (Schaer et al, 2006).  However little data are available on the dynamics and role of 
CD204 and CD163 expression on monocyte subsets following MI. 
162 
 
7.1.4 Relations to human monocytes, monocyte subsets and endothelial progenitor cells 
Our research group has previously described phenotypic variation amongst the three human 
monocyte subsets in healthy subjects (Shantsila et al, 2011), defined according to 
contemporary nomenclature (Ziegler-Heitbrock et al, 2010).  Whilst all three types of human 
monocyte subsets include a proportion of CXCR4-expressing cells, these proportions vary 
significantly between the subsets, being highest in CD14++CD16+CCR2+ (Mon2) 
‘intermediate’ monocytes (Shantsila et al, 2011).  However, the patterns of reparative 
CXCR4+ monocytes as well as CD34+ and KDR+ cells (i.e. cells with angiogenic potential) 
attributed to individual monocyte subsets post-MI have not been explored.  The role of 
endothelial progenitor cells (EPCs) in angiogenesis after MI is generally acknowledged.  
Various blood cells have been shown to demonstrate angiogenic potential, with monocyte-
derived cells being the largest pool of angiogenic cells (Shantsila et al, 2007).   
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7.2 AIMS AND HYPOTHESES 
 
In this study my aim was to assess numbers of CXCR4+, CD34+, KDR+ cells attributed to 
the three human monocyte subsets, and monocyte expression of CD204 and CD163 following 
STEMI.  Additionally, their associations with biological and physiological parameters related 
to myocardial damage and recovery following MI were also assessed.  Given the differences 
in expression of these parameters in healthy subjects previously reported (Shantsila et al, 
2011), I hypothesised that the number of CXCR4+ monocytes, CD34+/KDR+ cells and 
expression of monocyte scavenger receptors is changed in patients following STEMI.  
Additionally, I hypothesised that these changes are attributable to specific monocyte subsets 
and are associated with biomarkers of inflammation and convalescent LVEF following 
STEMI. 
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7.3 METHODS AND MATERIALS 
 
7.3.1 ST-segment elevation myocardial infarction patients 
50 consecutive patients diagnosed with STEMI fulfilling the study criteria were recruited 
from SWBH NHS Trust between November 2009 and November 2010 (chapter 3.1.1).  MI 
was diagnosed according to the consensus universal definition (Thygesen et al, 2007) (chapter 
1.1.3).  All STEMI patients underwent PPCI (chapter 1.1.5.1.2) and received standard 
treatment according to the contemporary ESC guidelines (Van de Werf et al, 2008).  The 
monocyte-derived CXCR4+, CD34+ and KDR+ cells and other biomarkers were assessed at 4 
time points following MI onset: within 24 hours of MI, after PPCI (day 1), day 3, day 7 and 
day 30.  33 STEMI subjects completed follow-up (chapter 5.4.1). 
 
7.3.2 Control group 
For a cross-sectional comparison, the 50 STEMI patients were compared to an age- and sex-
matched control group of 40 patients with stable CAD (chapter 3.1.2.1).  Exclusion criteria 
are summarised in chapter 3.1.3. 
 
7.3.3 Sample collection 
All subjects were asked to refrain from extreme physical exertion for at least 1 hour prior to 
sample collection (chapter 3.3.1).  Peripheral venous blood samples were collected from all 
participants and processed by flow cytometry within 60 minutes (chapter 3.2).  Plasma was 
separated by centrifugation and stored at –70oC for batched analysis at the end of the study 
(chapter 3.4).  Routine haematology and biochemistry investigations were undertaken by the 
hospital laboratory (chapter 3.5). 
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7.3.4 Flow cytometry 
Flow cytometric analysis was performed as described in chapter 3.2.  The absolute count of 
monocytes and counts of the three monocyte subsets and associated MPAs were performed as 
described in chapter 3.2.2.  Briefly, monocyte subsets were defined as CD14++CD16–CCR2+ 
(Mon1), CD14++CD16+CCR2+ (Mon2) and CD14+CD16++CCR2– (Mon3) in accordance 
with contemporary nomenclature (Ziegler-Heitbrock et al, 2010; Shantsila et al, 2011).  
Monocyte surface expression of CXCR4, CD34, KDR, CD204 and CD163 by each subset 
was analysed as described in chapter 3.2.3 (Figure 7.1). 
 
Plasma levels of IL-1β, IL-6, IL-10 and MCP-1 were measured by cytometric bead array 
technology as described in chapter 3.2.5. 
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Figure 7.1  Flow cytometric analysis of monocyte expression of CXCR4, CD163, CD34, 
KDR and CD204. 
 
 
A: Selection of CD14++CD16– monocytes (Mon1) and CD16+ monocytes based on 
CD14/CD16 expression.  B: Separation of CD14++CD16+CCR2+ (Mon2) and 
CD14+CD16++CCR2– (Mon3) subsets based on their CCR2 expression.  C: Measurement of 
CD163 expression and quantification of CXCR4+ cells related to the individual monocyte 
subsets (Mon1 [left], Mon2 [centre] and Mon3 [right]).  D: quantification of CD34+, KDR+, 
and CD34+KDR+ cells related to the individual monocyte subsets (Mon1 [left], Mon2 
[centre] and Mon3 [right]).  E: Measurement of CD204 expression on the monocyte subsets 
(Mon1 [left], Mon2 [centre] and Mon3 [right]). Mon1, CD14++CD16-CCR2+ (‘classical’) 
monocytes ;  Mon2, CD14++CD16+CCR2+ (‘intermediate’) monocytes ; Mon3, 
CD14+CD16++CCR2- (‘non-classical’) monocytes 
 
 
167 
 
7.3.5 Assessment of left ventricular function 
Patients underwent echocardiographic assessment of convalescent LVEF by Simpson’s 
method 6 weeks after STEMI as described in section 3.6. 
 
7.3.6 Statistical analysis 
Statistical analyses were performed as described in chapter 3.8.  Univariate and multivariate 
linear regression analyses were used to establish predictive value of the study parameters for 
LVEF at 6 weeks in STEMI patients. 
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7.4 RESULTS 
 
7.4.1 Demographics and clinical characteristics of the study population 
Fifty patients with STEMI (mean age 58 years, 86% male) and forty patients with stable CAD 
(mean age 60 years, 83% male) were recruited (Table 7.1).  Thirty three STEMI patients had 
data on CXCR4+, CD34+ and KDR+ monocytes and study parameters at all four time-points 
(section 5.4.1).  The study groups were well matched for most demographic and clinical 
parameters and medication (Table 7.1); however, glycoprotein IIbIIIa inhibitors were 
administered to the majority (96%) of STEMI patients but not to CAD patients.  Patients with 
MI had higher rates of clopidogrel or prasugrel usage than subjects with stable CAD 
(p<0.001). 
 
Table 7.1  Demographic and clinical characteristics of the study groups 
 STEMI 
(n=50) 
Stable CAD 
(n=40) 
p value 
Age, years 58 [12] 60 [11] 0.23 
Male, n (%) 43 (86) 33 (83) 0.77 
Systolic BP, mmHg 132 [18] 133 [15] 0.84 
Diastolic BP, mmHg 78 [14] 75 [9] 0.49 
Body mass index, kg/m
2
 30 [6] 29 [5] 0.47 
Smoking, n (%) 29 (58) 17 (43) 0.28 
Stroke, n (%) 3 (6) 5 (13) 0.28 
Hypertension, n (%) 24 (48) 20 (50) 0.83 
Diabetes, n (%) 16 (32) 8 (20) 0.34 
COPD, n (%) 3 (6) 3 (8) 1.00 
Creatinine, μmol/l 92 [19] 90 [18] 0.59 
Aspirin, n (%) 50 (100) 36 (90) 0.18 
Clopidogrel or prasugrel, n (%) 50 (100) 30 (75) <0.001 
Statin, n (%) 48 (96) 34 (85) 0.40 
ACE inhibitor, n (%) 45 (90) 29 (73) 0.14 
Diuretic, n (%) 2 (4) 5 (13) 0.23 
Beta-blocker, n (%) 35 (70) 27 (68) 1.00 
Calcium channel blocker, n (%) 8 (16) 11 (28) 0.28 
Non-normally distributed data are presented as median [interquartile range]; normally 
distributed data are presented as mean [standard deviation].  Categorical data are expressed as 
number (%).  ACE, angiotensin-converting enzyme; BP, blood pressure; CAD, coronary 
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artery disease; COPD, chronic obstructive pulmonary disease; STEMI, ST-elevation 
myocardial infarction. 
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7.4.2 Cross-sectional comparison of day 1 after ST-elevation myocardial infarction with 
coronary artery disease controls 
Compared to stable CAD, on day 1 following STEMI there were increased levels of CXCR4+ 
monocytes associated with the Mon1 (p=0.002) and Mon2 subsets (p=0.002), KDR+ 
monocytes associated with the Mon1 (p=0.02) and Mon2 subsets (p=0.012) and lower CD163 
expression by the Mon3 subset (p=0.008) (Table 7.2, Figure 7.2).  
 
Table 7.2  Angiogenic and reparative cells in ST elevation myocardial infarction compared to 
subjects with stable coronary artery disease 
 STEMI 
Day 1, n=50 
Stable CAD 
n=40 
p value  
CXCR4+ Mon1, per μl 389 [296-520] 301 [244-390] 0.002 
CXCR4+ Mon2, per μl 60 [25-126] 27 [21-41] 0.002 
CXCR4+ Mon3, per μl 25 [13-37] 21 [12-29] 0.18 
CD34+ Mon1, per μl 1.9 [1.0-4.2] 1.8 [0.2-3.8] 0.37 
CD34+ Mon2, per μl 0.7 [0.2-1.4] 0.4 [0.2-0.7] 0.19 
CD34+ Mon3, per μl 1.4 [0.9-2.1] 1.1 [0.4-2.7] 0.43 
KDR+ Mon1, per μl 34 [16-71] 19 [6-43] 0.020 
KDR+ Mon2, per μl 8.0 [3.0-17] 4.0 [1.5-8.3] 0.012 
KDR+ Mon3, per μl 2.7 [1.3-5.0] 2.2 [1.6-4.4] 0.75 
CD163 (Mon1), MFI 128 [79-169] 124 [88-163] 0.76 
CD163 (Mon2), MFI 240 [173-312] 214 [168-279] 0.22 
CD163 (Mon3), MFI 12 [10-16] 16 [12-23] 0.008 
CD204 (Mon1), MFI 11 [7-30] 13 [7-31] 0.79 
CD204 (Mon2), MFI 29 [15-57] 29 [16-62] 0.87 
CD204 (Mon3), MFI 32 [18-49] 27 [19-74] 0.85 
Data are presented as median [interquartile range]. Mon1, CD14++CD16–CCR2+ monocytes; 
Mon2, CD14++CD16+CCR2+ monocytes; Mon3, CD14+CD16++CCR2– monocytes; MFI, 
median fluorescent intensity; STEMI, ST-elevation myocardial infarction; CAD, coronary 
artery disease. 
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Figure 7.2  CXCR4+ Mon2 in the study patients with cross-sectional analysis and follow-up 
in ST-elevation myocardial infarction. 
 
CAD, coronary artery disease; STEMI, ST-elevation myocardial infarction; Mon2, 
CD14++CD16+CCR2+ monocytes.  Bars represent median and inter-quartile range.  
Horizontal lines represent statistically significant differences between groups, with individual 
p values. 
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7.4.3 Longitudinal changes in monocyte parameters following ST-elevation myocardial 
infarction 
Following STEMI, counts of CXCR4+ Mon1 (p=0.009) and CXCR4+ Mon2 (p<0.001) had 
reduced at 30 days (Table 7.3).  CD163 expression on Mon3 (reduced on day 1) did not 
change significantly, but CD163 expression on Mon1 (p<0.001) and Mon2 (p=0.02) (both 
unchanged on day 1) reduced significantly during follow-up with lowest values seen on day 3.  
CD204 expression by the Mon1 subset decreased on day 3 (p=0.025).  
 
Table 7.3  Monocyte parameters during follow up in patients with ST-elevation myocardial 
infarction 
 
Day 1 Day 3 Day 7 Day 30 
p 
value 
CXCR4+ Mon1, per μl 398 [345-552]‡ 372 [322-452] 385 [291-499] 320 [265-485] 0.009 
CXCR4+ Mon2, per μl 78 [20-125] †‡ 51 [29-107]†‡ 37 [25-52] 27 [18-47] <0.001 
CXCR4+ Mon3, per μl 25 [15-37] 20 [12-27] 26 [14-34] 20 [12-29] 0.23 
CD34+ Mon1, per μl 2.2 [1.6-4.9] 2.3 [1.3-4.6] 2.5 [1.5-5.1] 2.9 [0.8-9.2] 0.79 
CD34+ Mon2, per μl 0.6 [0.3-1.3] 0.8 [0.4-1.6] 0.6 [0.3-1.3] 0.4 [0.3-0.7] 0.11 
CD34+ Mon3, per μl 1.6 [0.9-2.1] 1.1 [0.5-2.0] 1.2 [0.7-1.8] 1.2 [0.6-1.8] 0.40 
KDR+ Mon1, per μl 42 [18-73] 21 [13-62] 25 [12-81] 44 [21-94] 0.03 
KDR+ Mon2, per μl 8.0 [3.1-24] 6.6 [2.4-9.4] 7.2 [2.6-13] 7.5 [2.7-12] 0.44 
KDR+ Mon3, per μl 3.8 [1.6-5.5] 2.6 [1.5-4.2] 3.0 [1.8-5.6] 4.0 [2.2-7.2] 0.15 
CD163 (Mon1), MFI 131 [77-181]
*
 92 [57-116]
‡
 109 [81-156] 121 [90-163] <0.001 
CD163 (Mon2), MFI 251 [180-317]
*†‡ 
198 [150-284] 214 [145-265] 199 [157-269] 0.02 
CD163 (Mon3), MFI 12 [10-15] 15 [10-22] 13 [9-20] 15 [12-23] 0.11 
CD204 (Mon1), MFI 11 [7-36]
*
 9 [5-22] 12 [8-28] 10 [7-46] 0.025 
CD204 (Mon2), MFI 34 [14-61] 37 [14-59] 37 [17-66] 40 [19-66] 0.11 
CD204 (Mon3), MFI 33 [17-49] 28 [17-48] 33 [14-63] 33 [17-53] 0.86 
*p<0.05 vs. Day 3, †p<0.05 vs. Day 7, ‡p<0.05 vs. Day 30. Data are presented as median 
[interquartile range]. Mon1, CD14++CD16–CCR2+ monocytes; Mon2, 
CD14++CD16+CCR2+ monocytes; Mon3, CD14+CD16++CCR2– monocytes; MFI, median 
fluorescent intensity. 
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7.4.4 Relations between monocyte parameters, plasma cytokines and myocardial 
damage 
In STEMI patients on day 1, only CXCR4+ Mon2 subset number was found to correlate 
significantly with peak troponin level (r=0.35, p=0.022).  IL6 levels correlated positively with 
counts of Mon2-derived CXCR4+ cells (r=0.63, p<0.001) and KDR+ cells (r=0.55, p<0.001) 
and negatively with Mon2 expression of CD204 (r=-0.29, p=0.044).  IL1β levels correlated 
positively with counts of KDR+ Mon1 (r=0.34, p=0.016) and Mon2 (r=0.36, p=0.010).  IL10 
concentration correlated positively with levels of CXCR4+ Mon2 (r=0.36, p=0.010) and 
negatively with KDR+ Mon3 (r=-0.29, p=0.039) and Mon2 expression of CD204 (r=-0.28, 
p=0.046).  No significant association was found between MCP-1 and any monocyte 
parameter.  Peak troponin level correlated positively with counts of CXCR4+ Mon2 (r=0.35, 
p=0.022), and showed a non-significant trend towards a positive association with CD163 
expression on Mon2 (r=0.28, p=0.077). 
 
7.4.5 Predictive value of monocyte angiogenic and reparative makers for left ventricular 
ejection fraction six weeks post ST-elevation myocardial infarction 
In STEMI patients, reduced CD163 expression by Mon1 on Day 1 and lower counts of 
CXCR4+ Mon2 (taken as an average of the four time points) were significantly associated 
with a higher LVEF after adjustment for age, sex, history of diabetes, and troponin levels 
(Table 7.4). 
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Table 7.4  Regression analysis of predictive value of monocyte angiogenic/reparative 
parameters for left ventricular ejection fraction 6 weeks post ST-elevation myocardial 
infarction 
 
Model β p value 
Unadjusted 
CD163 expression on Mon1
*
 -0.31 0.051 
CD163 expression on Mon2
*
 -0.38 0.015 
Counts of CXCR4+ Mon2
†
 -0.49 0.007 
Adjusted for age, sex, diabetes, and troponin levels 
CD163 expression on Mon1
*
 -0.37 0.044 
Counts of CXCR4+ Mon2
†
 -0.52 0.024 
*
Measured on Day 1, 
†
Measured as an average of the four time points 
 
β, adjusted regression coefficient; Mon1, CD14++CD16-CCR2+ (‘classical’) monocytes ;  
Mon2, CD14++CD16+CCR2+ (‘intermediate’) monocytes  
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7.5 DISCUSSION 
 
7.5.1 Myocardial repair and angiogenesis 
In this study I describe for the first time significant changes in expression of surface markers 
associated with repair (CXCR4) and angiogenesis (KDR) following STEMI, attributed to 
individual human monocyte subsets.  Of note, the highly significant increase in CXCR4+ and 
KDR+ monocyte number was strictly limited to the Mon1 and Mon2 (more prominently) 
subsets.  This parallels higher expression of CXCR4 and KDR by the Mon1 and particularly 
Mon2 subsets as compared to the Mon3 subset in our group’s previous study on healthy 
subjects (Shantsila et al, 2011).  The number of the CXCR4+ Mon2 subset on day 1 after 
STEMI (but not KDR+ Mon 2 cells) was observed to correlate significantly with peak 
troponin level.  The absence of an association between KDR+ Mon 2 number and peak 
troponin may be due to a predominant role of the degree of myocardial ischaemia rather than 
amount of myocardial necrosis per se in their mobilisation.  
 
Although a high count of the CXCR4+ Mon2 subset on day 1 after STEMI was a significant 
predictor of lower LVEF at 6 weeks, in keeping with the data of Liehn and colleagues (Liehn 
et al, 2011), it is difficult to speculate on the reasons for this.  This relationship could suggest 
potential detrimental properties of CXCR4+ monocytes or conversely their possible 
contribution to repair mechanisms in patients with more marked initial myocardial insults 
(Liehn et al, 2011).  The positive correlation between numbers of the CXCR4+ Mon2 subset 
and both pro- and anti-inflammatory cytokines further suggests that the role of these cells in 
post-MI processes is complex.  Such mechanisms should be explored in the future.   
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The findings in this study seem to be in accordance with published mouse data on the 
CXCL12/CXCR4 axis in relation to the myocardium. This pathway appears to be critically 
involved in embryonic cardiovascular development as CXCR4 or CXCL12 null mice develop 
lethal vascular malformations.  Assessments of its role in cardiac repair in a mouse model of 
myocardial infarction have produced conflicting findings.  Despite evidence implicating 
CXCR4+ bone marrow-derived cells in reparative processes, CXCR4
+/-
 mice developed 
smaller post-MI scars compared to wild-type mice expressing normal levels of CXCR4 
(Liehn et al, 2011).  These opposing observations are likely to reflect the pleiotropic effects of 
the CXCL12/CXCR4 axis and the diversity of cells mobilised via its activation.  CXCR4 
deficiency in mice was associated with reduced myocardial infiltration of neutrophils, reduced 
and delayed infiltration of ‘proinflammatory’ Gr-1high monocytes but an earlier infiltration 
with increased numbers of ‘reparative’ Gr-1low monocytes (Liehn et al, 2011).  
 
Although only limited parallels may be made between characteristics of monocyte subsets in 
mice and humans, the findings in this study seem to support experimental data showing that 
CXCR4+ cells derived from the Mon1 subset (‘equivalent’ to ‘inflammatory’ mouse 
monocytes), but not from the Mon3 subset (‘equivalent’ of ‘reparative’ mouse monocytes) 
increase in number after STEMI (Nahrendorf et al, 2007).  However, the most prominent 
changes I observed in CXCR4+ cells were attributed to the Mon2 subset.  The function of this 
subset remains elusive, and there is no direct mouse ‘equivalent’.  Indeed, according to the 
current consensus nomenclature, it is called an ‘intermediate’ subset (Ziegler-Heitbrock et al, 
2010).  Perhaps Mon2 monocytes could be considered a ‘top’ subset in many respects, as they 
have the highest expression of many ‘beneficial’ reparative markers (such as CXCR4, KDR 
and CD163).  
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Of the CD34+KDR+ monocytes in this study, only those derived from the Mon3 subset were 
increased in number after STEMI.  This corresponds to our group’s previous observation that 
the Mon3 subset has the highest expression of CD34 in healthy subjects (Shantsila et al, 
2011).  Indirectly, these observations support the hypothesis of differential involvement in 
reparative properties by individual human monocyte subsets following ischaemic injury. 
 
7.5.2 Monocyte scavenger receptor expression 
The reparative roles of scavenger receptors expressed by monocytes including CD204 and 
CD163 are increasingly appreciated (Kobayashi et al, 2007; Chen et al, 2010; Yu et al, 2011).  
Data from experimental models of myocardial infarction in mice suggest that CD204 
deficiency impairs post-MI remodelling via modulation of inflammatory cytokine and MMP-
9 production (Tsujita et al, 2007; Hu et al, 2011).  Although it was previously shown in 
peripheral blood films that CD204+ monocytes are increased in number following MI (Emura 
et al, 2007), my study suggests that this is likely to be due to monocytosis rather than 
increased monocyte expression of CD204 per se, which did not change significantly.  
However, following STEMI, CD204 expression by monocyte subsets was associated with 
plasma levels of inflammatory cytokines, suggesting a relationship with ischaemic myocardial 
injury.  Our group’s previous work found that CD204 expression on Mon1 was associated 
with tPA levels post MI, suggesting an additional relationship with fibrinolytic status 
(Shantsila et al, 2012). 
 
Of interest, a significant reduction in monocyte CD163 expression following STEMI was 
observed (on day 1 by Mon3, and later by Mon1 and Mon2).  A similar longitudinal trend was 
seen for CD204 expression by Mon1.  Although the mechanistic reasons for this reduction in 
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scavenger receptor expression after MI is unclear, this may be related to their increased 
utilisation in the setting of myocardial necrosis, reflecting higher demand for their functions.  
This may contribute to the independent association between reduced expression of CD163 by 
the Mon1 subset and higher LVEF 6 weeks after STEMI. 
 
In this study there were no significant correlations between plasma levels of MCP-1 and 
Mon2-related cells, as may have been expected given the reported role of MCP-1 in monocyte 
recruitment in humans (Mayr et al, 2009).  This suggests that the biology of monocyte 
recruitment into the circulation is complex and is perhaps modulated by background 
pathology (STEMI in my study) and chemokine gradients along the vascular bed and within 
target tissues (Ajuebor et al, 1998).  Furthermore, there may be more important signals for 
monocytes than MCP-1 in the context of STEMI, as suggested by the significant positive 
correlation between number of CXCR4+ monocytes and peak troponin levels (i.e. degree of 
myocardial damage).  The relationship between MCP-1 levels and monocyte count is also 
complicated by the fact that monocytes themselves are a major source of MCP-1 and are thus 
involved in the feedback regulation MCP-1 levels (Yoshimura et al, 1989). 
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7.6 LIMITATIONS 
 
This study has several limitations reflecting its observational and descriptive nature.  The 
number of participants is relatively small which precludes analysis between the study 
parameters and clinical outcomes other than convalescent LVEF.  Analysis of LVEF at only 
one time point (6 weeks) does not take into consideration baseline myocardial contractility 
and repeated high resolution imaging techniques (MRI) could be more robust in this regard.   
 
The observational nature of this study precludes the ability to infer direct mechanistic 
implications, which should be studied separately.  My observations were restricted to 
examination of peripheral venous blood, and it is likely that monocyte characteristics within 
the myocardium may differ.  However, such experiments were not within the remit of this 
study. 
 
It was logistically impossible to undertake sample collection at the same time each day.  
However, the majority of samples were collected from all subjects between 09.00 and 12.00.  
The remaining influence of diurnal variation on monocyte parameters should be considered as 
a limitation of my study (Shantsila et al, 2012).  
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7.7 CONCLUSIONS 
 
There is a significant increase in number of CXCR4+ and KDR+ monocytes in humans 
following MI, which is only associated with specific monocyte subsets.  This is most 
prominent for the Mon2 subset, previously reported to have distinct pro-angiogenic and pro-
reparative phenotypes.  Also, MI was associated with reduction in expression of the pro-
reparative scavenger receptor CD163 by all monocyte subsets, possibly reflecting it’s 
increased utilisation.  The correlation between numbers of the CXCR4+ Mon2 subset with 
both pro- and anti-inflammatory cytokines highlights the complex interplay of these cells in 
post-MI reparative processes.  Although both low numbers of the CXCR4+ Mon2 subset and 
low CD163 expression by Mon1 were associated with higher LVEF 6 weeks after STEMI, 
causative links between these associations are yet to be established.  Further research is 
needed to explore the potential of monocyte-derived cells in the modulation of post-ischaemic 
myocardial repair.  The observations in this study following STEMI suggest that the 
CD14++CD16+CCR2+ (Mon2) ‘Intermediate’ monocyte subset may be of particular interest. 
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CHAPTER 8 
 
RECEPTORS TO INTERLEUKIN 6 AND ADHESION 
MOLECULES ON CIRCULATING MONOCYTE SUBSETS IN 
MYOCARDIAL INFARCTION 
 
 
 
 
 
 
 
 
 
Contributory publication: Receptors to Interleukin-6 and adhesion molecules on circulating 
monocyte subsets in acute myocardial infarction.  Shantsila E, Tapp LD, Wrigley BJ, 
Montoro-Garcia S, Lip GY.  Thromb Haemost 2013; 110(2): 340-348. 
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Abstract 
 
The role of individual human monocyte subsets in inflammation and recovery after MI is 
insufficiently understood.  The objective of this study was to evaluate the dynamics of human 
monocyte subset expression of receptors to VCAM-1, ICAM-1, and IL6 following MI and 
their relations to inflammatory cytokines and fibrinolytic factors. 
 
Expression of VCAM-1r, ICAM-1r and IL6r by the CD14++CD16-CCR2+ (Mon1), 
CD14++CD16+CCR2+ (Mon2) and CD14+CD16++CCR2- (Mon3) monocyte subsets was 
quantified by flow cytometry in 50 patients with STEMI and 48 patients with NSTEMI and 
compared with 40 controls with stable CAD.  In STEMI, parameters were measured on days 1 
(after PPCI), 3, 7 and 30. 
 
On day 1 after STEMI, VCAM-1r expression was reduced on Mon1 (p=0.007), Mon2 
(p=0.036) and Mon3 (p=0.005), whilst in NSTEMI there was a significant increase in 
VACM-1r expression by Mon2 (p=0.024) and Mon3 (p=0.049).  VCAM-1r expression on 
Mon1 correlated positively with plasma IL-1β level (p=0.001).  There was no change in 
monocyte ICAM-1r expression.  IL6r expression was reduced on Mon2 on day 1 after STEMI 
(p=0.028), with increased expression on Mon1 and Mon2 during follow-up.  IL6r density on 
all subsets correlated negatively with plasma levels of tissue-type plasminogen activator (r=-
0.48, p=0.0005 for Mon1, r=-0.45, p=0.001 for Mon2 and r=-0.47, p=0.001 for Mon3). 
 
Expression of IL6r and VCAM-1r is reduced on human monocyte subsets involved in 
inflammatory responses following STEMI.  This may represent a regulatory feed-back 
183 
 
mechanism aiming to re-balance the marked inflammation typically present following MI or 
selective homing of monocytes with higher receptor expression to damaged myocardium. 
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8.1 INTRODUCTION 
 
The total blood monocyte count in circulation is typically increased in humans following 
acute MI.  Their elevated level is associated with poor cardiac recovery and an increased risk 
of death (Maekawa et al, 2002).  More specifically, the CD14++CD16+ (‘intermediate’) 
subset has recently been found to be an independent predictor of future adverse cardiovascular 
events in high risk patients (Rogacev et al, 2010; Rogacev et al, 2012). 
 
Monocytes exert their biological effects both in circulation and after their migration to the site 
of tissue injury.  Whilst in circulation, monocytes release a range of cytokines which promote 
systemic inflammatory effects (Shantsila & Lip, 2009).  In tissues, monocytes are involved in 
phagocytosis of necrotic and apoptotic cells, facilitate matrix remodelling by production of 
MMPs, and have roles in fibroblast formation and angiogenesis (Nahrendorf et al, 2007; 
Nahrendorf et al, 2010).  Monocytes are also involved in pro- and anti-thrombotic processes, 
including tissue factor expression, contribution to fibrinolysis and phagocytosis of thrombotic 
debris (Shantsila & Lip, 2009).   
 
Although monocytes are clearly implicated in the pathogenesis of CAD, a disease of 
inflammatory aetiology, it is perhaps inappropriate and over simplistic to consider monocytes 
as purely ‘damaging’ inflammatory cells, as emerging data has demonstrated additional 
reparative roles for monocytes (chapter 1.2).   Such diversity of roles may be attributed to 
their functional status and the presence of distinct subsets (Nahrendorf et al, 2007).  However, 
little data are available on changes in phenotype of human monocyte subsets following acute 
MI. 
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Amongst the receptors expressed on the surface of monocytes, three are of particular 
relevance to their inflammatory activity and migration to damaged tissues; ICAM-1 receptor, 
VCAM-1 receptor, and the IL6 receptor.  Cell adhesion molecules represent a marker of 
endothelial cell activation.  They play a key role in the recruitment of monocytes to inflamed 
tissues, particularly by facilitating monocyte adhesion to the endothelium (Bevilacqua et al, 
1994; Jang et al, 1994).  This is achieved via an interaction between integrin receptors (i.e. 
ICAM-1r and VCAM-1r) on the surface of monocytes, followed by monocyte adhesion to the 
endothelium and migration into sub-endothelial tissues (Cotran & Mayadas-Norton, 1998).  
Despite these important roles, little data is available regarding the expression of these 
receptors on monocyte subsets after MI and their relations to inflammation, apoptosis and 
cardiac recovery. 
 
Observational studies have identified that serum IL6 and soluble IL6r levels are elevated in 
acute MI compared to CAD (Anderson et al, 2013), and that elevation in IL6 levels after ACS 
correlates with an increased risk of major adverse cardiovascular events (Lee et al, 2005).  
Compelling genetic and biomarker evidence recently collated in a meta-analysis implicates a 
causal role for IL6r in the pathophysiological processes of atherosclerosis (Sarwar et al, 
2012), a disease hypothesised to result from persistent inflammation.  The Asp358Ala allele is 
a common functional variant of the IL6r.  This allele affects proteolytic cleavage of the 
membrane-bound IL6r, leading to reduced concentrations of membrane-bound IL6r and 
higher concentrations of the soluble form of IL6r in circulation.  This disrupts the IL6-driven 
inflammatory response by attenuation of IL6r-mediated signalling in hepatocytes and 
leucocytes, resulting in reduced production of important downstream acute phase proteins 
including CRP and fibrinogen.  Interestingly, Asp358Ala was not associated with IL6r mRNA 
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production in monocytes and was not associated with IL6 production by monocytes after 
stimulation by lipopolysaccharide.  The data suggest that the 358Ala allele and resultant 
shedding of IL6r into the circulation (rather than changes in production of IL6 or IL6r) is 
associated with a clear anti-inflammatory effect and a reduced risk of CAD.  This effect was 
independent of traditional cardiovascular risk factors including dyslipidaemia, cigarette 
smoking, diabetes, hypertension and obesity.  This lead to the conclusion that IL6r pathways 
have a direct causal relationship in the pathogenesis of CAD (Sarwar et al, 2012). 
 
Of importance, our research group has shown that the three human monocyte subsets defined 
according to contemporary guidelines (Ziegler-Heitbrock et al, 2010) exhibit significant 
differences in their expression of ICAM-1r, VCAM-1r and IL6r in healthy humans (Shantsila 
et al, 2011).  However, expression of these receptors on individual subsets in patients with MI 
has not been described.  
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8.2 AIMS AND HYPOTHESES 
 
To address these important questions, my objectives in this study were to: (i) examine 
differences in the expression of ICAM-1r, VCAM-1r and IL6r on the three human monocyte 
subsets between patients with STEMI, NSTEMI and subjects with stable CAD; (ii) assess 
dynamics of monocyte expression of these receptors during the acute and recovery phases 
after STEMI, and (iii) explore associations between these receptors and markers of systemic 
inflammation, myocardial damage and cardiac functional recovery following STEMI. 
 
 
8.3 METHODS AND MATERIALS 
 
8.3.1 Study populations 
Fifty consecutive patients with STEMI were recruited on admission to SWBH NHS Trust, 
and forty eight with NSTEMI were recruited on admission to SWBH NHS Trust and Heart of 
England NHS Foundation Trust between November 2009 and STEMI and May 2011.  MI 
was diagnosed according to the consensus universal definition (Thygesen et al, 2007).  
STEMI and NSTEMI were managed according to the respective contemporary ESC 
guidelines (Bassand et al, 2007; Van de Werf et al, 2008).  A proportion of STEMI patients 
did not complete follow-up due to withdrawal of consent, re-infarction or death (chapter 
5.4.1). 
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8.3.2 Control group 
For a cross-sectional comparison, patients with STEMI or NSTEMI were separately 
compared to an age- and sex-matched control group with stable CAD (n=40).  Inclusion and 
exclusion criteria are described in chapter 3.1.  No patients had a history of previous MI or 
LV systolic dysfunction.  Comparisons between subjects with STEMI and NSTEMI were not 
performed due to possible bias related to sample collection after PCI in STEMI, but before 
PCI in NSTEMI.  
 
8.3.3 Sample collection 
Venous blood samples were collected at 4 time points following STEMI: day 1 (within 24 
hours after PPCI), and days 3, 7, and 30.  In NSTEMI patients blood samples were collected 
on day 1 following admission (within 24 hours of MI onset), prior to PCI.  All NSTEMI 
patients had received loading doses of dual anti-platelet therapy (aspirin plus clopidogrel) and 
low-molecular weight heparin prior to venesection (chapter 1.1.6). 
All subjects were asked to refrain from extreme physical exertion for at least 1 hour prior to 
sample collection (chapter 3.3.1).  Peripheral venous blood samples were processed by flow 
cytometry within 60 minutes (chapter 3.2).  Plasma was separated by centrifugation and 
stored at –70oC for batched ELISA analysis (chapter 3.4). 
 
Routine haematology and biochemistry investigations were undertaken by the hospital 
laboratory (chapter 3.5). 
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8.3.4 Flow cytometry 
Expression of ICAM-1r, VCAM-1r, and IL6r by the three monocyte subsets was assessed by 
flow cytometry as described in chapter 3.2.3 (Figure 8.1).  Expression of surface markers was 
quantified as MFI.  Briefly, the three monocyte subsets were defined as CD14++CD16–
CCR2+ (Mon1), CD14++CD16+CCR2+ (Mon2) and CD14+CD16++CCR2- (Mon3) in 
accordance with contemporary nomenclature (Ziegler-Heitbrock et al, 2010; Shantsila et al, 
2011) (chapter 1.2). 
 
Plasma levels of IL1β and IL6 were measured by cytometric bead array technology as 
described in chapter 3.2.5. 
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Figure 8.1  Assessment of monocyte parameters by flow cytometry 
 
 
Monocyte subsets [D] based on forward scatter, side scatter and CD14 and CD16 expression 
[A, B, D] with lymphocytes excluded [C]. Individual monocyte subsets were further gated by 
their expression of IL-6 receptor [E-G], ICAM-1r (MAC-1) and VCAM-1r (integrin alpha 4) 
[H-J]. FSC, forward scatter; SSC, side scatter; Mon1, CD14++CD16– monocytes; Mon2, 
CD14++CD16+ monocytes; Mon3, CD14+CD16++ monocytes. 
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8.3.5 Enzyme-linked immunosorbent assays 
The fibrinolytic parameters tPA, PAI-1 antigen and activity were quantified by ELISA of 
citrated plasma as described in chapter 3.4 using commercially available ZYMUTEST kits.  
 
8.3.6 Assessment of left ventricular function 
Patients underwent echocardiographic assessment of LVEF by Simpson’s method 6 weeks 
after STEMI as described in chapter 3.6.  
 
8.3.7 Statistical analysis 
Statistical analyses were performed as described in chapter 3.8.   Cross-sectional comparisons 
between STEMI versus CAD and NSTEMI versus CAD (normally distributed data) were 
analysed by T-test.  The Friedman test with Dunn’s post-hoc test (where appropriate) was 
used for follow-up analysis.  Univariate and multivariate linear regression analyses were 
performed to establish predictive value of the study parameters for LVEF 6 weeks post 
STEMI. 
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8.4 RESULTS 
 
8.4.1 Subject characteristics 
The study groups were well matched for most demographic and clinical parameters and 
medication (Table 8.1).  Glycoprotein IIbIIIa inhibitors were administered to the majority 
(96%) of STEMI patients but only 10% of NSTEMI patients.  Clopidogrel or prasugrel were 
prescribed more often in subjects with MI than in those with stable CAD (p<0.001 for both). 
As compared to subjects with CAD, those with STEMI more often received angiotensin-
converting enzyme inhibitors (p=0.047), and those with NSTEMI had higher diastolic blood 
pressure (p=0.032), and were more often treated with statins (p=0.017).  The median peak 
troponin T value in patients admitted with STEMI was 2.50μg/l (interquartile range 1.19-5.50 
μg/l).  Thirty three STEMI patients had data on monocyte phenotype at all four time-points.  
Mean LVEF 6 weeks after STEMI was 54.1±14.6%. 
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 Table 8.1  Demographic and clinical characteristics of the study groups 
 
STEMI 
(n=50) 
NSTEMI 
(n=48) 
Stable CAD 
(n=40) 
p value 
STEMI vs CAD 
p value 
NSTEMI vs CAD 
Demographic and clinical characteristics 
Age, years 58 [12] 61 [12] 61 [9] 0.10 0.86 
Male, n (%) 43 (86) 38 (83) 30 (83) 0.73 0.93 
BP systolic, mmHg 132 [18] 137 [18] 133 [16] 0.82 0.44 
BP diastolic, mmHg 78 [14] 81 [10] 75 [9] 0.46 0.032 
Body mass index, kg/m2 30 [6] 28 [6] 29 [5] 0.47 0.81 
Smoking, n (%) 29 (58) 26 (57) 15 (42) 0.21 0.27 
Stroke, n (%) 3 (6) 2 (4) 5 (14) 0.18 0.11 
Hypertension, n (%) 24 (48) 27 (56) 19 (53) 0.48 0.89 
Diabetes, n (%) 16 (32) 14 (30) 8 (22) 0.40 0.49 
COPD, n (%) 3 (6) 3 (7) 3 (8) 0.62 0.70 
Creatinine, μmol/l 92 [19] 97 [23] 73 [14] 0.61 0.60 
Medications at time of recruitment 
Aspirin, n (%) 50 (100) 48 (100] 33 (92) 0.22 0.24 
Clopidogrel/prasugrel, n (%) 50 (100) 48 (100) 18 (47) <0.001 <0.001 
Statin, n (%) 48 (96) 48 (100) 30 (83) 0.28 0.017 
ACE inhibitor, n (%) 45 (90) 38 (83) 25 (69) 0.047 0.33 
Diuretic, n (%) 2 (4) 2 (4) 5 (14) 0.081 0.11 
Beta-blocker, n (%) 32 (70) 34 (71) 25 (69) 0.73 0.70 
CCB, n (%) 13 (28) 13 (27) 9 (25) 0.24 0.86 
Data are presented as mean [standard deviation], or number (%). ACE, angiotensin-
converting enzyme; BP, blood pressure; CAD, coronary artery disease; CCB, calcium channel 
blocker; COPD, chronic obstructive pulmonary disease; NSTEMI, non-ST-elevation 
myocardial infarction; STEMI, ST-elevation myocardial infarction.  
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8.4.2 Interleukin-6 receptor 
On day 1 after STEMI, the expression of IL6r on Mon2 was reduced compared to stable CAD 
(p=0.028), with no differences seen for other subsets (Table 8.2).  During follow-up, 
expression of IL6r increased on Mon1 (p=0.038 vs. day 1) and Mon2 (p=0.026 vs. day 1) by 
day 30 (Table 8.3).  There was no significant difference in IL6r expression between NSTEMI 
and stable CAD (Table 8.2).  
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 Table 8.2  Monocyte expression of receptors to interleukin-6 and adhesion molecules in ST 
elevation myocardial infarction and non-ST elevation myocardial infarction compared to 
stable coronary artery disease 
 
Receptor, MFI STEMI 
(n=50) 
NSTEMI 
(n=48) 
Stable CAD 
(n=40) 
p value 
STEMI vs. CAD 
p value 
NSTEMI vs. CAD 
IL6r (Mon1) 67 [14] 68 [17] 70 [16] 0.37 0.74 
IL6r (Mon2) 57 [12] 61 [13] 62 [15] 0.028 0.80 
IL6r (Mon3) 31 [9] 32 [9] 35 [26] 0.25 0.40 
VCAM-1r (Mon1) 9 [3] 12 [5] 11 [5] 0.007 0.40 
VCAM-1r (Mon2) 19 [8] 29 [10] 23 [10] 0.036 0.024 
VCAM-1r (Mon3) 31 [10] 45 [13] 39 [14] 0.005 0.049 
ICAM-1r (Mon1) 41 [19] 42 [18] 36 [16] 0.27 0.14 
ICAM-1r (Mon2) 69 [33] 75 [28] 65 [25] 0.47 0.10 
ICAM-1r (Mon3) 32 [18] 35 [18] 32 [16] 0.85 0.48 
Data are presented as mean [standard deviation]. CAD, coronary artery disease; ICAM-1r, 
receptor to intercellular adhesion molecule-1; IL6r, interleukin 6 receptor; Mon1, 
CD14++CD16– monocytes; Mon2, CD14++CD16+ monocytes; Mon3, CD14+CD16++ 
monocytes; MFI, median fluorescent intensity; STEMI, ST-elevation myocardial infarction; 
NSTEMI, non-ST-elevation myocardial infarction; VCAM-1r, receptor to vascular cell 
adhesion molecule-1. 
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 Table 8.3  Follow-up monocyte parameters in patients with ST elevation myocardial 
infarction 
 
Receptor, MFI Day 1 Day 3 Day 7 Day 30 p value 
IL6r (Mon1) 66 [16]‡ 68 [15] 66 [17] 73 [17] 0.048 
IL6r (Mon2) 56 [12]‡ 60 [13] 60 [14] 64 [14] 0.012 
IL6r (Mon3) 32 [11] 32 [9] 30 [8] 31 [9] 0.29 
VCAM-1r (Mon1) 10 [3]†‡ 10 [3]†‡ 12 [3] 13 [4] <0.001 
VCAM-1r (Mon2) 20 [7]*†‡ 23 [9] 25 [9] 26 [8] 0.009 
VCAM-1r (Mon3) 30 [11]*†‡ 38 [11] 37 [10] 40 [14] 0.003 
ICAM-1r (Mon1) 35 [27-53] 33 [24-50] 42 [30-56] 37 [28-51] 0.40 
ICAM-1r (Mon2) 61 [45-90] 62 [41-97] 70 [52-96] 61 [45-76] 0.17 
ICAM-1r (Mon3) 25 [18-41] 32 [20-42] 33 [27-45] 31 [21-42] 0.54 
*p<0.05 vs. day 3; †p<0.05 vs. day 7; ‡p<0.05 vs. day 30. Data are presented as mean 
[standard deviation]. CAD, coronary artery disease; ICAM-1r, receptor to intercellular 
adhesion molecule-1; IL6r, interleukin 6 receptor; Mon1, CD14++CD16– monocytes; Mon2, 
CD14++CD16+ monocytes; Mon3, CD14+CD16++ monocytes; MFI, median fluorescent 
intensity; STEMI, ST-elevation myocardial infarction; VCAM-1r, receptor to vascular cell 
adhesion molecule-1. 
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8.4.3 Relations between Interleukin-6 receptor parameters, plasma cytokines, 
fibrinolytic parameters and myocardial damage 
In STEMI, monocyte expression of IL6r correlated negatively with plasma tPA levels (r=-
0.48, p<0.0005 for Mon1, r=-0.45, p=0.001 for Mon2, r=-0.47, p=0.001 for Mon3) (Table 
8.4).  There was a non-significant trend towards a positive association between IL6r 
expression on Mon2 and plasma IL1β levels (r=0.26, p=0.07).  No correlation was found 
between monocyte IL6r density and peak blood troponin T levels.  Monocyte IL6r expression 
on day 1 after STEMI was not predictive of LVEF at 6 weeks (Table 8.5). 
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 Table 8.4  Correlation analysis between biomarkers and plasma interleukin-6 receptor 
expression in patients with ST elevation myocardial infarction 
 
 Mon1 Mon2 Mon3 
r p value r p value r p value 
Inflammatory markers 
Interleukin 1β 0.17 0.24 0.26 0.07 0.20 0.17 
Interleukin 6 -0.30 0.03 -0.41 0.003 -0.16 0.27 
Fibrinolytic factors 
tPA -0.48 0.0005 -0.45 0.001 -0.47 0.001 
PAI-1 antigen -0.15 0.29 -0.23 0.11 -0.13 0.35 
PAI-1 activity -0.07 0.65 -0.13 0.35 -0.06 0.66 
Myocardial damage 
Troponin T -0.23 0.14 -0.27 0.08 -0.05 0.77 
 
Mon1, CD14++CD16 monocytes; Mon2, CD14++CD16+ monocytes; Mon3, CD14+CD16++ 
monocytes; tPA, tissue-type plasminogen activation; PAI-1, plasminogen activator inhibitor-
1; STEMI, ST-elevation myocardial infarction. 
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Table 8.5  Regression analysis of predictive value of monocyte parameters for left ventricular 
ejection fraction at 6 weeks post-ST elevation myocardial infarction 
 
Receptor, MFI B [SE] β p value B [SE β p value 
 Univariate analysis Multivariate analysis* 
IL6r (Mon1) -0.03 [0.17] -0.03 0.83 -0.15 [0.16] -0.14 0.36 
IL6r (Mon2) 0.04 [0.21] 0.03 0.87 -0.16 [0.20] -0.13 0.43 
IL6r (Mon3) -0.06 [0.23] -0.04 0.80 -0.16 [0.22] -0.12 0.45 
VCAM-1r (Mon1) -1.50 [0.89] -0.26 0.10 -1.20 [0.98] -0.19 0.23 
VCAM-1r (Mon2) -0.03 [0.34] -0.01 0.94 0.22 [0.37] 0.09 0.56 
VCAM-1r (Mon3) 0.01 [0.22] 0.007 0.97 0.18 [0.22] 0.12 0.43 
ICAM-1r (Mon1) -0.33 [0.11] -0.42 0.007 -0.19 [0.12] -0.24 0.13 
ICAM-1r (Mon2) -0.17 [0.07] -0.37 0.016 -0.09 [0.08] -0.19 0.24 
ICAM-1r (Mon3) -0.23 [0.12] -0.29 0.066 -0.08 [0.13] -0.10 0.56 
*Adjusted to age and peak troponin T levels (i.e., significant predictors on the univariate 
analysis). ICAM-1r, receptor to intercellular adhesion molecule-1; IL6r, interleukin 6 
receptor; Mon1, CD14++CD16– monocytes; Mon2, CD14++CD16+ monocytes; Mon3, 
CD14+CD16++ monocytes; MFI, median fluorescent intensity; STEMI, ST-elevation 
myocardial infarction; VCAM-1r, receptor to vascular cell adhesion molecule-1. 
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8.4.4 Vascular cell adhesion molecule-1 receptor 
8.4.4.1 Vascular cell adhesion molecule-1 receptor expression and monocyte subsets 
On day 1 after STEMI, expression of VCAM-1r was significantly reduced compared to stable 
CAD on all monocyte subsets (p=0.007 for Mon1, p=0.036 for Mon2, and p=0.005 for Mon3) 
(Table 8.2).  VCAM-1r expression increased progressively during follow-up on all monocyte 
subsets: Mon1 (p=0.024 for day 1 vs. day 7, p=0.001 for day 1 vs. day 30, p=0.018 for day 3 
vs. day 7, and p<0.001 for day 3 vs. day 30); Mon2 (p=0.018 for day 1 vs. day3, p=0.017 for 
day 1 vs. day 7, and p=0.049 for day 1 vs. day 30), Mon3 (p<0.001 for day 1 vs. day3, 
p=0.001 for day 1 vs. day 7, and p=0.017 for day 1 vs. day 30) (Table 8.3).  In NSTEMI, 
expression of the VCAM-1 receptor was higher than in stable CAD on the Mon2 (p=0.024) 
and Mon3 (p=0.049) subsets. 
 
8.4.4.2. Relations between Vascular cell adhesion molecule-1 receptor expression, 
monocyte parameters, plasma cytokines, fibrinolytic parameters and myocardial 
damage 
In patients with STEMI, VCAM-1r expression on Mon1 correlated positively with plasma 
IL1β levels (r=0.44, p=0.001) (Table 8.6).  No correlation was found between monocyte 
VCAM-1r density, peak blood troponin T levels, or plasma markers of fibrinolysis. Monocyte 
VCAM-1r expression on day 1 after STEMI was not predictive of LVEF at 6 weeks (Table 
8.5). 
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 Table 8.6  Correlation analysis between biomarkers and Vascular cell adhesion molecule-1 
receptor expression in patients with ST elevation myocardial infarction 
 
 Mon1 Mon2 Mon3 
 r p value r p value r p value 
Inflammatory markers 
Interleukin 1β 0.44 0.001 0.24 0.10 0.06 0.70 
Interleukin 6 -0.19 0.20 -0.18 0.20 -0.18 0.20 
Fibrinolytic factors 
tPA 0.07 0.63 0.13 0.35 0.31 0.03 
PAI-1 antigen -0.14 0.33 -0.19 0.18 0.08 0.59 
PAI-1 activity -0.12 0.41 -0.05 0.74 0.06 0.66 
Myocardial damage 
Troponin T 0.14 0.36 -0.05 0.77 0.12 0.44 
Mon1, CD14++CD16 monocytes; Mon2, CD14++CD16+ monocytes; Mon3, CD14+CD16++ 
monocytes; tPA, tissue-type plasminogen activation; PAI-1, plasminogen activator inhibitor-
1; STEMI, ST-elevation myocardial infarction. 
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8.4.5. Intercellular cell adhesion molecule-1 receptor 
There were no differences in monocyte subset ICAM-1r expression on day 1 after STEMI or 
NSTEMI compared to stable CAD (Table 8.2).  There were no significant changes in 
monocyte subset ICAM-1r expression during follow-up in STEMI.  No correlation was 
observed between monocyte ICAM-1r expression and any of the blood markers tested in 
STEMI (Table 8.7). 
 
In a univariate analysis, ICAM-1r expression by Mon1 and Mon2 on day 1 after  STEMI was 
significantly negatively predictive of LVEF 6 weeks post-MI (β=-0.42 p=0.007 for Mon1, β=-
0.37, p=0.016 for Mon2), with a similar trend also seen for Mon3 (Table 8.5).  This parameter 
lost its predictive value in multivariate analysis after adjustment for age and peak troponin T 
levels (i.e. the significant predictors of LVEF in the univariate analysis). 
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Table 8.7  Correlation analysis between biomarkers and intercellular cell adhesion molecule-
1 receptor expression in patients with ST elevation myocardial infarction 
 
 Mon1 Mon2 Mon3 
 r p value r p value r p value 
Inflammatory markers 
Interleukin 1β 0.03 0.85 0.06 0.69 0.00 0.99 
Interleukin 6 -0.09 0.55 -0.09 0.52 -0.04 0.77 
Fibrinolytic factors 
tPA 0.01 0.94 0.03 0.81 0.15 0.29 
PAI-1 antigen 0.01 0.93 0.00 0.98 0.11 0.46 
PAI-1 activity 0.01 0.95 -0.03 0.85 0.02 0.89 
Myocardial damage 
Troponin T 0.28 0.07 0.27 0.09 0.14 0.38 
Mon1, CD14++CD16 monocytes; Mon2, CD14++CD16+ monocytes; Mon3, CD14+CD16++ 
monocytes; tPA, tissue-type plasminogen activation; PAI-1, plasminogen activator inhibitor-
1; STEMI, ST-elevation myocardial infarction. 
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8.5 DISCUSSION 
 
This study demonstrates a significant reduction in IL6r expression by the Mon2 subset 
following STEMI.  There was a gradual increase in expression of this receptor on Mon1 and 
Mon2 at 30 day follow-up.  A significant decrease in VCAM-1r density on circulating 
monocytes after STEMI was observed.  One may hypothesise that this may reflect selective 
homing of monocytes with high VCAM-1r expression to damaged myocardium.  Recent data 
suggests that after an MI, monocytes are recruited to a VCAM-expressing substrate at a rate 
50% higher compared to controls at high cardiovascular risk, and that CD14++CD16+ 
monocytes (ie Mon2) adhere with 7-fold higher efficiency compared to other subsets (Foster 
et al, 2013).  
 
A recent meta-analysis demonstrated that genetically-determined accelerated shedding of the 
IL6r into circulation potently protects against atherogenesis in humans, independently of 
established cardiovascular risk factors.  This was thought to be most likely due to disruption 
of IL6-mediated inflammation (Sarwar et al, 2012).  Monocytes have been shown to 
constitute a major population of circulating IL6r-expressing cell.  In healthy subjects, the 
Mon1 and Mon2 subsets have approximately twice higher IL-6r density than Mon3 (Shantsila 
et al, 2011).  The same pattern was seen in MI patients in this study.  Although the precise 
mechanism underlying IL6r cleavage from monocytes has not been established, it is thought 
to be modulated by both circulating and cell-bound enzymes (Reich et al, 2007).  In this 
study, the density of IL6r on all monocyte subsets was found to be highly significantly 
negatively correlated with plasma tPA levels, a fibrinolytic enzyme up-regulated in disorders 
of thrombosis and endothelial damage and dysfunction such as STEMI.  Thus suggests a 
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possible role for this enzyme in IL6r shedding.  Despite the proposition that IL6r remaining 
on effector cells is thought to be of more importance than that shed into the circulation 
(Sarwar et al, 2012), no association was observed between IL-6r density on any monocyte 
subset on day 1 after STEMI and cardiac contractility post-MI. 
 
This is the first study to assess VCAM-1r and ICAM-1r expression on individual monocyte 
subsets following MI and to explore their relationship to markers of inflammation, cardiac 
damage and recovery.  To allow these results to be interpreted, it should be borne in mind that 
the presence or absence of changes in receptor expression on circulating monocytes may 
depend upon a combination of (i) change in receptor expression in response to inflammation, 
(ii) shedding of receptors into the circulation, and ultimately (iii) speed of monocyte homing 
to the site of injury.  Indeed, accelerated adhesion of leukocytes to endothelial cells is one of 
the first events in the acute inflammatory response implicated in the pathogenesis of 
atherosclerosis.  Leukocyte surface glycoproteins such as ICAM-1r and VCAM-1r play a 
major role in this process.  Their expression can be up-regulated in response to chemotactic 
molecules released from sites of inflammation and injury (Mazzone & Ricevuti, 1995).  
 
On day 1 after STEMI, a significant reduction in VCAM-1r expression on all three monocyte 
subsets compared to stable CAD was observed.  However, in NSTEMI there was a significant 
up-regulation of VCAM-1r expression by the Mon2 and Mon3 subsets (with no change for 
Mon1).  These opposing patterns may be related to the difference in degree of myocardial 
damage and inflammation in STEMI compared to NSTEMI, as a significant positive 
correlation between VCAM-1r density on the ‘proinflammatory’ Mon1 subset and blood IL1β 
levels was observed.  In NSTEMI, this may lead to up-regulation of monocyte VCAM-1r 
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expression.  Conversely, in STEMI which is characterised by a much larger degree of 
myocardial damage and inflammation, accelerated recruitment of monocytes with higher 
VCAM-1r expression in STEMI could selectively remove such monocytes from the 
circulation.  
 
There was no change in monocyte ICAM-1r expression on day 1 after either STEMI or 
NSTEMI compared with CAD, and no change during follow-up in STEMI patients.  Previous 
data showed that in patients with unstable angina (but not in stable controls) monocyte 
ICAM-1r expression was selectively increased in the coronary circulation but not in the aorta, 
implying an abundance of highly ICAM-1r expressing monocytes at sites of vascular injury 
(Mazzone et al, 1993; De Servi et al, 1995).  In my study, ICAM-1r expression by Mon1 and 
Mon2 after STEMI was negatively associated with LVEF at 6 weeks on univariate analysis.  
This may reflect more pronounced myocardial recruitment of monocytes with higher ICAM-
1r expression in patients with a larger amount of infarcted myocardium and hence lower 
LVEF.  Indeed, the predictive value of this parameter for 6 week LVEF lost significance after 
adjustment for troponin levels, suggesting a relationship with degree of myocardial damage. 
 
Taken together, the findings in this study suggest that the overall net effect on expression of 
receptors to adhesion molecules by circulating monocytes following MI is complex.  Receptor 
expression may depend upon the rate of monocyte recruitment into damaged myocardium, 
possibly masking the highest degree of monocyte activation in patients with a larger infarct.  
Accumulation of activated monocytes could promote local detrimental processes including 
thrombosis and vasoconstriction, but also therapeutic processes including angiogenesis and 
removal of debris from sites of injury. 
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Transgenic mice without adhesion molecule receptors cannot localize leukocytes to the 
interstitium (Cotran & Mayadas-Norton, 1998).  Furthermore, in a canine experimental model 
of myocardial reperfusion injury, a monoclonal antibody against ICAM-1r significantly 
attenuated accumulation of inflammatory leukocytes within the myocardium, and potently 
reduced degree of infarction (Simpson et al, 1988).  Accordingly, pharmaceutical 
manipulation of monocyte expression of adhesion molecules may represent a therapeutic 
target for modulation of excessive recruitment of these cells in MI.  Additionally, although 
modulation of the pro-inflammatory pathway mediated by membrane-bound IL6r may also 
represent an attractive therapeutic strategy to reduce cardiovascular risk, IL6 may also bind 
with soluble IL6r which activates alternative non-pathological signalling pathways.  For 
example, trials of the monoclonal antibody Tocilizumab (a competitive inhibitor of IL6r) have 
been associated with adverse effects on the lipid profile (Sarwar et al, 2012).  This highlights 
the complexity of targeting discrete pathways, emphasising the fundamental requirement for 
further investigation into the relationships of monocyte subsets with inflammatory pathways 
associated with atherosclerosis and MI.  The results of phase 3 trials of anti-inflammatory 
agents in the secondary prevention of cardiovascular disease are awaited with much interest 
(Ridker, 2009; Ridker et al, 2011). 
 
There are two previous reports describing increased monocyte expression of ICAM-1r and 
VCAM-1r in MI which appear to contradict my results.  The first study (Hillis et al, 2001) 
only included 5 subjects with non-Q wave MI (approximately equivalent to NSTEMI) and 3 
subjects with a Q wave MI (approximately equivalent to STEMI) out of a total of 22 acute 
coronary syndrome (ACS) patients.  This suggests that the majority of patients did not have 
any degree of myocardial damage.  Their study population is therefore pathophysiologically 
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rather a heterogeneous group.  Additionally, none were treated by PCI, thrombolysis or 
glycoprotein IIb/IIIa inhibitors.  There is no data regarding receptor quantification (Hillis et 
al, 2001).  The second study compared 21 patients with ACS (mostly ‘unstable angina’ rather 
than myocardial infarction) with healthy controls rather than subjects with stable CAD 
(Murphy et al, 2003).  However, interpretation of the results and direct comparison between 
these two studies and my findings is limited by significant methodological differences.  
Firstly, heparinised blood samples were stored at room temperature for up to 4 hours before 
processing.  This may significantly affect monocyte phenotype (Shantsila et al, 2012).  Also 
no specific monocyte markers were used in the study.  
 
In the present study carefully defined 
groups of patients with specific types of MI (i.e. STEMI or NSTEMI) were analysed, and no 
patients with troponin-negative unstable angina (i.e. no myocardial damage) were included. 
My study is further strengthened by a validated methodological approach, which allows 
measurement of accurately defined monocyte subsets according to contemporary 
nomenclature (Shantsila et al, 2011). 
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8.6 LIMITATIONS 
 
This study is descriptive in nature and does not provide insight into intra-cardiac processes 
which may not parallel changes in blood.  Therefore, inferences made as to what increases or 
decreases in circulating monocytes and their expression of receptors may mean for the 
myocardial tissue itself are purely speculative.  Measurements were made on monocytes and 
biomarkers in circulation, whereas the origin of MI is perhaps a more localised event, with 
inflammation within an individual culprit atherosclerotic plaque.  Mouse data suggest that 
monocyte counts and activity in circulation may not reflect their accumulation and activity 
within tissues.  However, simultaneous assessment of study parameters in circulation and 
within the myocardium would be required to confirm the hypotheses proposed, which is 
clearly outside the constraints of this study.  Also, the specific mechanisms responsible for an 
increase or decrease in expression of monocyte receptors have not been studied; these may 
include increased expression of a receptor by circulating monocytes versus mobilisation of 
new monocytes with higher receptor density, and receptor shedding versus internalisation. 
 
Although significant correlations were found between several study parameters and 6 week 
LVEF, direct pathological links between these findings cannot be made and require further 
study.  The relatively modest reduction in mean LVEF at 6 weeks (mean EF 54.1±14.6%) 
after STEMI reflects the beneficial effect a PPCI programme has on limiting infarct size.  
However, this may potentially mask more marked changes in study parameters if patients 
were to have sustained more myocardial damage.  Indeed, the changes in monocyte 
parameters observed are a cumulative composite of the effects of MI itself, PPCI and 
medication.  This contrasts with animal models where the effects of MI alone can be studied.  
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Finally, it was logistically impossible to collect the samples at the same time each day.  
Although the majority of samples were collected between 09.00 and 12.00 and the remaining 
impact of diurnal variation in monocyte parameters is likely to be minimal, this should be 
considered as a limitation (Shantsila et al, 2012).     
 
The study population is relatively small which limits assessment of prognostic implications of 
the changes observed in STEMI.  Larger, prospective studies are required to address this 
issue.   
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8.7 CONCLUSIONS 
 
The IL6r pathway is thought to have a direct causal role in the pathogenesis of CAD.  This 
study describes specific changes in monocyte IL6r expression and associations related to 
individual monocyte subsets following STEMI.  Circulating monocyte subsets implicated in 
inflammatory responses appear to exhibit reduced IL6r expression in the acute phase 
following STEMI, possibly reflecting enzyme shedding.  This may represent a regulatory 
feed-back mechanism aiming to balance the excessive inflammation characteristic of acute 
MI.  The net effect of expression of receptors to adhesion molecules on circulating monocytes 
after MI may depend upon the rate of monocyte recruitment to damaged myocardium, 
possible masking monocyte activation in patients with bigger infarcts. 
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CHAPTER 9 
 
SUMMARY, CONCLUSIONS AND FUTURE DIRECTIONS 
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9.1 SUMMARY AND OVERALL CONCLUSIONS 
 
The principal aim of this thesis was to provide a detailed phenotypic comparison of 
differences between the three human monocyte subsets in the setting of CAD and MI, with 
emphasis on the Mon2 (’Intermediate’) and Mon3 (’Nonclassical’) subsets.   
 
Work in chapter 4, demonstrated multiple significant novel changes in monocyte phenotype in 
patients with CAD, attributable to specific subsets, and demonstrated significant differences 
in plasma levels of cytokines in CAD compared to healthy subjects (summarised in table 9.1). 
 
I observed significant reductions in CD14 expression on Mon1 and Mon3, and CD16 
expression on Mon1 and Mon2 in patients with CAD. 
 
Patients with CAD express higher Interleukin 6 receptor (IL6r) levels, and my findings 
suggest that Mon1 and Mon2 may be amongst the effector cells responsible for IL6r-mediated 
atherogenesis (Sarwar et al, 2012). 
 
My finding of a significantly higher expression of CXCR4 by Mon3 in CAD compared to 
healthy subjects suggests that these ‘non-classical’ monocytes may be a subset with enhanced 
CXCR4-dependent mobilisation to tissues in CAD, in keeping with their ‘patrolling’ 
behaviour (Cros et al, 2010). 
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The finding of a significant increase in CD34 expression by all three monocyte subsets in 
CAD may reflect a compensatory mechanism attempting to enhance angiogenic processes in 
response to low-grade ischaemia in stable CAD. 
 
The negative correlation with plasma IL6 reinforces the anti-inflammatory properties of the 
haptoglobin scavenger receptor CD163. 
 
The positive correlations between VEGFR1 expression on Mon1 and Mon2 with uPA levels 
and the negative correlation between plasma PAI-1 level and IL6r expression on Mon2 may 
reflect a role of fibrinolytic enzymes in the regulation of expression and cleavage of these 
receptors.  
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Table 9.1 Summary of expression of surface receptors by monocyte subsets, plasma cytokine 
levels and correlations with plasma biomarkers in coronary artery disease compared to 
healthy subjects 
 
 Receptor 
 
Mon1 
 
Mon2 
 
Mon3 
 
Surface expression 
 CD14 ↓  ↓ 
 CD16 ↓ ↓  
 IL6r ↑ ↑  
 CXCR4   ↑ 
 CD34 ↑ ↑ ↑ 
Correlation with IKKβ level 
 CXCR4 +   
 CD34 +   
 VEGFR1 - -  
 CD42a +   
Correlations with plasma level 
IL6 CD163 - - - 
 
MCP-1 
TLR4 + +  
VEGFR1  +  
CD204 - -  
IL1β CD42a +   
uPA VEGFR1 + +  
PAI-1 antigen 
VEGFR1  +  
IL6r  -  
PAI activity IL6r  -  
Plasma cytokines level in CAD 
IL10 ↓ 
MCP-1 ↓ 
↑ IL6 (strong trend) 
Mon1, CD14++CD16-CCR2+ monocytes; Mon2, CD14++CD16+CCR2+ monocytes; Mon3, 
CD14+CD16++CCR2- monocytes; CAD, coronary artery disease; IL, interleukin; IL6r, 
Interleukin 6 receptor; IKKβ, inhibitory κB kinases; MCP-1, monocyte chemoattractant 
proten-1; uPA, urokinase type plasminogen activator; PAI, plasminogen activator inhibitor 
type 1; ↑, increased expression; ↓, decreased expression; +, positive correlation; -, negative 
correlation 
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In chapter 5, I described for the first time the differential dynamics of the three human 
monocyte subsets following STEMI.  The findings are summarised in table 9.2.  The 
hypothesis that the Mon2 subset has unique properties is supported by the findings of specific 
and highly significant changes in their phenotype after STEMI (increased CD14 and CCR2 
expression, reduced CD16 expression).  Activity of the NFκB pathway was highest in Mon2 
on day 1 after STEMI, suggesting a prominent increase in functional activity; the significant 
reduction on day 7 (compared to other monocytes) suggests that Mon2 are most functionally 
active in the first few days after STEMI.  The significant reduction in Mon2 number on day 7 
is in keeping with the increased capacity for Ly-6C
low
 monocytes to migrate into the 
myocardium at this stage in mice. 
 
The only significant correlations between monocyte parameters and peak troponin level were 
with Mon2 number and characteristics.  Additionally, most monocyte-associated predictors of 
LVEF at 6 weeks were related to the Mon2 subset, including Mon2 number and number of 
MPAs associated with Mon2.  The only parameter independently predictive of LVEF at 6 
weeks was CD16 expression by Mon2 (lower CD16 expression predicted better LVEF).  
These findings suggest a close relationship between numerous Mon2 subset characteristics 
and the degree of myocardial damage and recovery following STEMI. 
 
The observation of no change in number of Mon3 after STEMI and little change in phenotype 
(only increase in CD14 expression) compared to Mon 2 supports the hypothesis that this 
subset has substantially different physiological roles compared to Mon1 and Mon2. 
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The complexity of Mon2 biology is suggested by its correlation with levels of both IL6 and 
IL10 (i.e. both ‘pro’- and ‘anti-inflammatory’ cytokines). 
 
This study demonstrates for the first time that the increase in MPA count persists at 30 days 
after STEMI, despite ongoing potent dual antiplatelet therapy, and after the monocyte count 
has returned to a level comparable to stable CAD.  This is in accordance with data describing 
the important regulatory role platelets have in modulating the functional activity of 
monocytes. 
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Table 9.2 Summary of changes in monocyte parameters and plasma cytokine levels following 
ST-elevation myocardial infarction 
 
 Day after STEMI 
Day1 Day3 Day7 Day30 
Monocytes 
 
Total 
monocytes 
number ↑   ↓ 
Mon1 number ↑    ↓ 
CCR2 
expression 
no change   ↓ 
IKKβ level ↑   ↓ 
Mon2 number ↑ (2.5 fold)   ↓  
proportion Mon2>Mon3   Mon2<Mon3 
CCR2 
expression 
↑   ↓ 
CD14 
expression 
↑  ↓  
CD16 
expression 
↓    
IKKβ level ↑  ↓  
Mon3 number no change no change no change no change 
proportion Mon3<Mon2   Mon3>Mon2 
CD14 
expression 
↑  ↓  
CCR2 
expression 
no change ↑ ↓ ↓ 
CD16 
expression 
no change no change no change no change 
IKKβ level ↑   ↓ 
Monocyte platelet aggregates 
 
Total number ↑   ↓ (but higher 
than CAD 
MPA Mon1 number ↑   ↓ (but higher 
than CAD) 
MFI ↑ remained ↑ remained ↑ remained ↑ 
MPA Mon2 number ↑   trend in ↓(but 
higher than 
CAD) 
MFI ↓    
%  Mon2>Mon1    
MPA Mon3 number no change no change no change no change 
Plasma cytokines 
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IL1β plasma 
level 
no change ↓  same as CAD 
IL6 
 
plasma 
level 
↑  ↓ same as CAD 
correlations 
(all 
positive) 
Mon1, 
Mon2, 
Total MPAs, 
MPA-Mon1, 
MPA-Mon2 
   
IL10 plasma 
level 
no change  ↑ same as CAD 
correlations positive 
correlation 
with Mon2 
   
MCP-1 plasma 
level 
↓  ↓ further same as CAD 
Mon1, CD14++CD16-CCR2+ monocytes; Mon, CD14++CD16+CCR2+ monocytes; Mon3, 
CD14+CD16++CCR2- monocytes; MPA, monocyte platelet aggregates; STEMI, ST 
elevation myocardial infarction; CAD, coronary artery disease; IKKβ, inhibitory κB kinases, 
MCP-1, monocyte chemoattractant protein-1; IL, interleukin; ↑, significant increased number; 
↓, significant decreased number; MFI, median fluorescent intensity; %, percentage of each 
subset aggregated with platelets 
 
 
 
In chapter 6, changes in monocyte parameters on day 1 following NSTEMI were described.  
These mirrored previous observations following STEMI (chapter 5), with significant but 
numerically less prominent increases in Mon1 and Mon2 number and no change in Mon3, and 
a trend (not statistically significant) towards a reduced relative proportion of Mon3 but 
increased relative proportion of Mon2. 
 
This study shows for the first time that MI is associated with increased numbers of TLR4+ 
monocytes, but TLR4 expression (percentage positive cells or MFI) by individual monocyte 
subsets per se is unchanged.  Moreover the increase in TLR4+ monocytes is only attributed to 
specific human monocyte subsets (Mon1 and Mon2 in STEMI, and Mon2 only in NSTEMI).  
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The relative clinical importance of monocyte number rather than level of TLR4 expression 
per se is suggested by the correlation between peak troponin level and TLR4+ Mon2 number 
(similarly to the correlation with total Mon2 subset count in chapter 5), but not with TLR4 
expression on any subset. 
 
There was no association between monocyte TLR4 expression and IKKβ activity, and no 
association between monocyte TLR4 expression and LVEF 6 weeks post STEMI.  Plasma 
IL6 level correlated positively with TLR4+ Mon2 count but negatively with TLR4 expression 
on Mon2.  This observation is in agreement with data describing the association of this subset 
with high IL6 levels in chapter 5.  In contrast, the negative association with TLR4 expression 
by other monocytes may reflect partial loss of TLR4 from activated monocytes.  These 
findings suggest that TLR4 expression may not be a reliable marker of monocyte activation in 
STEMI. 
 
In chapter 7, several significant novel observations were made regarding monocyte subsets 
and their associations with receptors implicated in reparative properties following STEMI 
(summarised in table 9.3). 
 
There was a significant increase in number of CXCR4+ and KDR+ monocytes following 
STEMI, only associated with Mon1 and Mon2 subsets. 
 
The number of the CXCR4+ Mon2 subset on day 1 after STEMI (but not KDR+ Mon 2 cells) 
correlated significantly with peak troponin level.   
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The significant reduction in expression of the pro-reparative scavenger receptor CD163 by all 
subsets following STEMI observed may be related to their increased utilisation in the setting 
of myocardial necrosis, reflecting higher demand for their functions.  This may contribute to 
the independent association between reduced expression of CD163 by the Mon1 subset and 
higher LVEF 6 weeks after STEMI. 
 
A high count of the CXCR4+ Mon2 subset and high CD163 expression by Mon1 after 
STEMI were significant predictors of lower LVEF at 6 weeks.  This could suggest potential 
detrimental properties of CXCR4+ and CD163+ monocytes or conversely their increased 
utilisation in repair mechanisms in patients with more marked infarction. 
 
The positive correlations between numbers of CXCR4+ Mon2 and both pro- and anti-
inflammatory cytokines further suggests that the role of these cells in post-MI reparative 
processes is complex. 
 
My study suggests the increase in CD204+ monocytes previously seen post-MI is due to 
monocytosis rather than increased monocyte expression of CD204 per se, which did not 
change significantly.  However, following STEMI, CD204 expression by monocyte subsets 
was associated with plasma levels of inflammatory cytokines, suggesting a relationship with 
ischaemic myocardial injury. 
 
Mon2 monocytes could be considered a ‘top’ rather than ‘intermediate’ subset as they have 
the highest expression of ‘beneficial’ reparative markers (CXCR4, KDR and CD163). 
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Table 9.3  Summary of changes in monocyte expression of CXCR4, KDR, CD163 and 
CD204 following ST-elevation myocardial infarction and their relations to plasma cytokines 
 
 Days after STEMI 
Day1 Day 3 Day7 Day 30 
Monocytes 
 
Mon1 CXCR4+ 
number 
↑   ↓ 
KDR+  
number 
↑    
CD163 
expression 
no change ↓   
CD204 
expression 
no change ↓   
Mon2 CXCR4+ 
number 
↑   ↓ 
KDR+  
number  
↑    
CD163 
expression 
no change ↓   
Mon3 CD163 
expression 
↓ no further 
change 
  
CXCR4+ 
number 
no change    
KDR+ 
number  
no change    
Correlations  
 
Peak 
troponin 
positive number of 
CXCR4+Mon2 
   
IL1β positive number of 
KDR+Mon1 
and KDR+Mon2 
   
IL6 positive number of 
CXCR4+Mon2 
and KDR+Mon2 
   
negative Mon2 CD204 
expression 
   
IL10 positive number of 
CXCR4+Mon2 
   
negative number of KDR+ 
Mon3 
   
negative Mon2 CD204 
expression 
   
Peak 
troponin 
positive number of 
CXCR4+Mon2 
   
223 
 
STEMI, ST-elevation myocardial infarction; Mon1, CD14++CD16-CCR2+ monocytes; Mon, 
CD14++CD16+CCR2+ monocytes; Mon3, CD14+CD16++CCR2- monocytes; MCP-1, 
monocyte chemoattractant protein-1; IL, interleukin; ↑, significant increased number; ↓, 
significant decreased number 
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Chapter 8 described specific changes in IL6r and adhesion molecule expression and 
associations with cytokines related to individual monocyte subsets following STEMI 
(summarised in table 9.4).  Circulating monocyte subsets implicated in inflammatory 
responses appear to exhibit reduced IL6r expression in the acute phase following STEMI, 
possibly reflecting enzyme shedding.  This may represent a regulatory feed-back mechanism 
aiming to balance the excessive inflammation in MI.  The density of IL6r on all monocyte 
subsets correlated negatively with plasma tPA levels, suggesting a possible role for this 
fibrinolytic enzyme in IL6r shedding. 
 
No association was observed between IL6r density on any monocyte subset on day 1 after 
STEMI and LVEF at 6 weeks. 
 
VCAM-1r number on all monocyte subsets decreased significantly after STEMI, whereas in 
NSTEMI there was a significant increase in VCAM-1r expression by Mon2 and Mon3.  This 
may reflect selective homing of monocytes with high VCAM-1r expression to large areas of 
damaged myocardium in STEMI. 
 
There was no change in monocyte ICAM-1r expression on day 1 after either STEMI or 
NSTEMI.  However, its expression on Mon1 was reduced at 30 day after STEMI.  The 
negative correlation between ICAM-1r expression by Mon1 and Mon2 after STEMI with 
LVEF at 6 weeks may reflect more pronounced myocardial recruitment of monocytes with 
higher ICAM-1r expression in patients with larger infarcts.  Indeed, the predictive value of 
this parameter for 6 week LVEF lost significance after adjustment for troponin levels, 
suggesting a relationship with degree of myocardial damage. 
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The findings in this study suggest that the overall net effect on expression of receptors to 
adhesion molecules by circulating monocytes following MI is complex.  This may depend 
upon the rate of monocyte recruitment into damaged myocardium, possibly masking the 
highest degree of monocyte activation in patients with a larger infarct.  Accumulation of 
activated monocytes could promote local detrimental processes including thrombosis and 
vasoconstriction, but also therapeutic processes including angiogenesis and removal of debris 
from sites of injury. 
 
Table 9.4  Summary of monocyte subsets and their relationships to Interleukin 6 receptor and 
adhesion molecules following ST-elevation myocardial infarction. 
 Day after STEMI 
Day1 Day3 Day7 Day30 
Monocytes 
 
Mon1 IL6r number no change   ↑ 
expression negative correlation with tPA    
VCAM-1r number ↓ 
positive correlation with IL1β 
 ↑ ↑ 
ICAM-1r number no change   ↓ 
expression negative correlation with 
LVEF 
   
Mon2 IL6r number ↓   ↑ 
expression negative correlation with tPA    
positive correlation IL1β 
(trend) 
   
VCAM-1r number ↓ ↑ ↑ ↑ 
ICAM-1r number no change    
expression negative correlation with 
LVEF 
   
Mon3 IL6r number no change    
expression negative correlation with tPA    
VCAM-1r number ↓ ↑ ↑ ↑ 
ICAM-1r number no change    
STEMI, ST-elevation myocardial infarction; Mon1, CD14++CD16-CCR2+ monocytes; Mon, 
CD14++CD16+CCR2+ monocytes; Mon3, CD14+CD16++CCR2- monocytes; IL, 
interleukin; IL6r, Interleukin6 receptor; ICAM-1r, intercellular cell adhesion molecule-1 
receptor; VCAM-1r, vascular cell adhesion molecule-1; tPA, tissue-type plasminogen 
activator; LVEF, left ventricular ejection fraction at 6 weeks; ↑, significantly increased 
number; ↓, significantly decreased number  
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9.2 FUTURE DIRECTIONS 
 
Despite major advances in our understanding of the mechanisms of CAD and the management 
of MI and consequent LV dysfunction, this disorder remains a major public health concern 
with much associated morbidity and mortality.  This indicates the requirement for ongoing 
research with the aims of better understanding the complex pathophysiology of this condition, 
and the development of further targeted therapies.  Future research may focus on diagnostic 
tests to risk stratify patients with CAD to discriminate a benign phenotype from a more 
aggressive form with propensity to plaque progression, destabilisation, rupture and 
consequent MI.  This may allow for interventions to halt or even reverse plaque progression.  
Additionally, in the event of MI the emphasis could be on reducing adverse LV remodelling 
and promotion of LV recovery and contractility.       
 
The work in this thesis is of an exploratory pilot study nature, with the aim of making 
observations which may be hypothesis generating for future research.  Ongoing prospective 
enrolment of patients to validate the findings in this thesis would be valuable.  A prospective 
study examining the predictive value of monocyte subset count and phenotype to estimate the 
degree of left ventricular impairment expected in the convalescent recovery phase could be of 
important clinical utility.  This would allow for the rapid identification of post-MI patients at 
highest risk of complications related to LV dysfunction and therefore appropriate targeting of 
therapies.  It was noted in this thesis that the management of STEMI has greatly improved 
over the last decade, with more successful reperfusion of the infarct-related artery and 
consequently improved preservation of left ventricular systolic function.  I used simple trans-
thoracic echocardiography to measure convalescent LVEF, but it could be more informative 
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to utilise more sophisticated imaging techniques such as cardiac MRI which has greater 
spatial resolution and can be used to investigate other important parameters involved in 
myocardial recovery post MI, such as the extent of microvascular obstruction. 
 
It would be informative to study the effects of interventions known to reduce cardiovascular 
risk on the three human monocyte subsets.  This could include lifestyle measures such as 
smoking cessation, dietary modification, weight loss, aerobic exercise, along with 
modification of established risk factors such as blood pressure control and cholesterol 
lowering.  Pleotropic effects including anti-inflammatory properties have been identified for 
certain therapies such as aspirin and the statin drugs, so it would also be important to study 
the effects of established medication used in CAD and MI including antiplatelet drugs 
(aspirin, clopidogrel, prasugrel, ticagrelor), statins and inhibitors of the renin-angiotensin-
aldosterone system.  Additionally there are major clinical trials of dedicated anti-
inflammatory agents investigating the effects of methotrexate (Cardiovascular Inflammation 
Reduction Trial; CIRT) (Ridker, 2009) and the neutralisation of Il-1β with Canakinumab 
(Canakinumab Anti-inflammatory Thrombosis Outcomes Study; CANTOS) (Ridker et al, 
2011) in atherosclerosis, and it would be informative to investigate the effects of these drugs 
on the three human monocyte subsets.  
 
It remains unclear whether the ‘intermediate’ CD14++CD16+CCR2+ subset is a truly 
biologically distinct cell type or whether these cells are in transition between the other 
subsets.  In vitro studies may be performed to purify and culture the CD14++CD16+CCR2+ 
subset and identify whether they can develop into ‘classical’ CD14++CD16-CCR2+ and/or 
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‘non-classical’ CD14+CD16++CCR2- monocytes, or give rise to a unique type of 
macrophage or dendritic cell.   It is also unclear whether the differentiation of human 
monocytes into specific subsets is already complete in the bone marrow and spleen or whether 
this maturation occurs in the circulation and tissues as has been demonstrated in mice.  The 
Mon1 subset has been reported to show some degree of CD16 expression after stimulation 
(Passacquale et al, 2011).  The changes in phenotype observed may reflect their 
differentiation towards the Mon2 subset or maturation into CD16+ macrophages. Our 
previous work demonstrated that all three monocyte subsets are present in bone marrow, 
which contained relatively higher proportions of Mon2 than found in circulation (Shantsila et 
al, 2011).  A rapid release of the Mon2 subset from bone marrow into the circulation may 
explain the dramatic increase in Mon2 count on day 1 after STEMI in this study.  Further 
research is required to answer these questions about monocyte subset origins and phenotypic 
differentiation.  
 
One of the major limitations of the observations made in this thesis is the measurement of 
monocyte count and phenotype solely in peripheral venous blood.  Numerous observations 
were made in relation to the absolute number of each monocyte subset in peripheral venous 
blood and their expression of a range of surface markers.  It would be informative to be able 
to quantify monocyte count and study their phenotype within the myocardium during life, as 
this may be the site at which monocytes maximally exert their roles.  In the human setting, 
direct tissue sampling from the myocardium especially in the context of acute MI would pose 
major ethical and practical dilemmas.  However, the identification of a monocyte ‘gradient’ 
may allow inferences to be made about where monocytes are taken up from circulation into 
tissue.  This could be calculated by sequential sampling of blood from multiple sites: 
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peripheral venous, right atrium, right ventricle, pulmonary artery, left atrium, left ventricle, 
aortic root, coronary artery ostium and the coronary sinus.  Performance of this experiment in 
an animal model and also humans with CAD and healthy controls would allow for important 
comparisons between species; the differences between human and animal monocyte subsets 
has hampered extrapolations between species, and this must be overcome.  If this proved 
successful and reliable it could perhaps be extended to the post-MI setting, firstly in an 
experimental animal model of MI.  Of particular interest in the MI setting would be to 
examine the subset count, phenotype and function in the occluded artery by means of 
analysing the material removed from the coronary artery during thrombus aspiration which is 
widely used during PPCI for STEMI. 
 
Van de Laan and colleagues recently described that 40% of monocytes in the infarct core of 
subjects who died from MI are CD14+CD16+ (van der Laan et al, 2013).  Further delineation 
of these cells into the Mon2 and Mon3 subsets would be very informative, to further expand 
our understanding of the temporo-spatial distribution of monocytes following MI which may 
suggest their functions in this setting. 
 
Non-invasive imaging techniques could also be utilised to allow identification of the three 
monocyte subsets within tissues including the myocardium. Imaging modalities using labelled 
nanoparticles including MRI (Sosnovik et al, 2007), PET (Lee et al, 2012b) and fluorescence 
molecular tomography (Nahrendorf et al, 2007) have been used to track monocytes and their 
molecular functions in mice.  Multi-modal hybrid imaging (PET/MRI) has recently been 
reported in mice to simultaneously quantify monocyte-associated detrimental myocardial 
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inflammation and also beneficial remodelling (Majmudar et al, 2013).   Ultimately these 
techniques may be utilised to study human monocytes in the CAD and post-MI settings. 
 
The observations made in the thesis and in other works have further characterised human 
monocyte subsets.  The ultimate aim of developing a detailed understanding of monocyte 
subset biology and pathophysiology is to investigate the potential to influence their functions 
for therapeutic benefit.  For example this may arrest the development of coronary plaques, 
rendering them less likely to become large enough to impinge sufficiently on the coronary 
artery lumen to obstruct normal flow and cause exertional angina.  Alternatively, it may be 
possible to modify the composition of coronary plaques to reduce the likelihood of 
progression to destabilisation and rupture which precipitates coronary artery thrombosis, 
obstruction and ultimately myocardial infarction.  Such a detailed understanding must travel 
beyond an over-simplistic labelling of a certain monocyte subset as ‘good’ or ‘bad’, 
‘deleterious’ or ‘reparative’.  The precise functions of monocyte subsets must be understood 
during each stage of their development, at different anatomical sites, and under healthy 
conditions and in disease settings.  Parallels must be drawn between human and animal 
monocyte subset biology, as any therapeutic manoeuvre must be studied first in an animal 
model.  The first such step would be to simply enhance or inhibit the function of a particular 
monocyte subset in healthy controls and subjects with CAD and MI to assess the overall 
effect on the myocardium.  This could be achieved by simply increasing or decreasing the 
number of a particular subset, or by stimulation/inhibition without altering the number of 
cells.  More specifically, this could focus on specific phenotypes of a subset identified by their 
expression of surface markers, such as monocytes with ‘reparative potential’.  The ability of 
monocyte subsets to modify their phenotype and functionality should be distinguished from 
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the release of newly synthesised monocytes from storage sites.  Pharmacological agents which 
specifically target individual monocyte subsets are not currently in existence.  Clinical studies 
investigating experimental therapies aimed at manipulating inflammation in CAD and MI 
have recently been reviewed by Baruch and colleagues (Baruch et al, 2013).   Close attention 
would be vital in monitoring the other known roles of monocytes if they are manipulated, 
such as innate immunity.  The duration of beneficial and also any deleterious effects of such 
actions should be studied longitudinally, beyond the lifespan of monocytes in existence at the 
time an agent is introduced to the body. 
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APPENDIX 3:  Standard Operating Procedure 201; Monocyte subsets and monocyte 
platelet aggregates by flow cytometry 
STANDARD OPERATING PROCEDURE 201 
 
MONOCYTE SUBSETS  
 
Monocyte platelet aggregates by flow cytometry 
SOP written by Eduard Shantsila and Andrew Blann 
 
N.B. Use of the flow cytometry is forbidden  
Without having been officially trained 
 
Required pre-training 
 
1. SOPs on venepuncture and on  good clinical practice 
 
2. SOP 195 – General operation of the flow cytometer 
 
Contents 
 
Introduction Page 1 
 
Materials and suppliers Page 2 
 
Detailed Method Page 3 
 
Interpretation Page 8 
 
Validation and quality control Page 9 
 
 
1. Introduction 
 
Monocytes are large mononuclear cells (MNCs) derived from the bone marrow but on transit 
to the tissues where they seem likely to become semi-resident macrophages. Traditionally, 
they have been defined by glass-slide morphology, size, and scatter, but we now have the 
ability to define monocytes by cell surface molecules, using the FACS. For example, CD14 is 
a receptor for LPS present on monocytes, macrophages and neutrophils. CD16 is an antigen 
found on the Fc receptors and is present on natural killer cells, neutrophil polymorphonuclear 
leukocytes, monocytes and macrophages. So leukocytes populations can be further classified 
by the density of the expression of these markers, for example…. 
 
 M1 = CD14 strong CD16  negative 
 M2 = CD14 strong  CD16 strong 
 M3 = CD14 weak CD16 strong 
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A further characteristic of monocytes in chemotaxis, such as to the chemokine monocyte 
chemoattractant protein-1 (MCP-1), a cytokine involved in monocyte infiltration in 
inflammatory diseases such as rheumatoid arthritis as well as in the inflammatory response 
against tumors. CCR2, short for chemokine (C-C motif) receptor 2, is a chemokine receptor 
for MCP-1 CCR2 has also recently been designated CD192.   
 
Platelets are anucleate fragments of the cytoplasm of the megakaryocyte. They form thrombi 
when self-aggregating but more so in the presence of fibrin. However, platelets may also bind 
to monocytes. Cell surface markers of platelets include CD42a, also known as GpIX. It 
follows that dual labelling of blood with a monocyte marker (CD14/CD16/CCR2) and a 
platelet marker (CD42a) will identify monocyte-platelet aggregates (MPAs).  
 
This SOP describes enumeration of monocyte subsets (dependent on expression of CD14, 
CD16 and CCR2) and their participation in the formation of MPAs. And of course you will 
need a platelet count for the project, derived from the full blood count, from the Advia (see 
SOP 171). 
 
2. Materials and Supplier contact details: 
 
Micro-reagents are kept in the fridge behind the door or on nearby shelves. Bulk fluids in 
boxes on other shelves and beneath the benches. 
 
1) BD “FACS Flow” Running solution [Becton Dickinson {BD}, Catalogue No. 342003] 
10L containers. 
 
2) 3 ml BD Falcon tubes [BD Catalogue No. 352054] 
 
3) BD“FACS Clean” Cleaning Solution [BD Catalogue No. 340345]  
 
4) BD Lysing solution [BD Catalogue No. 349202] 
 
5) Sterile Phosphate Buffered Saline solution, 0.5L bottles [Invitrogen Ltd, Catalogue No 
20012-068] 
 
6) CD14 -PE conjugated monoclonal antibody - 100 tests [BD Catalogue No. 555398] 
 
7) CD16 – Alex-flour 488 conjugated monoclonal antibody - 100 tests [ABD Serotec, 
Cambridge] 
 
8) CD42a-PerCP conjugated monoclonal antibody [BD Catalogue No. 340537]  
 
9) CCR2-APC conjugated monoclonal antibody [R&D Systems Europe Ltd, Cat No. 
FAB151A] 
 
[n.b. this combination of  antibodies constitute a Mastermix: See ADB, ES] 
 
10) Clear pipette tips [Alpha Laboratories Limited Catalogue No FR1250 1250ul Fastrak 
Refill NS]  
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11) Yellow pipette tips [[Alpha Laboratories Limited Catalogue No FR1200 200ul Fastrak 
Refill NS]  
 
12) Count beads [BD (Trucount tubes)]. This is a crucial aspect as it will give us the 
number of monocytes/ml of venous blood. The product tube has a statement of the 
number of beads in each tube and so from this you can work out beads/mL. 
 
Remember to dispose of all material thoughtfully.  
 
3. Detailed method 
 
 
3.1 General Preparation 
 
3.1.1 Lysing solution.   
 
Make from 50ml concentrate 10x FACS Lysing Solution (kept at room temperature). Dilute 
with 450ml distilled water in ½ litre bottle. This solution should not be used if it is older than 
a month (kept at room temperature). 
 
 
3.2 Blood sample preparation 
 
1. Add 12.5 L of Mastermix Absolute Monocyte Count (which includes CD14 2.5 μL, 
CD16 2.5μL, CD42a 5μL and CCR2 2.5 μL fluorochrome labelled antibodies) with an 
electronic micropipette.  Just place into the tube below a metal grid without touching 
the pellet. 
 
2. Gently vortex the EDTA blood sample.  Take 0.05 mL (=50 μL) of whole blood with 
electronic pipette and add to a Trucount tube.  
 
3. Do not touch the pellet (this is critical!). Mix the tube gently with the vortex (3 sec). 
Incubate for 15 minutes in the dark, room temperature, shaking with horizontal shaker 
(set at 500 units). Add 0.45 ml (=450 μL) pre-diluted BD FACS Lyse solution (see 
3.1.1) with a clear tip using the 1ml pipette. Incubate for 15 minutes on shaker as 
above. 
 
4. Add 1.5 ml of PBS solution without touching the sample, followed by gentle vortex to 
ensure thoroughly mixed 
 
 
3.3 Start up procedure [See SOP 195 on General Operation] 
 
Part 1 – restoring reagents and preparation 
 
1. Switch on Flow Cytometer by pressing the green switch on the right hand side.  The 
Apple Macintosh computer must also be switched on, but only 15 secs after the Flow 
Cytometer, or the link will not be recognized. Open the reagent panel on the left hand 
239 
 
side (LHS) by pulling the lid towards you. On the left is the sheath fluid reservoir, in 
the middle are switches and tubes, and on the right is the waste reservoir. 
 
2. Carefully unscrew the top of the sheath fluid reservoir and fill with sheath fluid (in 
large box on shelf at head height – use plastic tube) to the level indicated on the top 
right hand corner of the reservoir (little plastic bar). 
 
3. Carefully disconnect/unscrew the waste container and empty contents down sink with 
plenty of water.  Add approximately 40ml concentrated household bleach along with 
360 ml of distilled water and reconnect container (plastic tubes available). 
 
4. Pressurise the unit (takes about 20-30 sec) by moving the black toggle switch “Vent 
Valve” switch to the down/front position. It is located at the rear of the middle section 
between the sheath fluid tank and the waste container. 
 
5. Air must be excluded from the tubing system by flushing it out. Any excess air 
trapped in the sheath filter can, if necessary, be cleared by venting through the bleed 
tube (the dead-ended rubber tube with a cap). 
 
6. Close the drawer 
 
Part 2 - Cleaning the machine 
 
7. Ensure that a 3 ml Falcon tube (labelled 1) approximately 1/3 full of distilled water is 
positioned over the sample injection port (SIP) – a needle sheath - and that the swing 
arm is positioned under this tube.  Press the prime button on the panel.  When the 
system enters “standby” with in 30 seconds then press the “prime” button again. When 
the standby and low buttons comes on again then remove tube 1. We will re-use tube 1 
in the shut down procedure. 
 
8. Prepare a second falcon tube (labelled 2) with FACS-clean (should contain about 2750 
microlitres so that when inserted on to the sip it doesn’t touch the O ring). This is a 
smaller box on a shelf at above head height and above the bigger box of sheath flow 
fluid 
 
9. Present tube 2 to the SIP and place support arm underneath it. Press the buttons “run” 
and “high” on the panel at the same time, and run the FACS-clean in falcon tube 2 
with supporting arm to left or right open for one minute. Then return the supporting 
arm to underneath the tube and “run-high” five minutes.  This process ensures the 
machine is clean prior to running samples and helps minimise blockages.  
 
10. Return to falcon tube 1 with distilled water. Repeat the above step 9 with this distilled 
water tube. 
 
11. Press the ‘STANDBY’ and ‘LOW’ button on the system. 
 
12. The machine is now ready to run samples. 
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3.4 Running blood samples. 
 
Note. This must be learned from an experienced operator and you must seek scientific staff 
support to clear queries as the intricacies of the Cell Quest software are complex. 
 
1. Open CellQuest Pro software  
2. Click ‘File’ – ‘Open’  
3. Click on the ‘Monocyte Protocols’ folder within ‘Data 1’ folder.  
4. Click on the ‘Monocyte Absolute Count’. This will open study protocol. 
 
5. Click ‘Connect to Cytometer’, located under the ‘Acquire’ menu. 
 
6. Under the ‘Cytometer’ menu, click ‘Instrument Settings’.  The window appears 
displaying the compensations and threshold. Change settings by clicking on the open 
icon on the window which displays the folders select ‘Monocyte Protocols’ folder 
with in the ‘Data 1’ folder and click on the ‘Monocyte Absolute Count’ instrument 
settings in this folder. This will update the system settings to the preferred settings for 
the acquisition. Click ‘Set’ on the window and by clicking ‘Done’ the windows 
disappears.  Make sure to click ‘Set’ prior to clicking ‘Done’. 
 
7. Click the ‘Acquire’ menu once more and click ‘Show browser’.   
 
8. Click directory-‘Change’ in order to specify the location folder. 
 
9. Initial user must create new folder by clicking on ‘New folder’ and by entering the 
title of the folder and choose that folder. 
 
10. Change the custom suffix to the preferred title and number for data and click ‘OK’. 
 
11. Untick the setup box (by clicking on it) in the browser Acquisition window. Now 
insert your sample and press “RUN” and “HIGH”.  
 
12. Open swing arm at bottom right of the cytometer and replace the Falcon tube with the 
sample to be run.  Replace the swing arm under the Falcon tube. 
 
13. Press the buttons ‘Run’ and ‘High’ on the control panel of the cytometer.  
 
14. Click ‘Acquire’ on the browser menu.  The sample will now run for ~ 12 mins.  Cell 
events will be displayed on the screen throughout the process (n.b. the higher the cell 
density, the more rapidly the cells will be acquired). 
 
15. Click on ‘Counters’ under the ‘Acquire’ and observe the events per second which 
varies from 1000 to 8000 depending on various factors. The objective is to acquire 
10,000 count beads for analysis. 
 
16. Observe the acquisition closely since the system may get blocked (which happens very 
rarely) and the plots may not show any progress and the counters may not show any 
events per second. 
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17. Click pause on the acquisition window and replace the sample from the SIP with 
sterile PBS and run for 20/30 seconds minutes (clicking acquire wouldn’t change the 
results) and then continue acquisition with your sample on the SIP. If the problem still 
persists please inform the senior scientific staff and seek assistance. 
 
18. After attaining the target events the analysis stops and the file number changes 
automatically. Click on ‘print’ under the ‘files’. Confirmation window appears again 
click on print. 
 
19. Vortex your next sample gently. Re-programme the software with a new sample 
number, and repeat the step 11. 
 
20. If the cytometer is not ready message appears open the drawer and check the fluids 
level which may need refilling or emptying. The system may run out of Sheath fluid if 
there are more samples. 
 
21. Be absolutely sure you have downloaded your results on to paper. Keep this paper 
safe. Do not assume the computer will keep the results safe, even if you have directed 
it to do so. Obtain all the raw data (cell numbers) and apply them into the specific 
spreadsheet you have designed for your project. The same spreadsheet should have the 
WBC and platelet count results from the Advia 
 
 
3.5 Shut-down procedure   [See SOP 195 on General Operation] 
 
1. In this section we re-use tubes 1 and 2 with distilled water and FACS clean 
respectively. Install FACS Clean tube 2 over the SIP needle. Press button ‘High’ and 
‘Run’ on the panel. Leave the support arm out at 90 degrees for approximately 1 
minute.  This cleans the outer portion of the aspiration sheath.  The fluid will be 
rapidly aspirated, so ensure that the tube doesn’t empty completely. 
 
2. Now replace the side arm under the Falcon tube and allow it to run for approximately 
5 minutes.  This cleans the inner portion of the aspiration sheath and the FACS 
machine itself. 
 
3. Repeat steps 2 and 3 with the distilled water tube 1.  Once step 3 is complete, Leave 
the sheath in falcon tube 1 containing distilled water and press ‘STANDBY’. 
 
4. Open the reservoir draw and depressurize the machine by moving the “Vent Valve” 
toggle switch to the up/rear position.  The machine will hiss as it depressurizes. 
 
5. Leave the machine on for a further 5 minutes to allow the laser lamp to cool.  Turning 
the machine off prematurely will result in the lamp cracking. 
 
6. Finally power down the FACScalibur (green button) and Apple Mac, and then clean 
up! 
 
7. Note: * IF THE SYSTEM IS TO BE USED AGAIN ON THE SAME DAY… 
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LEAVE THE SYSTEM ON STANDBY and then 
DEPRESSURISE THE SYSTEM. 
4. Interpretation of plots 
 
For the first couple of analyses you will need to have all this explained to you by Dr Blann or 
Dr Shantsila. These numbers refer to the illustrative plot and nine individual plots… 
 
 
TOP THREE PLOTS 
 
1. The top left initial plots show the FSC/SSC plot (forward and side scatter, all in 
green). This is needed to gate the presumed monocytes. Be generous at this stage, 
include all monocytes. Contamination by granulocytes and lymphocytes will be 
removed during the next stage.  
 
2. Immediately to the right (i.e. centre) is a plot of the cells stained with CD14 (light 
blue) which further gates the monocytes to separate them from granulocytes. Note a 
large residual proportion of granulocytes at the top of the SSC index. 
 
3. Top right is plot of CD14/CD16 events (red/brown). Four gates have been drawn to 
define different populations of monocytes. M1 defines CD14strong/CD16-ve, whilst 
M4 defines cells expressing a lot of CD16. The latter will be sub-typed shortly. 
 
CENTRE THREE PLOTS 
 
4. Centre left is a plot of the Count beads (green), which are sampled at a concentration 
of, for example, 50,000 beads/tube. From this you will get monocytes/mL and thus 
MPAs/mL. The CD14-PE horizontal axis is irrelevant. 
 
5. Centre middle is (green) plot of CD16 versus CD14, which allows you to gate and 
exclude lymphocytes from analysis. Note that pattern is a bit like the upper right box, 
but with CD14-ve/CD16-ve events present. 
 
6. Centre right is a plot derived from Gate 4. It shows events (cells) that express high and 
low levels of CCR2 according to side scatter. There is a gating line down the middle 
of this plot to give cells staining high and low staining for CCR2. Gate 5 is cells 
staining weakly for CCR2 (=M3) whilst Gate 6 is cells staining strongly for CCR2 
(=M2). 
 
 
LOWER THREE PLOTS (all CD42a versus CCR2) 
 
7. Lower left is a plot of CD42a versus CCR2 on population M1. MPAs are to the right 
of the line  
 
8. Lower middle is a plot of CD42a versus CCR2 in M2. MPAs are to the right of the 
line  
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9. Lower right is a plot of CD42a versus CCR2 in M3. MPAs are to the right of the line  
 
 
Other numbers on the sheet (1- 12) refer to mathematical analyses, not to plots, as, follows…. 
 
5. Interpretation of results (numbers) 
 
This is complicated, so pay attention. There are 12 analyses – the first 4 are raw data: 
 
1. The total number of events counted and the acquisition date are given top left of the 
numbers section (i.e. 60,964 on 08-Apr-10). 
 
2. On the far right is number of count beads (9127) used to quantify events to cells/μL  
 
3. On the left is some maths from the opening plots showing number of total events 
collected in this particular analysis and the proportion that are monocytes. 
 
4. Below this is the maths from Gates 5 and 6 (SSC and CCR2, middle right plot). So 
there are 667 M2 events and 871 M3 events, giving you relative proportions.  This 
data is used to calculate the absolute count of subsets M2 and M3.  
 
From these analyses numbers 1 – 4 the machine works out for you (given the count bead 
number in analysis 2 i.e. 9127) the percentage and numbers of monocytes and monocyte 
subsets, and these are given as numbers 5 – 12 as follows….  
 
5. Mon is the total number of monocytes per μl, i.e. 582.95 cells/μL. 
6. Mon 1 is the number of M1 monocytes per μl, i.e. 409.5 cells/μL.  
7. Mon 2 is the number of M2 monocytes per μl, i.e. 98.23 cells/μL 
8. Mon 3 is the number of M3 monocytes per μl, i.e. 75.22 cells/μL 
 
The machine has also worked out the % of each subset immediately below. 
 
Next – for MPAs… 
 
9. MPA is the total number of MPAs per μL, i.e. 102.86 cells/μL 
10. MPA1 is the total number of MPAs in the M1 population, i.e. 71.29 cells/μL 
11. MPA2 is the total number of MPAs in the M2 population, i.e. 19.28 cells/μL 
12. MPA3 is the total number of MPAs in the M3 population, i.e. 12.29 cells/μL 
 
From this you can work out the proportions given a calculator. It follows that since you have 
the platelet count from the Advia, you can also work out how many of the total platelet pool 
are bound to monocytes. But this is for a separate analysis.  
 
 
Conclusion 
 
Using this dataset as a template, the numbers that need to go into your spreadsheet are as 
follows… 
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Total monocyte count = 582.95 cells/μL 
 
Subsets:  M1 count = 409.50 cells/μL (70.25%) 
M2 count = 98.23 cells/μL (16.85%) 
M3 count = 75.22 cells/μL (12.9%) 
 
Total MPA count = 102.86 cells/μL 
 
Subsets: MPA1 count = 71.29 cells/μL 
  MPA2 count = 19.28 cells/μL 
  MPA3 count = 12.29 cells/μL 
 
Once in the spreadsheet, you can easily do the arithmetic for conversion to % 
 
 
6. Validation and quality control 
 
The intra-assay reproducibility of the methods was assessed on six samples of blood; one set 
of three from a healthy male and second set of three from a woman with a history of renal and 
ovarian cancer. The inter-assay reproducibility was derived ‘x’ samples from a healthy middle 
aged man. 
 
Intra-assay coefficients of variation (CV) (%) were as follows:  
 
   Subject A  Subject B   Mean 
Mon1   0.9   1.4   1.15 
Mon2   10.6   9.9   10.25 
Mon3   3.9   4.7   4.3 
Total Mon  0.6   0.4   0.5 
 
MPA1   3.4   5.2   4.3 
MPA2   14.1   9.7   11.9 
MPA3   8.2   6.8   7.5 
Total MPA  3.2   4.5   3.85 
 
     Median intra assay CV 4.6%  
 
 
Inter-assay coefficients of variation (CV) (%) were as follows: 
 
 
 
 
SOP 201: Enumeration of monocytes subsets and  
monocyte platelet aggregates by flow cytometry 
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Signed off………………Andrew Blann…………………… 2010……….. 
 
 
 
Figures not electronic: illustrative plot (see ADB): Raw analyses available from ADB 
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APPENDIX 4:  Standard Operating Procedure 210; Cytometric bead array 
STANDARD OPERATING PROCEDURE 210 
 
Cytometric Bead Array 
 
Dr. Eduard Shantsila and Dr. Silvia Montero-Garcia. 
 
N.B. Use of the flow cytometry is forbidden 
Without having been officially trained 
 
Required pre-training 
 
3. SOPs on venepuncture and on  good clinical practice 
 
4. SOP 195 – General operation of the flow cytometer 
 
Contents 
 
Introduction   Page 1 
 
Materials and suppliers Page 2 
 
Detailed Method  Page 2 
 
 
1. Introduction 
 
The cytometric bead array (CBA) assay combined with flow cytometry (FC) can be used to 
measure multiple soluble analytes with a particle-based immunoassay in a single tube. This 
technique may supplant a conventional ELISA with less volume sample for multiple markers 
(less dilution too), less time and lower costs. And even more, it seems more reliable than 
conventional ELISA since each bead can be considered as individual test and in one sample 
you are counting hundreds of beads for each marker instead of only duplicate wells. We will 
use as many kits as markers (up to 30 markers with the FACScalibur). 
 
Samples are incubated, in batch, with beads bearing a specific antibody, then with PE-
conjugated antibodies to form sandwich complexes (like in ELISA), shortly washed and 
acquired by FC in couple minutes. Easy and fast! The FC data will be then collected and 
analyze in CBA software (bought license). This software enables linear regression analyses 
using the standard curves of known concentration. 
 
This SOP is relevant for IL6, MCP-1 and fractalkine.  
 
Measurement of IL-1 and IL-10 failed quality control 
2. Materials and Supplier contact details: 
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2.1 BD “FACS Flow” Running solution [Becton Dickinson, Catalogue No. 342003]10L 
containers.  
2.2 BD “FACS Clean” Cleaning Solution [Becton Dickinson, Catalogue No. 340345]  
2.3 3 ml BD Falcon tubes [Becton Dickinson, Catalogue No. 352054] 
2.4 15 ml Falcon tube 
2.5 Clear pipette tips [Alpha Laboratories Limited, Catalogue No FR1250 1250 ul 
Fastrak Refill NS]  
2.6 Yellow pipette tips [Alpha Laboratories Limited Catalogue No FR1200 200 ul 
Fastrak Refill NS]  
2.7 Human IL-1β Flex Set [Becton Dickinson, Catalogue No. 558279] 
2.8 Human IL-6 Flex Set [Becton Dickinson, Catalogue No. 558276] 
2.9 Human IL-10 Flex Set [Becton Dickinson, Catalogue No. 558274] 
2.10 Human MCP-1 Flex Set [Becton Dickinson, Catalogue No. 558287] 
2.11 Human Fractalkine Flex set [Becton Dickinson] 
2.12 Human Soluble Protein Master Buffer Kit [Becton Dickinson, Catalogue No.558264] 
 
 
3. Detailed Method      
Bring all reagents to room temperature before use (they are stored at +4
o
C, generally in the 
‘fridge in the flow cytometer room) 
 
3.1. Preparation of the standards (standard curves) 
 
3.1.1 In a 15 mL falcon tube labelled as “TOP STANDARD” put the 4 standards together 
(all the beads from each kit standard vial) and mix carefully with 4 mL of RPMI-
diluent buffer. DO NOT VORTEX, but wait 15 min until all the beads are fully 
dispersed. 
3.1.2 Prepare 10 clean falcon tubes, label them with the following dilutions names (top row 
table 1) and add 0.5 mL of RPMI-diluent buffer to each (middle row Table 1). 
3.1.3 Then make serial (double) dilutions by taking 0.5 mL of the more concentrated 
dilution to the less concentrated. Mix by pipetting up and down three or four times, 
again do not vortex. Total: 11 standard tubes with the following concentrations of each 
marker per tube (bottom row Table 1). 
3.1.4 Although BD only recommends storage at 4˚C for one week, the tubes below have 
been frozen at -70˚C in order to use them in the next assays.  
3.1.5 Prepare 11 new FC tubes, label them with the same concentrations and add 50 μL of 
the below dilutions. These are the tubes for the standard curve that we are going to 
process by FC. Run the tubes from the least concentrated (0 pg/mL) up to the most 
(2500 pg/mL). 
Table 1 
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Top 
standard 
 
1/ 
2 
 
1/ 
4 
 
1/ 
8 
 
1/ 
16 
 
1/ 
32 
 
1/ 
64 
 
1/ 
128 
 
1/ 
256 
 
1/ 
512 
 
0 
(negative 
control) 
 
RPMI-diluent 
buffer (mL) 
 
 
4 
 
0.5 
 
0.5 
 
0.5 
 
0.5 
 
0.5 
 
0.5 
 
0.5 
 
0.5 
 
0.5 
 
0.5 
 
Final 
concentration 
(pg/mL) 
 
 
2500 
 
1250 
 
625 
 
312.5 
 
156 
 
80 
 
40 
 
20 
 
10 
 
5 
 
0 
 
 
3.2. Preparation of the sample tubes 
 
3.2.1 Mark one FC tube per sample 
3.2.2 Add 50 μL of the serum or plasma (sample) to each tube.  
3.2.3 We are not doing replicates!! 
 
3.3. Master Mix beads preparation 
 
3.3.1 Each kit has a blue tab tube which contains specific capture beads for the chosen marker 
(50X). We will use 1 μL of this solution (beads-Ab) per marker and sample 
 
3.3.2 For the Master Mix (MM) it is convenient to prepare 2 samples more than we need in 
order not to run out of beads. We will use these capture beads for: 
 Standards 
 Samples 
 2 extra samples 
 
3.3.3 Vortex each capture beads vial for 15 seconds to resuspend the solution 
3.3.4 Transfer the required volume of each marker bead (1 μL x number of sample), mix all 
together in a FC tube labelled “MM beads” 
3.3.5 Add 0.5 mL of wash buffer (which is basically PBS) 
3.3.6 Centrifuge at 300 g, 5 min 
3.3.7 Carefully discard the supernatant, do not touch the pellet (beads) 
3.3.8 Calculate the volume of diluent required to dilute the beads, taking into account that 
we are mixing 4 marker beads. Each bead must be diluted in 50 μL with the diluent 
for serum/plasma. 50 minus 4 = 46, hence 46 μL of diluent per sample x number of 
samples 
3.3.9 Incubate ”MM beads” for 15 min at RT prior to use 
3.3.10 Add 50 μL of “MM beads” to each sample: standards and samples 
3.3.11 Leave the samples in the rotator (slowly) for a couple of minutes, in order to mix well. 
3.3.12 Then, incubate at RT for 1hour in darkness 
 
 
3.4. Preparation of PE-detection reagent 
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3.4.1  Protect PE Detection Reagent (PE-R) from prolonged exposure to light 
3.4.2  At this point we have samples incubating with the specific markers beads, but we  
need to stain the beads-bound to analytes with PE 
3.4.3  Each kit contains its own PE-Detection Reagent (50X). 
3.4.4  Like in the case of beads, we will transfer 1 μL/sample of each PE-R to a new FC 
tube labelled “PE-Detection reagent mixture”, and mix the 4 PE-R together. 
3.4.5 These reagents do not need to be washed 
3.4.6 Calculate the volume of diluent required to dilute the PE-R, taking into account that 
we are mixing 4 PE-R. Each PE-R must be dilute in 50 μL with the detection dilution 
buffer. Example : 50 – 4 = 46, hence 46 μL of diluent per sample x number of 
samples 
3.4.7 Add 50 μL of “PE-Detection reagent mixture” to each 1 hour incubated sample: 
standards and samples 
3.4.8 Leave the samples in the rotator (slowly) for a couple of minutes, in order to 
homogenate. 
3.4.9 Then incubate at RT for 2 hours in darkness 
 
3.5. Running samples in flow cytometer 
 
3.5.1 Add to each incubated sample (1 hour with beads and 2 hours with PE-R), 1 mL wash 
buffer to stop the incubation 
3.5.2 Centrifuge 300 g, 5min 
3.5.3 Discard supernatant carefully without touching the beads 
3.5.4 Add 300 μL wash Buffer to each sample 
3.5.5 Switch on the flow cytometer (SOP 195 – General operation of the flow cytometer) 
3.5.6 Open CBA protocol and CBA instrument settings in CBA folder (or a copy of it in 
your folder) 
3.5.7 Vortex slowly the tubes to resuspend beads before FC 
3.5.8 Run FC “CBA Array Protocol” at low speed (acquisition will be completed 
automatically once 1200 beads are collected). 
3.5.9 Run first standards from bottom to top concentration 
3.5.10 Run the samples 
3.5.11 Copy folder with results in a USB. 
3.5.12 NB!!! You do not need to make any printouts 
3.5.13 Switch off the flow cytometer (SOP 195 – General operation of the flow cytometer) 
3.5.14 Go to a computer with the FACArray 2.0 software to calculate concentrations of the 
cytokines in your samples. The results will be presented in pg/mL. 
3.5.15 Print a report to have a hard copy of your results (an example is attached). 
3.5.16 Export data into a spreadsheet for statistical analysis. 
 
 
SOP 210: Cytometric Bead Array analysis by flow cytometry 
 
Signed off………………………………………………………………….. 
 
 
Appendices: Becton Dickinson kit insert of MCP-1 protocol 
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  Validation data x 2  
Assay performance 
 
 
  
Lower limit of sensitivity 
 
 
Intra-assay CV 
 
IL-6 
 
 
1 pg/mL 
 
19.8%* 
 
IL-1 beta 
 
 
1 pg/mL 
 
Not possible* 
 
IL-10 
 
 
1 pg/mL 
 
Not possible* 
 
MCP-1 
 
 
1 pg/mL 
 
12.2%* 
 
Fractalkine 
(February 2012) 
 
 
10 pg/mL 
(the point at which left tail of 
standard curve flattens out) 
 
 
3.1% 
(n=10) 
 
 
*n=8, **Analyte undetectable in the plasma, so assay unvalidated 
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